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Abstract 
Background 
Immune responses targeting microbes can contribute to chronic inflammation, particularly 
when the microbes are persistent such as herpes-family Cytomegalovirus (CMV) and Epstein-
Barr virus (EBV). Such persistence of antigens can cause T cell exhaustion characterized by 
loss of appropriate effector functions, expression of inhibitory receptors, as well as failure to 
return to homeostatic pre-inflammatory conditions.  This results in immune senescence and 
dysregulation which may cause disrupted cell populations, homing and cytokine productions 
that mediate immunopathology and compromise anti-microbial defences. 
Aims 
The aim of the study was to determine whether microbe-specific particularly, interferon-
gamma immune responses measured in 2 disease states, where a herpes viral inflammatory 
aetiology and immune dysregulation are suggested, acute Myocardial Infarction (MI) with 
reperfusion and Chronic Fatigue Syndrome (CFS), are indicative of disease presence and 
severity. 
Patients  
MI occurs due to blockage of the coronary artery, and treatment involves stent insertion, 
allowing reperfusion (R), which has associated immunopathology due to T cell homing. A total 
of 52 MI patients were studied. Blood samples were taken before and after reperfusion to 
investigate the dynamics of specific T cell homing to the heart, that may contribute to disease 
severity (reperfusion damage). For 50 CFS patients with measured disease levels, blood 
samples were taken to examine immune responses including those against microbes implicated 
in disease (CMV & EBV) compared to healthy controls. 
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Methods 
T cell immunity was measured by ELIspot and flow cytometry, and cytokine levels in cell 
culture supernatants were measured using multiplex technology. Statistical analyses were 
carried out for normality in data sets. The Mann-Whitney test or unpaired t test was used to 
determine the difference between two unrelated groups. Differences between repeat or paired 
measurements were determined by Wilcoxon signed rank tests or paired t tests. Associations 
between measurements were investigated using Spearman correlation. 
Results and Discussion 
In MI patients, compared to before reperfusion, levels of the following cell populations fell 
significantly after reperfusion: terminally-differentiated CD8+ PD-1+effector memory cells 
(p=0.016) and CMV-specific IFN-secreting CD4+ T cells (p=0.002) the latter also being 
associated with injury. This suggests specific pathogenic T cell homing to the heart during 
reperfusion.  
In CFS patients, increased disease severity was associated with increased non-specific IFN 
production (p=0.008), and reduced percentage of NK cells (p=0.0047). NK cell deficiency may 
reduce antiviral defences and allow detrimental viral reactivation. 
Conclusion 
T cell responses against CMV appeared to have greater involvement in MI + R than CFS. 
Immune responses involving IFN-γ are demonstrated in both conditions as being associated 
with disease, and so this cytokine may be considered a disease biomarker and a therapeutic 
target for both. 
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1 
 
CHAPTER ONE 
 
Introduction and Literature review 
 
1.1 Scope of thesis-setting the scene 
 
Uncontrolled or excessive inflammation is central to many of today’s major diseases, including 
heart disease, autoimmune and degenerative diseases, and fatigue-inducing conditions; which 
may have direct or indirect microbial involvement. The understanding of such diseases 
involves the study of diseased patients themselves as well as animal models of disease, and in 
vitro analysis of key mechanisms involved or implicated. The combination of such research 
avenues contributes to improved disease diagnosis, monitoring and treatments. This thesis 
examines the role of immune responses, mainly T and B cell responses, focussing especially 
on specificity for Cytomegalovirus and Epstein-Barr virus, in two disease states: acute 
myocardial infarction with reperfusion (MI+R); and Chronic Fatigue Syndrome (CFS). Such 
anti-microbial immunity has been implicated in both these diseases. It is important to set the 
scene for these disease states and to introduce the immune processes investigated in this thesis. 
In acute MI, commonly known as a “heart attack”, the coronary artery becomes blocked usually 
due to the rupture of an atherosclerotic plaque (see page 29). The muscle of the heart, the 
myocardium, becomes starved of oxygen (ischemia) and local cells die causing inflammation 
and damage the muscle at the endothelium. Blood clotting will also be initiated. Cardiac 
surgeons will insert a stent (an expandable metal cage) which opens the artery and re-
establishes blood flow. The damaged myocardium is, however, prone to reperfusion injury, 
believed to be in part caused by the homing of inflammatory T cells to the region. CMV and 
EBV reactive T cells are the most abundant T cells in the body (of sero-positive individuals) 
and are thought to be major contributors to the immunopathology, and hence the subject of the 
first study in this thesis. 
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CFS is a condition in which sufferers endure debilitating fatigue accompanied by pain in 
muscles, and hence its other name myalgic encephalomyeltitis (ME). Whilst fatigue can 
accompany a range of well-known diseases (such as infections and autoimmunity), CFS is 
defined as having an unknown cause (idiopathic). There are likely to be many mechanistic 
pathways that converge to give rise to inflammatory cytokines in the central nervous system 
and “sickness behaviour”. CFS has often been observed following an infection and clinical 
researchers have proposed that sufferers have dysregulated immune responses against microbes 
that cause inflammation, reduced protection from infection, and potentially a vicious cycle of 
infection, inflammation and dysregulation. A greater understanding of immunity in CFS, 
particularly against persistent infections such as CMV and EBV, may reveal mechanistic 
pathways and suggest ways to improve disease management. This is the subject of the second 
study of this thesis. 
The common theme of the thesis is the characterization of immune responses, particularly 
interferon-gamma, against persistent microbes such as CMV and EBV, and their possible 
contribution to diseases presence or severity.  
1.2 Introduction to the immune system 
 
The environment is abundant with pathogenic microbes, commensal microbes, toxic 
substances and allergic proteins. The immune system thus uses a wide variety of mechanisms 
to defend from pathogens and tolerate harmless molecules to maintain homeostatic balance 
(Chaplin, 2010). Anatomical and physiological barriers, innate immunity and adaptive 
immunity constitute the three arms of host defence. Intact skin, mucosal-ciliary clearance, low 
pH of the stomach and lysozyme in secretions are the hallmarks of the anatomical and 
physiological barriers (Turvey & Broide, 2010). The protection conferred by the anatomical 
and physiologic barriers are augmented by the immune responses of the innate immune system. 
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The innate immune system broadly recognizes molecular patterns on pathogens and toxic 
substances that are not expressed by the human body (Turvey & Broide, 2010). Some of the 
microbial patterns recognized by the innate immune system are complex polysaccharides, 
glycolipids, lipoproteins, nucleic acids and nucleotides (Iwasaki & Medzhitov, 2015). The 
innate immune system swiftly encounters invading pathogens and usually eliminates them. The 
adaptive immune system comprises adaptive immune cells (T and B cells) that somatically 
rearrange gene segments to produce antigen receptors that bind to antigenic molecules with 
high specificity. Cells of the adaptive immune system are long lived and mount a stronger, 
faster effective immune when re-encountered with the same pathogen, this being known as 
immune memory (Chaplin, 2010).  
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1.3 Innate Immune System  
The innate system is the first line of defence against invading pathogens after physical barriers 
are breached. Cellular internalization mechanisms and inflammation and protein cascades 
(including complement) constitute the main arms of the innate immune system. The innate 
immune system broadly identifies pathogen-associated molecular patterns (PAMPs) using 
germline encoded pattern-recognition receptors (PRRs) expressed by immune cells. The innate 
immune system is thought to not undergo lasting changes following exposure to the pathogen 
i.e. there is no difference in the quality of immune response during the first and second exposure 
to the same pathogen (Sompayrac, 2015). However, recent research points to a memory 
component of the innate immune system. The memory component of innate immunity is 
acquired due to transcriptional changes and epigenetic reprogramming whereas immunologic 
memory in the adaptive immune system is acquired due to somatic rearrangement of genes and 
clonal expansion (Netea et al., 2016). 
 
1.3.2 Inflammation 
 
The presence of pathogens or dead cells within host tissues causes a ‘state of inflammation’ 
which is characterized by the presence of innate and adaptive immune cells and their secretory 
products. If infections cannot be contained by the innate system, the adaptive arm of the 
immune system is recruited to combat the infections. The adaptive arm of the immune system 
takes more time to develop and is more potent than the innate immune system. The PRRs of 
tissue resident immune cells such as macrophages and mast cells, recognize PAMPs or 
damage-associated molecular patterns (DAMPs) on dead or damaged cells. Once activated, the 
PRRs initiate a signalling cascade reaction which results in the secretion of cytokines. These 
cytokines play a major role in the recruitment of immune cells into the area of infection or 
damage (Newton & Dixit, 2012). Induction of inflammation by pathogen recognition initiates 
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the production and release of inflammatory mediators which cause changes in the blood vessels 
and the influx of immune cells. Vasoactive amines such as histamine and serotonin, which are 
released due to mast cell and basophil degranulation, have both potent vasodilating and 
vasoconstricting effects. Other molecules such as kinnins, bradykinin and fibrin also cause 
vasodilation and allow increased vascular permeability which allow the entry of leukocytes 
into the inflamed area (Medzhitov, 2008). 
Neutrophils are polymorphonuclear leukocytes that are the first immune cells to respond to 
acute inflammation. Neutrophils are produced in the bone marrow from myeloid progenitor 
cells (Kolaczkowska & Kubes, 2013). Neutrophils possess granules which contain a host of 
pro-inflammatory proteins such as myeloperoxidase, lactoferrin and matrix metalloproteinase 
9 (MMP9). Neutrophils can kill phagocytosed pathogens by lowering pH, secreting reactive 
oxygen species (ROS), degranulation (can be intra or extracellular) and by neutrophil 
extracellular traps (NET). The NET consists of a DNA scaffold on which histones and granular 
products are attached and in which pathogens are trapped and killed (Kolaczkowska & Kubes, 
2013). 
Natural killer cells (NK) are considered group 1 innate lymphoid cells. Group 1 innate 
lymphoid cells are those that secrete IFN-γ but are unable to secrete TH2 and TH17 associated 
cytokines (Spits et al., 2013). Main functions of NK cells involve antibody-dependent cell 
cytotoxicity (ADCC), the recognition of lost MHC expression on tumour cells or                
virally-infected cells, secretion of cytokines and chemokines to influence other immune cells 
and to offer costimulatory support for the activation of T cell and B cells (Toledo et al., 2010).  
During their development NK cells acquire CD122, which binds to its ligand IL-15 allowing 
differentiation into immature NK cells. The acquisition of CD94, NKG2A, NKp46 marks the 
transformation to CD56bright NK cells. CD56bright NK cells express CD122, produce IFN-γ as 
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well as expressing T-bet transcription factor. It is suggested that CD56dim NK cells arise owing 
to CD56dim having shorter telomeres than CD56bright cells (Yu et al., 2013).  Min-Oo et al., 
2013 suggested three possible ways NK memory cells could develop, i) cytokine stimulation, 
ii) exposure to CMV and iii) hapten-specific for liver localized NK cells. Romee et al., in 2012 
showed that NK cells pre-activated with IL-12 and IL-18 showed increased production of IFN-
γ after 21 days of in vitro resting followed by subsequent reactivation with IL-12+IL-15 and 
IL-12+IL-18. They also found that CD107a expression in pre-activated NK cells and control 
NK cells were similar. Thus, increased production of IFN-γ and similar levels of CD107a 
expression suggest that NK cells exhibit memory like characteristics. In addition, both 
CD56bright and CD56dim NK cells were also found to be capable of memory. O’ Sullivan et al., 
in 2015 showed that during viral infection, autophagy and mitochondrial changes are induced 
in NK cells. The authors transferred purified NK cells expressing Ly49H receptor that 
recognizes m157 glycoprotein of mouse cytomegalovirus (MCMV) into mice deficient in 
Ly49H receptor. The transferred NK cells underwent rapid proliferation which was 
accompanied by mitochondrial depolarization and increase in mitochondrial reactive oxygen 
species. However, from week 2 to week 4 after the adoptive transfer of NK cells, there was a 
pronounced drop in the mitochondrial dysfunction, which the authors attributed to NK cells 
entering the memory phase. In addition, Cyto-ID (autophagy detection reagent) staining and 
transmission electron microscopy showed the presence of autophagosomes in NK cells during 
active proliferation, which sequentially decreased during the transition from effector phase to 
the memory phase. Moreover, selective ablation of Atg3 gene in mice by the introduction of 
tamoxifen led to the significant reduction of Ly49H+ NK cells in tamoxifen-induced mice after 
the start of the contraction phase. Thus, the authors showed that autophagy was required for 
the formation of memory NK cells.  
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NK cells can be broadly divided into two main subsets, CD56bright and CD56dim NK cells. The 
CD56bright cells are only present in small numbers in peripheral blood but are more numerous 
in secondary lymphoid tissues. The CD56bright cells provide a persistent supply of cytokines to 
support immune responses against pathogens. However, unlike CD56dim NK cells, they possess 
limited cytolytic capacity.  On the other hand, CD56dim cells have lower proliferative capacity 
and lower telomere length than CD56bright cells but secrete substantial amounts of IFN-γ and 
carry out potent cytolytic functions upon activation (Bellora et al., 2014). NK cell functioning 
is carried out by the presence of activating and inhibitory receptors on the cell surface. The 
activating receptors of NK cells are called natural cytotoxicity receptors (NCRs) which include 
molecules such as NKp30, NKp44, NKp46, DNAM-1, NK2G2D and CD16. All these cell 
surface receptors share an immunoreceptor tyrosine activating motif (ITAM) and adaptor 
proteins such as CD3ζ, FcRγ and DAP12. NK2GD associates itself with DAP10 adaptor 
protein. The binding of these receptors to their specific ligand causes the phosphorylation of 
tyrosine residues within ITAM, which in turn causes a signalling cascade resulting in 
downstream effector functions (Cheent & Khakhoo, 2009). A prime example of this 
mechanism is the antibody dependent cell cytotoxicity (ADCC). The Fc region of an IgG-
coated cell, marked for destruction, binds to the FcγRIIIA receptor (CD16) on NK cells and 
induces the phosphorylation of tyrosine residues in ITAMs by kinases of the Syc family. This 
activates tyrosine kinases, SYK and ZAP70, causing a signalling cascade that result in the 
release of cytolytic granules (Perforin and Granzyme B) and cytokines (IFN-γ). However, it is 
important to note that the action of CD244 and DNAM-1, in conjunction with CD16, is vital 
for efficient ADCC to take place (Bryceson et al., 2011). Inhibitory receptors such as killer 
immunoglobulin receptors (KIRs) and CD94/NKG2A contain immunoreceptor tyrosine 
inhibitory motifs (ITIMs). The binding of a ligand to its specific inhibitory receptor causes the 
activation of the Src kinases, which in turn causes the phosphorylation of tyrosine residues on 
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ITIMs. This causes the recruitment of tyrosine phosphatases, which dephosphorylate the 
protein substrates of tyrosine kinases involved in the activation pathway and dampens the 
functioning of activating receptors. Recognition of target cells with no or deficient MHC class 
I molecules on the cell surface is one of the most important functions of NK cells. The 
inhibitory receptors bind to MHC class I molecules on normal cells and dampen the activating 
signals. However, on tumour cells, or virally infected cells, which have supressed MHC class 
I expression, the inhibitory receptors cannot associate with the MHC molecules and this leads 
to a full-fledged engagement of the activation receptors. 
1.3 Antigen Presenting Cells (APCs) of the immune system 
 
It is widely accepted that extracellular pathogens and antigens are processed by APCs and 
presented on MHC class II molecules for CD4+ T cells of the adaptive immune system to 
recognize (Kambayashi & Laufer, 2014). On the other hand, intracellular antigens, particularly 
viral, are processed and expressed on MHC class I molecules for the CD8+ cytotoxic T 
lymphocytes (CTLs) to recognise (Leone et al., 2013). Professional APCs prime naïve CD8+ 
T cells through the process of cross presentation. Thus, dendritic cells (DCs) express high 
levels of MHC class II molecules but are also capable of cross presentation on MHC class I 
molecules (Joffre et al., 2012).   DCs can be divided into two major classes, 1) conventional or 
classical DCs and 2) Plasmacytoid DCs (pDCs). The cDCs can be further classified into two 
main subsets, i) CD1c+ cDCs and ii) CD141+cDCs. CD1c+ DCs are specialized in presenting 
antigen to CD4+ T cells and support Th2 and Th17 mediated immune responses against 
extracellular pathogens, whereas CD141+ DCs are specialized in mediating Th1 immune 
responses and in the cross presentation and in the priming of CD8+ T cells (Breton et al., 2016). 
Plasmacytoid DCs are a distinct lineage of cells that arise from the bone marrow derived cells. 
PDCs, during steady state conditions are present in the blood and lymphoid organs. However, 
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during infections, these cells are also found at the site of infection. The characteristic feature 
of pDCs is the ability to rapidly secrete high amounts of IFN-α. Apart from the primary function 
of secreting IFN-α, pDCs are involved in a myriad of functioning including natural killer 
activation, immunocyte recruitment, promoting CD8+ T and CD4+ T cell responses and antigen 
presentation (Swiecki & Colonna, 2015). 
Macrophages, like DCs, are a myeloid leukocyte population originating in the bone marrow 
from progenitor cells. Monocytes, precursors of macrophages, are released into circulation and 
differentiate into macrophages upon migration to tissues. Macrophages possess a wide variety 
of cell surface receptors including toll-like receptors and scavenger receptors to regulate 
immune response and phagocytose pathogens (Murray & Wynn, 2011). Macrophages have a 
plethora of functions. They are involved in pro- and anti-inflammatory activities, help in tissue 
organization, contribute to the differentiation of T cells into specific subsets, have anti-tumour 
activity, anti-microbial activity and anti-parasitic activity. Two main subsets of macrophages 
exist, the M1 macrophage and the M2 macrophage. The M1 macrophage is pro-inflammatory 
whereas M2 macrophages are anti-inflammatory (Mills, 2015). Macrophages that metabolize 
arginine to nitric oxide and citrulline, catalysed by nitric oxide synthase (NOS), become the 
pro-inflammatory macrophages (M1) and the macrophages that that convert arginine into 
ornithine and urea via the enzyme arginase become anti-inflammatory macrophages (M2) 
(Rath et al., 2014).  
10 
 
1.5 MHC & Antigen processing pathways 
Major histocompatibility complex (MHC), also called human leukocyte antigen (HLA), 
contains more than 100 genes and is present on chromosome 6 in humans. The genes in the 
MHC locus can be divided into MHC class I, class II and class III. The class I MHC molecules 
comprise three joined α chains, α1, α2 and α3, and assemble with β2microglobulin (Wood, 
2006). The α1, α2 chains make up the N terminal region of the molecule and form an anti-
parallel β-pleated base on which two parallel α chains can rest and form a narrow peptide 
binding pit which allows only peptides 8 to 11 amino acids long to bind. While the α1 and α2 
chains are polymorphic, allowing a wide range of foreign peptides to bind, the α3 domain is 
conserved and has a binding site for CD8 receptor and is non-covalently linked to the 
β2microglobulin (β2m). All the chains fold to form an Ig domain-like structure stabilized by 
disulphide bonds (S-S). The MHC class I molecule also has a hydrophobic section that passes 
through the plasma membrane, and a cytoplasmic tail. 
The main classes of MHC class II genes are HLA-DP, DQ and DR. MHC class II molecules 
have two α chains and two β chains which are non-covalently bound to each other. The N 
terminal regions of the α1 and β1chains interact to form a large peptide binding pit which can 
accommodate peptides 12 to 20 amino acids long. The β2 chain contains a binding site for CD4 
receptor. The base of the peptide-binding pit is formed from 4 β pleated strands and 1 α-helix 
strand of the α1 chain, and 4 β pleated strands and 1 α-helix strand from the β1 chain. The α1 
and β1 chains exhibit polymorphism while the α2 and β2 chain are non-polymorphic and adopt 
an Ig domain like structure supported by a disulphide bond. The MHC class II molecule has 
two hydrophobic residues (one each for α chain & β chain) spanning the plasma membrane 
with two cytoplasmic tails (Abbas, Litchman & Pillai, 2012). The MHC polymorphism is vital 
to defend the body against a wide range of pathogens. Each MHC molecule can present an 
extremely large numbers of peptide sequences. The presence of three to six MHC class I 
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molecules and three to twelve MHC class II molecules indicate that in theory, MHC class I 
could present up to 6 x 206-7 and MHC class II molecules could present up to 12 x 2010 peptides. 
However, the combination of the presence of only 200,000 MHC class I molecules and 20,000 
MHC class II molecules in T and B cells and the increased presentation of certain peptides 
indicate that the actual number of peptides presented by a single cell is likely to be around 
10,000 (Rock et al., 2016). 
As mentioned earlier, antigen processing pathways can be of two types depending upon the 
location of foreign pathogens. Intracellular pathogens are mainly processed via the endogenous 
antigen processing pathway involving MHC class I molecules. In contrast, the pathogens that 
originate from outside the cells are taken up by cellular internalization mechanisms such as 
phagocytosis, macropinocytosis and receptor mediated endocytosis, and are processed via the 
exogenous antigen processing pathways; and peptide peptides are presented by MHC class II 
molecules. MHC class I molecules are present on all nucleated cells, which makes evolutionary 
sense as all nucleated cells are prone to infection, and present peptide to CD8+ T cells through 
the peptide-MHC class I complex leading to cytotoxic mechanisms and death of the infected 
cell. MHC class II molecules are only expressed by specialised cells (professional antigen 
presenting cells) which are capable of engulfing pathogenic material and presenting peptides 
through the peptide-MHC class II complex to CD4+ T cells, which on activation release 
cytokines and initiate an immune response which engages several arms of the immune system. 
It makes evolutionary sense to limit the expression of MHC class II molecules to a few select 
cells to limit the inflammatory response which otherwise would be extremely powerful for the 
immune system to control (Neefjes et al., 2011). 
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1.6 Adaptive Immune system 
 
The adaptive immune system came into existence approximately 500 million years ago through 
the evolution of somatic recombination. It provides a more focussed, potent response to 
pathogenic challenge compared to the innate immune system, as well as generating larger 
responses to counter pathogens. The adaptive immune system is mainly comprised of T cells 
and B cells, although natural killer (NK) cells can act as adaptive immune cells in the absence 
of T cell and B cells (discussed later). The recognition of pathogen associated molecular 
patterns (PAMPs) by pattern recognition receptors (PRRs) of the innate immune system kick-
starts an inflammatory reaction that contributes to activate the adaptive arm of the immune 
system (Flajnik & Kasahara, 2010). 
1.6.1 B cells 
B cells are derived from the stepwise differentiation of the hematopoietic stem cell (HSC) in 
the bone marrow, apart from B1 cells, which develop in the fetal liver. The expression of paired 
box protein 5 (Pax5) on common lymphoid progenitor (CLPs) cells imprints B cell lineage. 
The bone marrow stromal cells provide an important cocktail of chemokines, cytokines and 
growth factors for the maturing B lymphocyte. B cell development progresses through VDJ 
recombination of immunoglobulin gene segments from pro-B cell to pre-B cell to immature B 
cells. The immature B cells, after the central tolerance mechanism, transport to the spleen 
where they differentiate into transitional (T1 and T2) B cells. After undergoing peripheral 
tolerance mechanism and under the influence of B cell activating factor (BAFF), alternative 
NF-κB signalling, NOTCH2 transcription factor and Bruton’s tyrosine kinase (BTK), the T2 
B cells differentiate into mature marginal zone B cells (MZ) and mature follicular B cells (FO). 
The marginal zone B cells are retained in the spleen whereas the follicular B cells seed the 
secondary lymphoid organs. (Hoffman et al., 2016). The immature B1 cells travel to the spleen 
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where they undergo transformation into transitional B1 cells, like the one mentioned above. 
The transformation from transitional B1 cell to mature B1 cell is dependent on classical NF-
κB signalling effectors such as BTK and NF-κB1. It is important to mention that B1 cells and 
MZ B cells are innate-like, whereas FO B cells constitute the adaptive arm of the B 
lymphocytes (Montecino-Rodriguez and Dorshkind, 2011). These naïve B cells that encounter 
foreign antigens become mature B cells. The mature B cells then leave circulation and enter 
the germinal centre (GC) in the spleen and become long lived, class switch-capable memory B 
cells and short-lived effector plasma cells. 
 
Figure 1.1 B cell generation from HSC and diversification. B cell progenitors develop from HSC and 
seed the Pleural and peritoneal cavities, the marginal zone of spleen and Lymph nodes where the 
different subsets of B cell develop (Taken from Hoffman et al., 2016) 
B1 cells have the following cellular phenotype: CD27+CD43+CD20+CD70-.  B1 cells also 
secrete IgM and IgA without the requirement of T cells for activation (Martin et al., 2001). So, 
the cellular phenotype of B cells is CD27+CD43+CD20+CD70-IgM+IgA+. The Marginal Zone 
B cells have immunophenotype:  IgM+IgDlowCD21highCD23-CD1dhigh and follicular B cells 
have the immunophenotype: IgMlowIgDhighCD21mediumCD23+CD1dlow (Cerutti et al., 2013). 
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Regulatory B cells (Bregs) represent the immunosuppressive counterpart in B cells of 
regulatory T cells. The signature molecules secreted by Bregs are IL-10, TGF- and IL-35. In 
an inflammatory setting, Bregs function by dampening T cell mediated inflammatory 
exacerbation and skewing T cell differentiation into a regulatory type (Rosser & Mauri, 2015). 
Bregs also play an important role in the regulation of the regulatory T cell population.  
Mammary adenocarcinoma-induced B cell deficient mice were associated with marked 
reduced tumour growth and were also associated with increased expression of Th1 cytokines 
and cytotoxic T lymphocyte response. In addition, the percentage of regulatory T cells were 
also reduced in B cell deficient mice compared to immunocompetent mice. These reduced 
regulatory T cells showed decreased expansion as well as proliferation compared to wild type 
mice. These results thus indicate that regulatory B cells play a vital role in contributing to the 
control of regulatory T cells (Tadmor et al., 2011). Bosma et al., in 2012 identified an important 
role for regulatory B cells in the maintenance of invariant natural killer T cell homeostasis. 
Depletion of B cells from PBMC led to the defective expansion of iNKT cells. This reduced 
expansion was associated with decreased expression of CD25 and Ki67. Also, the blockage of 
the CD1d-iTCR interaction led to the marked inhibition of proliferation suggesting that CD1d+ 
B cells play an active role in the expansion, proliferation as well as the maintenance of invariant 
natural killer T cell population.    
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Table 1.1phenotypes of B cells during different stages of development and differentiation 
B cell type Cellular phenotype Reference 
Pro-B cell CD34+CD19+CD10+CD79a+ Blom & Spits, 
(2006) Pre-B cell CD34-CD19+CD10+CD79a+ 
Immature B cell IgM+IgD-/loBAFF-RloCD10+CD19+ 
CD79a+ 
Blom & Spits, 
(2006) and Pieper et 
al., (2013) 
Transitional B cells CD45+CD19+CD10+IgM+IgD+/lo Agrawal et al., 
(2013) 
Marginal zone cells IgM+IgDlowCD21highCD1dhigh Cerutti et al., (2013) 
and McCulloch et 
al., (2017) 
Follicular cells IgMlowIgDhighCD21+ 
CD23+CD21medCD1dlow 
Cerutti et al., (2013) 
Short lived plasma cells IgMloCD38++CD138+ CD27+BCMA+ Pieper et al., (2013) 
Long lived plasma cells IgAloIgGloCD38++CD138+ 
CD27+BCMA+ 
Memory B cells IgG+BAFF-R+CD21+CD23+ 
CD27+TACI+ 
Regulatory B cells (Bregs)  CD5+CD1dhigh Tedder et al., (2017) 
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1.6.2Tcells                                                                                                                                                                               
Early T cell progenitors (ETPs) derive from HSCs in the bone marrow or fetal liver and seed 
the cortex-medulla junction (CMJ) of the thymus through the expression of P-selectin (Ladi et 
al., 2006). The migration of double negative (DN, for CD4 and CD8) thymocytes to the sub-
capsular region of the cortex from CMJ occurs by chemotaxis with the help of CCL25 (ligand 
for CCR9, expressed on DN thymocytes), CXCL12 (ligand for CXCR4, expressed on DN 
thymocytes), VCAM-1 and CCRL1 (Nitta & Suzuki, 2016) expressed on thymic epithelial 
cells. ETPs in the thymus initially have the phenotype, CD4-CD8-CD25-CD44+.VDJ 
recombination involving the formation of β, γ, δ chains of TCR occurs when the DN 
thymocytes have the phenotype, CD4-CD8-CD25+CD44-. The final stage of differentiation of 
DN thymocytes is characterized by the phenotype, CD4-CD8-CD25-CD44-. The final stage of 
DN thymocytes differentiation occurs at the subscapular region of the cortex. The generation 
of the β chain allows DN thymocytes to proliferate into double positive (CD4+CD8+) 
thymocytes and imprints ETPs for αβT cell lineage. VDJ association of α chain with β chain 
generates αβTCR, which is expressed on double positive thymocytes (Nitta & Suzuki, 2016). 
Double positive thymocytes are then exposed to self-peptide-MHC complexes (spMHC) on 
thymic epithelial cells (TECs). Reactivity of thymocytes to spMHC complexes determines the 
fate of these cells. High level of reaction to spMHC complexes leads to negative selection and 
the eventual apoptosis of thymocytes. Only double positive thymocytes that show low levels 
of reactivity to spMHC complexes survive and differentiate into single positive CD4+ and 
CD8+ thymocytes (Klein et al., 2014). The single positive thymocytes (SPT) downregulate 
CXCR4 and express CCR7. Ligands of CCR7, CCL19 and CCL21, bind to CCR7 and help in 
the migration of SPT into the medullary section of the thymus (Halkias et al., 2014). 
Autoimmune regulator- (AIRE) dependent selection of single positive thymocytes takes place 
in the medulla. AIRE ensures the presentation of tissue specific antigens to single positive 
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thymocytes by medulla-specific thymic epithelial cells.  Double positive thymocytes that have 
escaped the tolerance mechanism of cortex region and single positive thymocytes in medulla 
that have high reactivity to tissue specific self-antigens undergo apoptosis. Single positive 
thymocytes that have low reactivity to tissue specific self-antigens complete the maturation 
process and become single positive CD62LhiCD69low naïve T cells (Takahama, 2006) 
Table 1.2 Important cell surface receptors present on CD4+ T cell subsets 
   Molecules prefixed CXCR or CCR are chemokine receptors controlling T cell homing. 
 
 
 
 
 
Cell 
type 
Cell surface 
molecule 
Signature 
cytokine 
Function References 
Th1 CXCR3, 
CCR5 
IFN-γ, TNF-α Pro-inflammatory reaction 
and macrophage mediated 
phagocytosis. 
Zhu & Paul, 
(2008) 
Th2 CCR3, 
CCR4, 
CCR8 
IL-4, IL-5, IL-
13 
Allergy specific immune 
responses and against 
helminths 
Th17 CCR4, 
CCR6 
IL-17A, IL-
17F, IL-22 
Clearance of extracellular 
pathogens, but implicated in 
the exacerbation of 
autoimmune diseases 
Lee et al., 
(2012) 
TFH CXCR5, 
CD84, 
OX40, ICOS 
IL-21, IL-4 Maturation of B cell in the 
germinal centre. 
Ma et al., 
(2012) 
Cytolytic  CD11a, 
CD11b, 
CD57 
Perforin, 
granzymeB 
and FasL. 
Killing of infected cells Soghoian & 
Streeck, 
(2010) 
Tregs CD25, 
CTLA4, 
GITR, CCR9 
IL-10 Dampens inflammation  Sakaguchi et 
al., (2010) 
18 
 
Table 1.3 Important cell surface receptors present on CD8+ T cell subsets 
 
Cell type Cell surface 
molecule 
Signature 
cytokine 
Function References 
Tc1 CD44, CD127, 
CD27, KLRGI 
IFN-γ, TNF-α Clearance of 
intracellular 
pathogens 
Kaech & 
Cui 2012); 
Mittrucker 
et al., (2014) 
Tc2 CD3, CD8, IL-4 IL-4, IL-5, IL-13 Development and 
progression of 
rheumatoid 
arthritis 
Tc17 CCR6, CD161, 
CCR5, IL-23R 
IL-17, IL-21 Ambivalent 
functionality in 
tumour micro 
environment 
Adopt a pro-
inflammatory 
profile during 
transplantation 
and in 
autoimmune 
disorders. 
Mittrucker 
et al., (2014) 
and 
Srenathan et 
al., (2016) 
Tc9 CCR6, PD-1 IL-9, IL-10 Dampen CD4+ T 
cell activation 
through IL-10 
production 
Chang et al., 
(2013) 
TcRegs Foxp3, CCR6, 
CCR7  
IL-10, TGF-β, 
IFN-γ 
Supresses the 
activation of T 
cells as well as 
promotes the 
differentiation of 
Th1 by secreting 
IFN-γ. 
 
Li et al., 
(2011) 
TFC CD8, CXCR5, 
CCR7lo 
MIP-1β, IFN-γ, 
TNF-α 
Killing of 
infected B cells 
and follicular 
helper T cells as 
well as the killing 
of HIV infected T 
cells  
Leong et al., 
(2016); 
Petrovas et 
al., (2017) 
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The low expression of CD69 on mature naïve T cells is accompanied by high expression of 
sphingosine-1 phosphate receptor (S1PR1), which binds to sphingosine phosphate produced 
by perivascular cells of the cortex-medulla junction and circulating blood, and in a chemotactic 
manner allow exit from the thymus. Among the naïve T cells produced are also the regulatory 
T cells (Tregs). Epithelial cells of the Hassal’s corpuscles in the thymus produce thymic stromal 
lymhopoietin (TSLP), which activate medullary dendritic cells (mDC). Activated DCs express 
high levels of CD80 and CD86 and promote MHC dependent transformation of CD4+CD25- 
single positive thymocytes into Foxp3+CD4+CD25+ naïve Tregs cells. The presence of 
forkhead transcription factor and CD25 cell surface marker is an indication of regulatory T cell 
imprint (Ladi et al., 2006). 
Naive T cells, apart from circulating in the blood stream, are confined to the secondary 
lymphoid organs such as periarteriolar lymphoid sheath (PALS) in the spleen, Peyer’s patches 
and paracortex of the lymph nodes, due to the presence of tissue specific receptors (CCR7) and 
selectins (CD62L). Irrespective of place of pathogen entry, antigen presenting cells such as 
DCs present processed pathogen ‘antigens’ to naïve CD4 and CD8 T cells in the associated 
lymph nodes.  
The VDJ recombination, in T cells, takes places in a similar fashion to the process that occurs 
in B cells. The D and J segments are rearranged to form DJ complex. The DJ complex then 
associates with the variable region to complete the VDJ recombination process. The T cell 
receptor (TCR) β chain is assembled first and it is interesting to note that progenitor T cells 
that do not make a productive rearrangement modify their second allele to undergo productive 
rearrangements. The TCRβ chain then associates itself with a surrogate TCRα chain (Pre-Tα). 
This pre-receptor complex is formed in double negative thymocytes. The transformation of 
double negative thymocytes into double positive thymocytes is accompanied by the association 
of TCRα chain to the pre-existing TCRβ chain. The formation of TCRαβ on double positive 
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thymocytes signals the differentiation of these cells into single positive immature T cells 
(Bassing et al., 2002). 
Whilst macrophages and B cell play a ‘secondary’ role, dendritic cells are the primary antigen 
presenters to naive T cells (Jenkins et al., 2001). Mempel and colleagues in 2004, using two-
photon microscopy, showed that activation of naïve CD4+ and CD8+ T cells by dendritic cells 
take place in three distinct phases. The first phase involved short contacts between T cells and 
LPS-activated DCs in the lymph node, 8 hours after homing. T cells also showed an 
upregulation of CD44 and CD69, while the expression of CD25 was low. There was also no 
expression of IL-2 and IFN-γ.  In phase two of naïve T cell priming, stronger and more 
prolonged interactions between DCs and T cells were observed from 12 to 20 hours. The levels 
of IL-2 and IFN-γ were highest after 20 hours and CD69 and CD44 were also highly activated. 
Phase 3 of T cell priming commenced 24 hours after homing to the lymph node. T cells 
migrated from the lymph node, proliferated, whilst maintaining a high expression of CD44+ 
and lower expression of CD25 and CD69. Once activated, CD4+ and CD8+ T cells transform 
into effector cells, which provide an immediate immune response against infections, and cause 
inflammation, by the production of a wide variety of cytokines, and once infection is resolved, 
become long lived memory cells.  Two subsets of memory T cells are the effector memory T 
cells and central memory T cells.  
Effector memory T cells possess a surface receptor profile that allows their preferred homing 
to peripheral tissues. CD62L- CCR7- but CD45RO+. On the other hand, central memory T cells 
possess receptors that promote their homing to the lymphoid tissues: CD62L+ CCR7+ and 
CD45RO+. Naïve T cells possess markers that also allow homing to lymphoid tissues- CD62L+ 
CCR7+ but CD45RO- and CD45RA+. A population of terminally differentiated T cells which 
are CD62L- CCR7- but CD45RA+ are referred to as the TEMRA. 
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1.6.2.1 T cell polarization 
 
1.6.2.1.1 CD4+ T cells 
 
The polarization of activated naïve CD4+ T cells into different subsets primarily depends upon 
cytokines acting on CD4+ T cells during activation. The action of cytokines activates specific 
transcription factors, which leads to production of a particular subset of CD4+ T cell.  Apart 
from the traditional Th1, Th2 and Th17 subsets, there are induced T regulatory cells (iTreg), 
follicular T helper cells (TFH) and cytolytic CD4
+ T cells. There is also considerable plasticity 
within CD4+ T cell subsets depending upon the infectious state of the host (Swain et al., 2012) 
(Figure 1.2). 
 
Figure 1.2. Polarization and Subset polarization of activated CD4+ T cells.  Different cytokines 
activate different transcription factors which cause the generation of various subsets of CD4+ T cells 
and each of these subsets have specific functions. FOXP3 forkhead box P3, RORγT Retinoic acid 
related orphan receptor-γT, GATA-3 GATA binding protein 3, BCL-6 B cell lymphoma 6, T-bet T box 
transcription factor, EOMES eomesdermin (Taken from Swain et al., 2012). 
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Th1 cells, characterized by the presence of transcription factor T-bet, are vital for mounting 
pro-inflammatory immune responses against intracellular pathogens via the secretion of IFN-
γ, the signature cytokine in Th1 cells. In the absence of T-bet, eomesdermin assumes 
responsibility for the induction of IFN-γ. As well as these transcription factors, signal 
transducer STAT-4 and transcriptional repressor Runx3, also amplify and induce the release of 
IFN-γ from Th1 cells. IL-12 and IL-18 act in a synergistic manner to induce the production of 
IFN-γ in activated Th1 cells. Other major cytokines produced by Th1 cells are IL-2, TNF-α 
and lymphotoxin. (Zhu & Paul, 2008). IFN-γ produced by Th1 cells activate macrophages to 
release matrix metalloproteinase (MMPs), nitric oxide and pro-inflammatory cytokines to kill 
pathogens that have been ingested. Th1 cells, through the release of pro-inflammatory 
cytokines, also recruit CD8+ T cells and NK cells to the sites of pathogenic infection 
(Annunziato et al., 2015), Th1 cells are also implicated in the exacerbation of autoimmune 
diseases such as experimental autoimmune encephalomyelitis (EAE), inflammatory bowel 
disorders (IBD) and collagen induced arthritis (Cosmi et al., 2014) and chronic inflammatory 
diseases such as atherosclerosis (Hoffmann et al., 2015). Th2 cell differentiation from naïve T 
cells require the activation of the GATA-3 transcription factor. GATA-3 is expressed only by 
Th2 cells and continued expression of GATA-3 is required for the maintenance of Th2 
phenotype (Zheng & Flavell, 1997).  The expression of GATA-3 is controlled by IL-4 and the 
signal transducers STAT5 and STAT6 (Paul & Zhu, 2010). The main function of Th2 cells is 
to confer protection of the host from extracellular parasites such as helminths, but they also 
mediate allergic reactions. The presence of allergens and parasites induce the expression of IL-
25, IL-33 and thymic stromal lymhopoietin (TSLP) from epithelial cells which activate type 2 
innate lymphoid cells (ILC2). ILC2 induce dendritic cells to activate Th2 immune responses. 
Th2 cells, apart from releasing their signature cytokines IL-4, IL-5 and IL-13, also release IL-
9 and IL-10. IL-4 induces immunoglobulin class switching to IgE in B cells. The IgE immune 
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complexes then bind to FcεRI receptor on basophils and mast cells. This results in the release 
of various products such as histamine, proteases, serotonin and heparin. The release of these 
products leads to smooth muscle constriction, vascular permeability and migration of 
leukocytes to the sites to infection and leading to allergic responses. Release of IL-5 leads to 
the recruitment of eosinophils in asthma. IL-4 and IL-13 released by Th2 cells also promote 
the development of M2 macrophages that are anti-inflammatory, promote tissue repair but also 
help in the removal of parasites (Licona-Limon et al., 2013). 
Activated naïve CD4+ T cells, responding to IL-6, activates the bcl6 transcription factor which 
directs the development of Follicular T helper cell (TFH) cells. Inducible costimulator (ICOS) 
directs follicular helper T cells to the B cell follicle. These cells express the chemokine 
receptor, CXCR5, and lack CCR7, and play a major role in T cell dependent B cells responses 
to infection.  Presentation of antigens by B cells in the light zone of the germinal centre (GC) 
activates TFH cells. Activated TFH cells help in the survival and proliferation of B cells. B cells 
then travel to the dark zone where they undergo CSR and SHM. B cell then return to the light 
zone for further multiple rounds of signalling with TFH cells. Thus, these T cells help in the 
generation of high quality antigen specific B cells, which produce immunoglobulins to 
neutralize pathogens (Crotty, 2014).  
Harrington et al., in 2005 showed that Th17 cell are a distinct T helper cell subset that develop 
distinctly from Th1 and Th2 cells. IL-23 stimulation had little effect on Th1 and Th2 cells but 
led to the development of Th17 cells from naïve CD4+ T cells. The Th17 cells had minimal 
expression of IFN-γ and expressed high levels of IL-17F. Furthermore, it was also shown that 
development of Th17 cells did not require the transcription factor T-bet. Ivanov et al., in 2006 
showed that the transcription factor, orphan receptor RORγt, is indispensable for the 
development of Th17 cells. IL-6 also upregulates the expression of RORγt and IL-23 receptor, 
thus promoting the generation of Th17 cells. Cytokines released by Th17 cells drive 
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contribution to autoimmune disorders such as multiple sclerosis, psoriasis, inflammatory bowel 
disease and rheumatoid arthritis but also confer protective cover against pathogens such as 
Klebsiella pneumoniae, Mycoplasma pneumoniae, Mycobacterium tuberculosis, Candida 
albicans and Bordetella pertussis (Korn et al., 2009).  Only T cells in the thymus expressing 
Foxp3, which bind to self-peptide MHC complex with a higher affinity than other T cells, 
develop into natural T regulatory cells (Tregs). Foxp3+ interacts with nuclear factor of activated 
T cells (NFAT) to repress the formation of IL-2 and upregulate CD25, cytotoxic T cell 
associated antigen (CTLA-4) and glucocorticoid induced TNF-receptor (GITR). IL-2, apart 
from activating Th1 and Th2 cells and playing a vital role in the functioning of CD8+ T cells 
and natural killer cells, also induces the production of Tregs through CD25(IL-2α chain). Thus 
IL-2 maintains a negative feedback control mechanism whereby pro-inflammatory T cells are 
controlled by immunosuppressive regulatory T cells.  
Regulatory T cells express a range of chemokine receptors and adhesion molecules for homing 
into lymphoid tissue and sites of infection. Although some of the cell surface receptors 
expressed by Tregs are CCR7, CCR4, CCR5, CCR6, CD103, CXCR4 and CXCR5, the main 
markers are CD25 and FoxP3.  Functions of regulatory T cells include supressing immune 
responses towards self-antigens, tumour cells and non-self-antigens, establishing immune 
tolerance towards organ grafts and preventing host vs graft disease. Naïve T cells in the 
periphery can also be induced to differentiate into induced regulatory T cells (iTregs) by the 
action of IL-2 and transforming growth factor (TGF-β) (Sakaguchi et al., 2008).  
Cytolytic CD4+ T cells make up the cytotoxic arm of T helper cells. Cytolytic CD4+ T cells, 
unlike Th1 cells, lack CD27, CD28, express CD11a, CD11b, CD57+ are CCR7lo and produce 
perforin and granzymeB. Thus, it has been suggested that the phenotype of cytolytic CD4+ T 
cells resemble that of a terminally differentiated effector cell. Cytolytic CD4+ T cells perform 
their cytotoxic functions in several ways. The Fas ligand (FasL) on CD4+ cytolytic T cells 
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binding to its receptor (Fas) on target cells causes the apoptosis of the infected target cells by 
caspase activation. These cells also kill target cells by releasing perforin and granzymeB 
cytotoxic granules. Furthermore, it is also suggested that cytolytic CD4+ T cells also cause 
apoptosis of target cells through Tumour necrosis factor apoptosis inducing ligand (TRAIL) 
(Soghoian & Streeck, 2010). In addition to all T helper cell subsets mentioned above, Zhang et 
al., in 2013, discovered a novel T helper subset, ThGM, which express high levels of CD45, 
CD95 and CD69, produce copious amount of GM-CSF and induce other T helper subsets to 
produce their signature cytokines and thus, might play an important role in the regulation of 
the immune response. 
1.6.2.1.2 CD8+ T cells 
 
Naïve CD8 T cells are activated by dendritic cells in a TCR dependant manner which is 
accompanied by changes to their migration patterns, gene expression and functionality. Naïve 
CD8 T cells proliferate and transform into cytotoxic T lymphocytes. TCR affinity to its specific 
antigen is a critical factor in determining the time spent by CD8 T cells in the lymph nodes 
(Halle et al., 2017). Cells with low affinity acquire S1PR1 and leave the lymph nodes faster 
(Breart & Bousso, 2016) whereas the cells with a much stronger affinity for its cognate antigen 
migrate to the interfollicular regions of the lymph nodes via CXCR3 for further TCR 
stimulation (Ozga et al., 2016). After sufficient priming CD8 T cells leave the lymph nodes 
and enter the lymph as well as the blood stream to enter peripheral tissues to combat pathogens. 
Once CD8 T cells enter the tissue, they acquire tissue resident memory phenotype (TRM) 
typified by the expression of CD69, CD103 and increased expression of granzyme B. These 
tissue resident cells are however unable to re-enter circulation and so provide immediate 
immune protection to the tissues (Bergsbaken & Bevan, 2015). The survival of tissue resident 
memory T cells is dependent upon the uptake of exogenous lipid. Tissue resident memory CD8 
T cells in the skin of experimental mice expressed high levels of Fatty acid binding proteins 4 
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and 5. Furthermore, the targeted deletion of FABP4 and FABP5 led to low survival rate of 
these cells in vivo.  
Joshi et al., in 2007 suggested that CD8+ T cells could be divided into short-lived effector cells 
(SLEC) and memory precursor effector cells (MPEC). Naïve CD8+ T cells primed by antigenic 
stimulation differentiate into short-lived effector and long-lived memory cells. These effector 
cytotoxic T cells (CTLs) kill infected cells and pathogens by releasing proteins such as perforin 
and granzyme B. They are also release IFN-γ and Tumour necrosis factor (TNF) which mediate 
pathogen removal. After the elimination of pathogen, effector CD8+ T cells are rapidly 
removed from circulation by apoptosis and a small percentage of effector cells transform into 
memory CD8+ T cells (Sarkar et al., 2008).  Effector cytotoxic CD8+ T cells, with the 
phenotype CD44hiCD62LlowCD27lowKLRG1hiIL7Rαlo, Memory precursor CD8+ T cells have 
the phenotype:  CD44hi CD27hi KLRG1low IL7Rαhi and lack CD62L. Apart from Type 1 
Cytotoxic CD8+ T cells (Tc1 cells), other subtypes of CD8+ T cells are Tc2 (CD8+ T cells 
secreting IL-4, IL-5), Tc17 (IL-17 secreting CD8+ T cells), Tc9 (IL-9 secreting CD8+ T cells) 
and CD8+ regulatory T cells. Tc2 cells are similar to Th2 cells, but aggravate allergy and 
autoimmune disorders (Mittrucker et al., 2014).  Hamada et al., in 2009 identified a unique 
Tc17 subset of CD8+ T cells similar to Th17 cells belonging to the subset of CD4+ T cells in 
the lungs of experimental mice.  Cell suspensions of spleen, lung, bronchoalveolar lavage 
(BAL) and lymph nodes indicated the expression of IL-17 by CD8 T cells. The authors also 
used anti-IL-17 antibody to deplete IL-17. This resulted in the reduction of immunity to 
influenza in mice. Tc17 cells promote autoimmunity, ambivalent response in tumour 
microenvironment and elicit a strong pro-inflammatory response against influenza infection 
(Mittrucker et al., 2014).  
Visekruna et al., in 2013 identified a novel subpopulation of CD8+ T cells, Tc9 cells. The 
author showed that in the absence of ‘skewing cytokines’ CD8+ T cells were able to develop 
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an effector phenotype characterized by the production of granzyme B and IFN-. However, the 
addition of TGF- and IL-4 supressed the production of granzyme B and induced the release 
of IL-9, while the production of IFN- did not differ. The authors also performed quantitative 
RT-PCR to understand the transcriptional process in Tc9 cells. It was found that Tc9 cells 
produce low levels of IL-5, IL-13 and IFN- and displayed lower levels of cytotoxicity 
compared to cytotoxic T lymphocytes or Tc2 cells. As for the role Tc9 play in immunity, the 
authors showed that they play a role in the exacerbation of allergic airway disease along with 
Tc2 cells. Similar to the work by Visekruna group, Lu et al., (2014) also showed diminished 
expression of IFN-, granzyme B and perforin as well as transcriptional controllers such as 
Eomes and Tbx21, while showing increased expression of IRF-4 and Pu.1 These Tc9 cells also 
showed enhanced expression of IL-2 and IL-9. Apart from these cytokines, these cells also 
secrete IL-4, IL-10 and IL-17.  
1.6.2.1.3 Plasticity of T cells 
 
Differentiated CD4+ T cells, in the absence of external influence by cytokines, retain their 
phenotypic stability aided by epigenetic modifications and microRNA expression. However, 
there exists considerable plasticity among the T helper populations. Th2 cells, in the presence 
of IL-12, can be stimulated to produce IFN-γ, the signature Th1 cytokine. Th2 cells can also 
be transformed into Th9 cells in the presence of TGF-β. Furthermore, Th17 cells induce insulin 
dependent diabetes mellitus (IDDM) only after acquiring Th1 phenotype. In addition, IDDM 
in NOD/SCID mice was abrogated when injected with anti-IFN-γ antibody but not with anti-
IL17A antibody (Cosmi et al., 2014). CD8+ T cells, like CD4+ T cells, show considerable 
plasticity. Tc2 cells, counterpart of Th2 cells, can produce IL-4, IL-13 and IFN-γ. Similarly, 
Tc17 cells produce both IL-17 and IFN-γ in experimental autoimmune encephalomyelitis. Tc1 
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cells produce IL-10 to dampen inflammatory response and CD8+ regulatory T cells produce 
IL-17 and IFN-γ (Mittrucker et al., 2014). 
1.7 Cardiovascular Disease 
 
Cardiovascular disease accounts for 30% of all mortalities across the globe and costs the world 
economy $862 billion; and the cost for treatment is projected to increase further in the next two 
decades with an ageing population. Atherosclerosis is the major pathological process that leads 
to cardiovascular diseases, particularly myocardial infarction (Swirski & Nahrendorf, 2013). It 
is therefore imperative to increase the understanding the mechanisms of disease and translate 
this into improved diagnosis, treatments or cures. 
Atherosclerosis is a chronic inflammatory disease caused by the retention of low density 
lipoproteins (LDL) in the intima of the arteries. Cardiovascular risk factors such as smoking, 
diabetes, hypertension, autoimmune disorders, dyslipidaemia and other chronic inflammatory 
conditions cause endothelial dysfunction and lead to the increased retention of lipids in the 
intima (Patel & Blazing, 2013). Endothelial injury causes changes in the structural integrity of 
the endothelium leading to the disappearance of the elastin layer and the subsequent exposure 
of the proteoglycans. It is the binding of Apo-lipoprotein B100 (ApoB100) present in the LDL 
particles, to the proteoglycans that causes the retention of the lipids. The inflammatory 
responses of the immune cells toward the retained lipids lead to the accumulation of apoptotic 
cells, cell debris and cholesterol crystals that contribute to the formation of the atherosclerotic 
plaque. A fibrous layer comprised of collagen and vascular smooth muscle cells usually covers 
the plaque. The lesions, due to sustained inflammatory response, grow and lead to the 
narrowing of the blood vessels. Thrombosis occurs following plaque rupture (Weber & Noels, 
2011) which blocks the vessel leading to myocardial ischemia, starving of oxygen supply to 
the heart muscle. If the vessel blocked is the coronary artery, then a heart attack will usually 
occur (Refer to Figure.1.3). 
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Figure 1.3 Stages of atherosclerotic lesions in an impaired endothelium. Early fatty streak lesions 
characterized by retention of Apo-lipoproteinB-100 in the endothelial wall provokes the migration of 
inflammatory immune cells which further increases and establishes the lesion size leading to the 
eventual rupture and blocking of arterial walls (Taken from Moore & Tabas, 2011).   
Cardiovascular disease risk factors like smoking, diabetes, hyperlipidaemia and hypertension 
cause ‘oxidative stress’ which causes an increase in the concentration of reactive oxygen 
species (ROS) in the arterial intima.  This leads to a marked reduction in the bio-availability of 
nitric oxide (NO), a potent vasodilator. The decrease in concentration of nitric oxide gives rise 
to endothelial dysfunction, which is a major factor in the advent of atherosclerosis. Reduced 
NO leads to pro-inflammatory, vasoconstrictive and defective anti-coagulatory properties of 
the endothelium (Bonetti et al., 2003). This functional impairment of the endothelium leads to 
the retention of lipids in the intima. A study by Morel et al., (1984) showed that human 
endothelial cells and smooth muscle cells, in vitro, in the presence of butylated hydroxytoluene 
(BHT, an antioxidant) did not modify LDL particles but modified them in the absence of BHT. 
This may suggest dysfunctional endothelial cells in vivo might be involved in the minimal 
oxidation of LDL in the intima of the arteries. Minimally modified LDL particles, due to 
dysfunctional endothelial cells, induce the endothelial cells to express adhesion molecules and 
release chemokines that causes the recruitment of immune cells such as monocytes and T cells. 
30 
 
This influx is responsible for the development of early lesions called the ‘fatty streak’. The 
monocytes present in the intima differentiate into macrophages under the influence of 
macrophage colony stimulating factor (M-CSF) released by the activated endothelial cells. The 
macrophages then take up the oxidized-LDL (ox-LDL) through their scavenger receptors and 
transform into lipid-filled ‘foam cells’ which, after apoptosis, contribute to the build-up of the 
atherosclerotic plaque (Hansson & Hermansson, 2011). 
Studying mouse models of atherosclerosis is extremely important to gather insights into 
atherosclerosis and myocardial infarction mechanisms in humans. Researchers have 
consistently used two major models: Apoe-/- and Ldlr-/- mice to study atherosclerosis. The apo-
lipoprotein E model involves the targeted deletion of the lipid transporter gene ‘ApoE’. The 
ApoE is involved in the metabolism and transport of very low-density lipoproteins (VLDL) 
from the myocardium. The deletion of the gene coupled with the mice being fed a high fat diet, 
leads to the retention of lipids (hyperlipidaemia) at the endothelial layer of the myocardium 
and contributes to the increase in the size of atherosclerotic lesions (Pendse et al., 2009). The 
Ldlr-/- model involves the targeted disruption of the low-density lipoprotein receptor (Ldlr). 
Ishibashi et al., in 1994 used this model to show the formation of atherosclerotic lesions and 
xanthomatosis in mice. The deletion of LDL receptor causes the retention of VLDL, LDL and 
intermediate density lipoproteins (IDL) and exacerbates lesion formation which coincided with 
marked increase in plasma cholesterol from 246 to >1500 mg/dl (dl-decilitre). The plasma 
cholesterol levels of wild type control mice remained <160mg/dl. Both wild type control mice 
and Ldlr-/- mice received a 1.25 % cholesterol diet (Normal Chow diet infused with cholesterol, 
cocoa butter, casein and sodium cholate). 
1.7.1 Innate immune responses to Atherosclerosis  
 
Van Leeuwen et al., (2008), investigated the role of neutrophils in the development of 
atherosclerosis.  Ldlr- mice were fed a high fat diet and the atherosclerotic lesions were 
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investigated for neutrophils by staining with monoclonal antibodies for Ly-6G, a marker for 
murine neutrophils, and myeloperoxidase (MPO) specific monoclonal antibody to test the 
expression of MPO in the tissues. Neutrophils were present abundantly in the intermediate and 
advanced atherosclerotic lesions but were not present in early lesions. There was also a marked 
increase in the expression and plasma levels of MPO, which directly correlated with the 
increase in atherosclerosis development. Double staining for Ly-6G and MPO markers 
revealed that neutrophils were the predominant producers of MPO, whereas the monocytes 
weakly expressed MPO. Ionita et al., in 2010 stained human carotid atherosclerotic plaques 
with mouse anti-human CD66b, anti-MPO and anti-naphthol AS-D chloroacetate esterase to 
identify neutrophils. It was found that mainly neutrophils and a subset of plaque macrophages 
present in the plaque were responsible for the production of MPO. Other studies have also 
shown neutrophils are the predominant producers of MPO. Naruko et al., (2002) analysed 
coronary artery segments from AMI patients as well as atherectomy sections of patients with 
stable and unstable angina pectoris. In AMI patients with plaque rupture and Plaque erosion, 
double immunostaining with monoclonal antibodies for CD66b, elastase, MPO-7 and CD68 
(cell surface molecule on macrophages), CD11b and MPO showed that majority of MPO 
producing cells were neutrophils.   
Neutrophils which extrasvasate into the tissues in response to inflammation release preformed 
granule proteins including LL-37 and azurocidin, which activate and recruit monocytes into 
the lesions. Neutrophils release MPO, which reduces Nitric oxide content thereby causing 
‘oxidative stress’ which then leads to dysfunction of the endothelium. Neutrophils also release 
lipid mediators such as leukotriene B4 that increases the expression of adhesion molecules on 
the endothelial cells and helps maintain steady neutrophil inflammatory functions in the 
atherosclerotic tissues. 
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Neutrophils, apart from being potent pro-inflammatory cells, also quench inflammation by 
releasing molecules such as protectins (neuroprotectins) which reduce the expression of 
VCAM-1 on endothelial cells, which then subsequently leads to reduced leukocyte recruitment, 
and smaller plaques. Another potent molecule released is the lipoxinA4 that reduces the 
generation of reactive oxygen species and decreases the expression of P-selectins on 
endothelial cells (Baetta & Corsini, 2010). 
The striking feature of macrophages in the atherosclerotic lesions is their multifunctional 
capability. The macrophages release inflammatory mediators, which attract other 
immunocytes, further impair the endothelial cells, and release proteinases that cause the 
dysfunction of the extra-cellular matrix (Swirski & Nahrendorf, 2013). Nahrendorf et al., in 
2007 found that monocytes and macrophages also resolve inflammation. Ly-6Chi monocyte 
subset dominates the initial stages of myocardial injury in atherosclerotic C57BL/6 mice by 
displaying inflammatory functions whereas the Ly-6Clo monocyte subset resolves 
inflammation by promoting angiogenesis and granular tissue formation through extra cellular 
matrix deposition during the later stages of myocardial injury (4 to 7 days after myocardial 
infarction) 
Erbel et al., (2007) showed that dendritic cells are present in an activated state in the 
atherosclerotic plaque.  A comparison between symptomatic and asymptomatic patients 
undergoing endarterectomy (a procedure for the removal of lesions in the artery) for ischemic 
conditions was done using carotid artery tissues. The target cells in the tissues of symptomatic 
patients showed a marked increase in the expression of not only CD83, a marker for mature 
dendritic cells but also CD86, a co-stimulatory molecule, which is involved in T cell activation. 
The activated dendritic cells also release chemokines like CCL19 and CCL21 that recruit the 
CCR7-expressing naïve as well as central memory T cells into the atherosclerotic plaque. The 
quantitative PCR reaction performed also showed a very high number of IFN-γ and TNF-α 
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transcripts that directly correlated with the T cell presence in the plaque tissue.  Thus, the 
dendritic cells present in the plaque tissues play a vital role in the inflammatory processes and 
lead to the advancement of the atherosclerotic lesions. 
1.7.2 Adaptive immunity in Atherosclerosis  
 
Chronic inflammation, caused by the adaptive immune system (T and B lymphocytes) in the 
heart tissue is the driving force behind the occurrence of atherosclerosis. The local cells of the 
innate immune system release cytokines and chemokines that attract T and B lymphocytes into 
the lesions and exacerbate inflammation. Different subsets of T and B cells have contrasting 
inflammatory actions on atherosclerotic lesions, which further complicate the understanding of 
coronary heart disease (CHD). TH1 cells are pro-inflammatory, the roles of TH2 and TH17 cells 
are indefinite and Regulatory T cells (Tregs) confer suppression of inflammation (Oufella et 
al., 2014). IL-13, a TH2 cytokine, when administered into Ldlr
-/- mice was shown to decrease 
the expression levels of VCAM-1, thereby, reducing monocyte influx into atherosclerotic 
lesions. In addition, IL-13 also induces the activation of anti-inflammatory M2 macrophages 
over the pro-inflammatory M1 macrophages. Binder et al., in 2004 reported that IL-5 
deficiency led to increased atherosclerotic development.  Also, IL-5 induced the production of 
IgM from B 1 cells, which are atheroprotective. In contrast, transfer of bone marrow stem cells 
from IL-4-/- mice into Ldlr-/- led to the decrease in the atherosclerotic development. This 
suggests that the deficiency of IL-4 led to the decrease in atherosclerosis development. Similar 
to TH2 cells, the roles of TH17 cells are also unclear. Breeding of IL-17A
-/-ApoE-/- and IL-17RA-
/-ApoE-/- mice led to the reduction in atherosclerotic lesion size in the aorta. Van Es et al., in 
2010 used dendritic cells transfected with mRNA coding for Foxp3 to understand the role 
regulatory T cells essay in atherosclerosis. Ldlr-/- mice were vaccinated with transfected DCs 
to induce a cytotoxic immune response against Foxp3. It was found that the percentage of 
Foxp3 Tregs in Ldlr-/- transfected with Foxp3 was 27% lower than Ldlr-/- mice transfected with 
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GFP. This reduction also led to the increase in atherosclerotic lesion formation in Ldlr-/- mice. 
George et al., in 2012 showed that patients who suffered from two myocardial infarctions have 
significantly lower levels of CD4+CD25+ regulatory T cells and IL-10 than controls who 
underwent elective coronary angiography. Furthermore, Klingenberg et al., (2013) used      
Ldlr-/- mice that received bone marrow from depletion of regulatory T cells (DEREG) mice and 
were injected with diphtheria toxin (DT) to deplete Foxp3+ T regulatory cells. This depletion 
of regulatory T cells leads to the significant increase in atherosclerosis as well as increase in 
very low-density lipoproteins (VLDL).  
With respect to B cells, Kyaw et al., in 2010 showed that CD20 antibody mediated depletion 
of B cells from ApoE-/- mice ameliorated atherosclerosis development. In addition, the transfer 
of conventional B2 B cells into mice led to the increase in lesion size, whereas the adoptive 
transfer of B1 cells did not support the formation of lesions. Thus, the authors concluded that 
the B2 subset was pro-atherogenic whereas B1 subset was anti-atherogenic. Moreover, a report 
by Oufella et al., in 2010 showed that CD20 antibody mediated depletion of B cells in ApoE-/- 
led to the reduction in the development of atherosclerosis. Another report by the Kyaw research 
group in 2012 showed that BAFF receptor deficient ApoE-/- mice showed a reduction in B2 
cells but not B1 cells in blood, spleen, peripheral lymph nodes and peritoneal cavity. This 
reduction in B2 cells also led to the decrease in atherosclerotic lesion size as well as IgG1 and 
IgG2a levels. Thus, it is important to research the functions of different subsets of T and B 
lymphocytes at the atherosclerotic lesions to understand the role of lymphocytes and improve 
disease state by devising treatments. 
1.7.2.1 T cells in Atherosclerosis  
 
T cells in the atherosclerotic lesion regions are recruited in parallel with the monocytes by 
chemokines and via the adhesion molecules on the impaired endothelium. Dendritic cells also 
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play a major role in presenting oxidised LDL (antigens) within lymph nodes where the T cells 
reside, and program them to ‘home’ to the plaque regions. The activated T cells in the plaque 
regions release pro-inflammatory mediators, which promote the growth of lesions and 
exacerbate atherosclerosis. T helper1(Th1) cells are the major promoters of atherosclerosis due 
to their release of IFN-γ which causes increased expression of inflammatory mediators and 
enhanced expression of adhesion molecules on dysfunctional endothelial cells (Hansson & 
Hermansson, 2011).  The pro-atherogenic nature of IFN-γ is evident in the reduction in lesion 
size when the expression of IFN-γ is reduced.  Research by several groups prove the major role 
for IFN-γ. Gupta et al., in 1997 showed that in ApoE-/- mice, there was substantial influx of 
CD4+ and CD8+ T cells in the intima of the arterial walls, whereas in ApoE-/-IFN-γR-/- double 
knockout mice showed a 59% reduction in lipid content in the lesions compared to the ApoE-/- 
mice. Buono et al., in 2003 showed that in IFN-γ-/-Ldlr-/- mice, the atherosclerotic lesions size 
reduced by 43% in the aortal arch and 65% in the descending aorta after 20 weeks of high 
cholesterol diet than in control mice. Another important observation is that the deletion of the 
Tbx21 gene which codes for the transcription factor T-bet also led to the marked reduction of 
lesion size in Ldlr- mice. It is widely known that activation of T-bet leads to the differentiation 
of the naïve T cells into Th1 cells (Hansson & Hermansson, 2011). 
The role of Th2 cells is debatable as the presence of IL-33 (a potent activator of Th2 cells) leads 
to reduced atherosclerosis (Hansson & Hermansson, 2011).  Contradictory to the theory that 
Th2 cells reduces atherosclerosis, a study by Davenport & Tipping, (2003) showed using a 
double knockout ApoE- IL-4- mouse model that the deficiency of IL-4 leads to reduced plaque 
formation in the aortic arch at 30 weeks but there was no significant difference in the lesion 
size with ApoE- only mice at 45 weeks. IL-4 increases the expression of monocyte 
chemoattractant protein 1 (MCP-1) which leads to the recruitment of monocytes. Increase in 
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levels of IL-4 also leads to the upregulation of adhesion molecule VCAM-1 and promotes the 
formation of oxidized lipoproteins (Davenport & Tipping, 2003). 
The role of Th17 cells in CHD, like Th2 cells, is also debatable. A study by Smith and 
Colleagues in 2010 implicates 1L-17A in an atherogenic capacity. The mRNA level of IL-17A 
was significantly higher in ApoE- mice than in C57BL/6 control mice and directly correlated 
with increased lesion size. The IL-17A level was also strikingly higher than other cytokines in 
the IL-17 family. It was further shown that blocking IL-17A using a fusion protein reduced 
atherosclerotic plaque development. Thus, while the role of Th1 cells is clearly atherogenic, the 
roles of Th17 and Th2 cells remain unclear. 
Kyaw et al., (2013) showed that depletion of CD8+ T cells reduces atherosclerosis. The 
depletion of CD8α+ T cells and CD8β+ T cells in ApoE- mice showed a profound decrease in 
lipid accumulation, atherosclerotic lesion size and macrophage accumulation. The results of 
the TUNEL assay and hematoxylin and eosin staining performed on plaque sections showed 
that CD8+ T cells contribute greatly to the increase in apoptotic cells and cell necrosis by 
releasing perforin and granzyme B, which demonstrates their role in atherogenic effects of 
CD8+ T cells.  
The molecules programmed death ligand 1(PD-1) and PD-2 on T cells inhibit the activation 
(both CD4+ & CD8+) through binding of ligands on tissue cells. The mouse model PD-L1/2(-/-) 
Ldlr (-/-) mice had a marked increase in the number of T cells compared to control mice           
(Ldlr (-/-)) and increased atherosclerotic lesions. Thus, PDL1 and PDL2 play a vital role in 
regulating T cell population in the plaque regions (Gotsman et al., 2007). Regulatory T (Tregs) 
cells have an atheroprotective role in atherosclerosis. These cells are the major producers of 
TGF-β and IL-10, which suppress inflammation and confer protection against inflammation-
induced injuries (Hansson & Hermansson, 2011). Oufella et al., (2006) showed that the number 
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of Tregs cells was reduced in CD80
-CD86 and CD28 deficient Ldlr- mice that points to the 
possible role of regulatory T cells having an atheroprotective role in atherosclerosis. 
T cell homing in atherosclerotic lesions involves a wide variety of chemokines. The role of 
CCR7 on T cells, and its ligands CCL19 and CCL21, in homing and migration of T cells into 
the heart is contradictory. Lesion size increased in CCR7-/-ApoE-/- mice whereas lesions size 
decreased in CCR7-/-Ldlr-/- mice suggesting conflicting results when two different mouse 
models were used. Li & Ley in 2015 suggested the use of T cell specific CCR7 knockout mice 
to study atherosclerosis. The use of NB-74330 as an antagonist for CXCR3 in Ldlr-/- mice 
reduced lesion size by 53% compared to control mice, which indicates that the presence of 
CXCR3 is vital for the migration of pro-inflammatory cells into the lesion area. The increased 
number of regulatory T cells in the lesion region also suggested a shift from a pro-inflammatory 
to anti-inflammatory environment (Van Wanrooij et al., 2008). Thus, while the roles of Th1 
cells are clearly atherogenic, the role of Th2 and Th17 cells in atherosclerosis is less clear. 
1.7.2.2 Role of T cells in Myocardial Infarction and Reperfusion (MI+R) injury 
 
Thygesen et al., in 2012, defined myocardial infarction as death of myocardial cells due to 
ischemia (lack of oxygen supply to the heart). Stent or balloon inflation by primary 
percutaneous coronary intervention (PPCI) causes transient ischemia irrespective of chest or 
ST elevated changes. It is important to note that myocardial injury with necrosis may occur as 
the result of pre-PPCI procedure or due to microvascular plugging and atherosclerotic plaques. 
This procedure results in inflammation of the myocardium, thus the                                     
myocardial infarction-related reperfusion injury is usually associated with elevated troponin 
levels. Studying the role of T cells in the myocardium might provide important insights into 
the immunological aspects of myocardial infarction, potentially indicating diagnostic and 
therapeutic targets.  
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Lluberas et al., in 2015 showed that, in ST segment elevated myocardial infarction (STEMI) 
patients, CD4+CD28null T cells preferentially accumulated in the intracoronary regions at the 
plaque rupture site compared to peripheral blood. In addition, they also compared T cells levels 
with evolution of STEMI ~6 hours (from pain to balloon time). It was found that T cell numbers 
were higher near the plaque regions than in peripheral blood. Moreover, CD4+CD28null T cells 
were significantly higher in patients with higher creatine kinase levels, thus suggesting that 
myocardial injury is increased with the increase in T cells in the plaque regions. The levels of 
IFN-γ and IL-10 were also increased. This shows how the immune system maintains the 
balance between potent pro-inflammatory reaction and potent anti-inflammatory reaction. 
Mathes et al., (2016) showed that MHC class II KO mice, which are incapable of developing 
MHC class II restricted CD4+ T cells, had significantly lower infarct size and improved 
microvascular reperfusion. Also, the ejection fraction as determined by in-vivo magnetic 
resonance tomography was better preserved in MHC class II KO mice. The research group also 
used CD4 KO mice and reconstituted them with Foxp3+ and Foxp3- CD4 T cells. It was found 
that CD4 KO mice with CD4+ CD25+ T cells had a significant increase in infarct size similar 
to MHC class II KO mice.  Interestingly, using immunofluorescence to carry out histological 
examination, the authors found out that CD4+ T cells remain in the microvascular bed rather 
than infiltrate or enter the myocardium, 24 hours after reperfusion.  
The myocardium, under ischemic pressure, undergoes ventricular remodelling to maintain 
blood flow to the heart. However, persistent inflammation in the heart tissue leads to impaired 
ventricular remodelling, damage to extracellular matrix and apoptosis of immune cells. 
Persistent inflammation is caused by pro-inflammatory cytokines and infiltration of pro-
inflammatory immune cells.  Regulatory T cells induce the differentiation of anti-inflammatory 
M2 macrophages, secrete TGF-β, and dampen the inflammation by inhibiting TNF-α, MMPs. 
The dampening of inflammation helps in repairing the injured myocardium (Fang et al., 2015). 
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Hoffmann et al in 2012 showed, 24 hours after PPCI, the central memory compartment of 
CD4+ T cells was highly elevated whereas the levels of naïve and TEMRA cells dropped. The 
elevation and drop in cell numbers was attributed to the both the blockage in the arteries as 
well as reperfusion injury caused by PPCI. The research group also developed a hierarchical 
clustering analysis, which identified a memory CD4+ T cell expressing CD57+ which was 
negative for KLRG1. Further, the mean fluorescent intensity of CD57+ increased whereas MFI 
for KLRG1 and PD-1 remained unchanged. Further, the MFI for naïve CD4+ and CD4+ central 
memory cells did not differ from each other whereas the MFI for effector memory cells and 
TEMRAs were significantly higher than MFI of naïve CD4+ T cells which indicates that the 
expression of CD57 occurred after cell divisions. Among the CD4+ sub population, the MFI of 
effector memory and TEMRA were higher than in naïve T cells. The mean telomere lengths of 
CD4+ T cells was shorter in STEMI patients than in healthy controls indicating cellular ageing. 
Interestingly, there was also a selective depletion of CD4+CCR7+ T cells during the first 30 
minutes after reperfusion. However, this population started to increase between the 30 minutes 
to the 2-hour time point. Thus, the expression of CD57+ and depletion of CCR7+ cells represent 
changes in the CD4+ T cell compartment due to myocardial infarction and reperfusion injury. 
Damas et al., in 2007 also showed that in patients with stable and unstable angina pectoris, 
there was a significant drop in CD4+CCR7+ T cells compared to healthy controls. This drop in 
CD4+ also coincided with the increase in serum levels of CCL19 and CCL21, both of which 
are ligands for CCR7.  
ApoE-/- mice with advanced atherosclerotic lesions showed increased levels of CCL19, CCL21 
and CCR7 expression within the atherosclerotic plaques. In addition, patients undergoing 
carotid endarterectomy also showed increased levels of CCL19, CCL21 and increased 
expression of CCR7 in the atherosclerotic lesions, which strongly indicate the homing of 
CCR7+ T cells in the plaque regions. Carotid endarterectomy is a surgical procedure designed 
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to remove fatty acid deposits from the carotid arteries that supply blood to the head and neck 
regions in patients suffering from carotid artery stenosis, one of the main reasons for the 
occurrence of ischemic stroke (National health service, 2018). The strong role CCR7 plays in 
the exacerbation of atherosclerosis was studied by Luchtefeld et al., in 2010 in great detail. A 
cross of mice lacking the low-density lipoprotein receptor (Ldlr-/-) and CCR7 was fed with a 
high cholesterol diet. It was found that Ldlr-/- CCR7- mice showed greater than 50 percent 
decrease in atherosclerotic lesion size compared to the lesion size in Ldlr-/- mice. The drop in 
lesion size was also accompanied by a significant decrease in the release of IFN-γ in Ldlr-/- 
CCR7- mice compared to Ldlr-/- mice. Thus, these results suggest that CCR7 mediated 
migration of T cells into the myocardium or atherosclerotic lesions leads to the exacerbation 
of heart disease.   
Low circulating lymphocyte counts in STEMI patients after PPCI was associated with 
mortality. 90 minutes after PPCI-mediated reperfusion, effector memory and terminally 
differentiated effector memory T cells (both CD4+ and CD8+) showed a larger drop in 
percentages than naïve and central memory T cells. The drop in effector T cell and effector 
memory (TEMRA) correlated with level of microvascular obstruction (MVO). Furthermore, the 
level of Fractalkine receptor CX3CR1 correlated with the drop in T cell counts. Serum 
fractalkine levels were highest at 90-minute time point which coincided with the loss of T cells 
from the myocardium. Thus, it is also suggested that fractalkine levels might play a vital role 
in the level of microvascular obstruction (MVO) (Boag et al., 2015). 
1.8 Ageing and Immune senescence is rapid in CMV seropositive patients 
 
The telomeres are DNA-protein complexes present in the ends of chromosomes that prevent 
the ends of chromosomes from recombination and degradation. Telomeres are tandem repeats 
of TTAGGG sequences. Telomere length shortens with each cell division owing to the inability 
of the DNA polymerase to replicate the 5’ end of the strand. Thus, the telomeres are considered 
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molecular clocks in ageing (Blasco, 2005). Immune senescence is the age-related dysfunction 
of the immune system that leads to the decrease in the naïve T cell population and a decrease 
in the range and functions of the T cell subsets thereby leading to impaired ability of the 
immune system in the elderly to mount effective defenses against pathogens (Pawelec et al., 
2009).  
1.8.1 A primer on Cytomegalovirus 
 
Cytomegalovirus (CMV) is a ubiquitous β-type 5 human herpes virus. CMV is the largest 
member of the human herpes virus family. The double stranded DNA of CMV is enclosed by 
protein-rich tegument matrix, which is itself enveloped by a lipid bilayer. The infection causing 
genes of CMV are located in the tegument matrix (Crough & Khanna. 2009). The 
seroprevalence of CMV in Asia and Africa is considered 100 %, whereas in Europe, the 
seroprevalence is approximately 80% (Rosa & Diamond, 2012). The main modes of CMV 
transmission through individuals are sexual contact, placental transfer, solid organ 
transplantation and stem cell transplant. After CMV enters the host, it establishes lifelong 
latency in an immunocompetent individual. CMV establishes latency through latency genes 
before proceeding to activate genes that cause infection. The conversion from latency mode to 
infection mode occurs due to inflammation, stress, and other infections (Crough & Khanna, 
2009). CMV establishes latency due to the suppression of lytic genes such as the immediate 
early (IE) genes. This results in the lack of production of infectious viral particles and viral 
gene expression is primarily focussed on the expression of latency genes (Poole et al., 2014). 
It is widely known that active CMV infection results in the modulation of numerous cell 
activities such as transcription, translation and immune surveillance, however, it is interesting 
to note that CMV latency also elicits a host of beneficial cell activities such as metabolism, cell 
signalling, transcription and translation (Poole & Sinclair, 2015). Mason et al., in 2012 
screened cell culture of supernatants of CD34+ progenitor cells infected with Merlin, a clinical 
42 
 
CMV strain, as well an UV-inactivated version of Merlin to account for changes resulting from 
viral binding. The authors identified a significant increase in both CCL8 and CCL2 during the 
latent infection of CD34+ cells compared to UV-inactivated infection of CD34+ cells. The 
increased expression of CCL8 induced the migration and recruitment of CD4+ T cells via CCR5 
and CCR3. There was also no observable migration of NK cells, CD8+ T cells and B cells. 
Although, the latent infection caused the migration of CD4+ T cells, latently infected CD34+ 
progenitor cells also secreted cellular IL-10 and TGF-β which causes the dampening the 
immune activity of CD4+ T cells. These results indicate how the CMV maintains latency 
despite being under immune surveillance.    
Transmission of CMV from mother to child occurs via three routes, 1. intrauterine 
transmission, 2. intrapartum transmission and 3. post-natal transmission. Intrauterine 
transmission of CMV comprises either the direct entry of CMV into the placenta or amniotic 
fluid. It could also occur due to the leucocyte transmigration into the placenta. Intrapartum 
transmission is caused by viral shedding by CMV seropositive mothers during delivery. Post-
natal transmission of virus is the entry of CMV into neonates through breast milk feeding 
(Joseph et al., 2018). Most neonates (85-90 percent) have asymptotic infection whereas the 
remaining 10-15 percent of neonates show clinical manifestations. Some of the clinical 
manifestations are jaundice, petechial rash, hepatosplenomegaly, microcephaly, atopic atrophy 
and lethargy (Boppana et al., 2013).  Congenital CMV infection poses a significant global 
burden where children are born with, or develop over a period of time, permanent disabilities 
such as hearing loss, cerebral palsy and loss of eyesight. The prevalence of congenital CMV is 
much higher in developing countries than it is in developed countries (Fowler & Boppana, 
2018). Detection of CMV in neonates through rapid culture or PCR is thus imperative to 
prevent long term disability (James & Kimberlin, 2016). The prevention of CMV infection 
using CMV hyperimmune serum has been suggested. Pregnant women were given 
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hyperimmune globulin every 4 weeks till 36 weeks or until the detection of CMV in the 
amniotic fluid. A randomized double-blind study involving placebo controls showed no 
statistically significant difference between the placebo group and the group comprising of 
pregnant women (Revello et al., 2014). The current accepted treatment for congenital CMV 
infection is the administration of valganciclovir. Kimberlin et al., in 2015 compared the 
efficacy in the use of valganciclovir for 6 weeks and for 6 months. Although both groups did 
not differ in the hearing levels in neonates at the 2-year period, the neonates belonging in the 
6-month groups showed better neurological development as evidenced by better scores on the 
Bayley scales of toddler and infant development. 
CMV also causes significant mortality and morbidity in solid organ transplantation (SOT) in 
immunocompromised recipients. Lytic CMV replication occurs either due to latent CMV 
infection or due to de novo primary CMV infection (Han, 2017). The CMV seronegative 
patients who receive organs from CMV seropositive donors face the highest risk for CMV 
disease. Other major risk factors involved in solid organ transplantation are history of graft 
treatment as well as type of immunomodulatory drugs administered (Beam & Razonable, 
2012). The Burden of CMV infection in D+R- SOT patients could be reduced by anti-viral 
prophylaxis (Han 2017). In the absence of adequate anti-CMV immunity in D+R- SOT patients, 
the risk of late onset CMV disease is highly increased. Limaye et al., in 2016 tested the efficacy 
of plasma IL-10 levels in determining the propensity of SOT patients to develop late onset 
CMV disease. CMV specific T cell responses were detectable during VALGAN prophylaxis 
when the IL-10 levels were undetectable. Thus, the extension of VALGAN administration 
beyond the initial treatment period could delay or reduce the incidence of the late onset CMV 
disease in SOT patients. Another important factor that could influence plasma IL-10 could be 
the presence of anti-graft rejection immune supressing drugs. So, SOT patients who are forced 
to consume immune supressing drugs may be more prone to late onset CMV disease. 
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Apart from all the negative aspects of CMV infection in SOT, it is also important to note there 
might be beneficial effects of CMV infections. Litjens et al., (2018) recently published an 
excellent review on the potential benefits of CMV infection due to transplantation. In a cohort 
of allogeneic hematopoietic stem cell transplantation (HCT) patients with acute myeloid 
leukaemia (AML), it was found that pre-emptive anti-CMV therapy showed a significantly 
reduced risk for the AML to relapse within 10 years after transplantation. However, this 
protection correlated only for AML and not for acute lymphoblastic leukaemia and chronic 
myeloid leukaemia.        
1.8.2 Role of CMV in immunosenescence 
 
Immunosenescence or ageing of the immune system is characterized by loss of proper 
functioning of immune system, chronic inflammation and autoimmunity, all of which are 
associated with comorbidities and mortality (Müller et al., 2017). It is suggested that altered 
transcription and altered epigenetics are major influences in immunosenescence. CD28- 
memory T cells had elevated levels of T-bet and EOMES than CD28+ memory T cells. In 
addition, epigenetic mechanisms such as DNA methylation, modifications to histone proteins, 
and structural changes in chromatin and microRNA regulation are thought to play a vital role 
in the alterations to T cell repertoire. Furthermore, nutrition, environmental factors and lifestyle 
too play a role in accelerating or decelerating immunosenescence (Tu & Rao, 2016). However, 
in this thesis, the focus will be on the role of CMV in immunosenescence. Koch research group 
in 2008 used multicolour flow cytometric analysis to identify changes in T cell homeostasis in 
younger and elderly cohort. For the CD4+ T cell compartment, the loss of naïve CD4+ T cells 
in elderly populations did not show a significant change compared to the younger cohort, 
furthermore, there was an increase in proportion of CD4+ central memory T cells in the elderly 
population. Whereas for CD8+ T cell compartment, there was a significant drop in naïve cell 
count but a significant gain in terminally differentiated effector memory count (TEMRA) in the 
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elderly population. This suggested that the drop in naïve CD8+ count was accompanied by the 
increase in terminally differentiated effector memory CD8+ T cell count. This research group, 
however, did not consider the CMV serostatus of these individuals and did not include the 
impact of active CMV on the changes to the CD8+ T cell compartment.  The drop in naïve 
CD8+ T cell count and increase in CD8+ TEMRA T cell count is a strong indicator of 
immunosenescence. Weinberger et al., in 2007 showed that although percentages of naïve and 
memory CD8+ T cells dropped and percentages of CD28-CD8+ effector T cells in elderly CMV 
seropositive individuals were higher than in elderly CMV seronegative individuals, CD28-
CD8+ effector T cells negatively correlate with CD28+CD45RA+ naïve and CD28+CD45RA- 
memory cells irrespective of CMV serostatus. This indicated ageing was the primary cause of 
the changes in the T cell pool. With respect to CMV seropositive CD4+ T cells, the effector 
cells negatively correlated with memory cells but not naïve cells. Also, in the elderly cohort 
with latent CMV presence, the CD8+ effector cells positively and negatively correlated with 
CD4+ effector and memory cells, respectively. Thus, they suggested that the presence of CMV 
induces changes in both CD4+ and CD8+ T cell compartment (Weinberger et al., 2007).  
Consistent with Weinberger and Koch research group, Wertheimer et al., in 2014 showed that, 
in CMV seronegative healthy individuals, naïve CD8+ T cell drop was accompanied by the 
increase in the effector memory and central memory CD8+ T cells with age and central memory 
CD4+ T cells also showed a slight significance increase in cell numbers with age. However, 
apart from percentages of T cells, absolute numbers of T cells were also considered unlike in 
the Koch and Weinberger research group.  Absolute numbers of naïve, central memory and 
effector memory CD4+ T cells in CMV seronegative individuals did not change with age. 
Furthermore, absolute numbers of naïve CD8+ T cells showed a steep drop whereas numbers 
of effector memory (EM) and central memory (CM) CD8+ T cells showed no change or 
decreased minimally. In CMV seropositive healthy individuals, the drop in absolute numbers 
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of naïve CD8+ T cells was steeper but not significantly than in CMV seronegative healthy 
individuals. Absolute counts of CD4+ EM and CD8+ EM cells was significantly higher in CMV 
seropositive individuals than in CMV seronegative individuals. Thus, this research group 
attributed the loss of naïve CD8+ T cells to ageing and the increase in EM CD8+ and CD4+ T 
cells to CMV seropositivity (possibly due to persistent activation of CMV). Thus, this study 
concluded that ageing and CMV seropositivity jointly influence the changes in the T cell 
compartment.  Turner et al., (2014) showed that CMV seropositive young healthy individuals 
(Mean age: 21; BMI:22.7) show initial signs of Immunosenescence. CMV seropositive healthy 
individuals had significantly higher lymphocyte count and lower CD4/CD8 ratio than CMV 
seronegative healthy individuals. Among lymphocytes, effector memory and late differentiated 
in both CD4+ and CD8+ T cells were higher in CMV seropositive individuals. In addition to 
differences in lymphocyte counts, plasma levels of IL-6 were also higher in CMV seropositive 
individuals. However, Turner and Wertheimer groups did not study the effects of CMV on 
telomere lengths of T cells in their study cohort. Van de Berg research group in 2010 studied 
the changes in telomere lengths of T cell populations in CMV seropositive renal transplant 
patients. The drop in naïve CD27+CD8+ T cell count was accompanied by the increase in 
CD8+CD27- differentiated T cells in CMV seronegative transplant patients receiving renal 
transplants from CMV seropositive donors (Primary CMV infection). The lymphocyte pool 
did not differ in CMV seronegative patients receiving renal transplants from CMV seronegative 
donors. In CMV seropositive renal transplant patients, the mean telomere lengths of 
lymphocytes significantly dropped after primary CMV infections whereas the drop in telomere 
length of lymphocytes in CMV seronegative renal transplant patients did not achieve 
significance.  Telomere length of naïve CD27+CD8+ T cells was longer than the telomere length 
of CD8+CD27- differentiated T cells. Even among the healthy cohort, telomere length of CMV 
seropositive individuals were shorter than CMV seronegative individuals and the drop in 
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telomere length in CMV seropositive individuals positively correlated with differentiated CD4+ 
and CD8+ T cells. Thus, these studies clearly indicate that in ageing, the presence of CMV 
cause the decrease in telomere length and changes in the circulating T cell pool.  
The role of CMV-induced immunosenescence in CHD is profound. A study found that 
telomere lengths of monocytes, granulocytes, CD4+ T cells and CD19+ B cells were 
approximately 500 base pairs shorter in CHD patients than in age-matched healthy controls 
(Spyridopoulos et al., 2009). However, the telomere length of CD8+ T cells, more specifically, 
CD28-CD8+ T cells in CHD patients was 1000bp shorter than in age-matched controls; also, 
telomere lengths of CD8+CD27-CD28-CD45RA+ T cells correlated with left ventricular 
function (ejection fraction) in CHD patients, suggesting a link between CD8+ T cells and 
myocardial dysfunction in CHD patients or high-risk individuals. Moreover, only telomere 
lengths of CD8+CD28- T cells in CMV seropositive healthy controls was higher than in CMV 
seropositive CHD patients. Thus, continued CMV-specific immune response in CHD patients 
causes profound changes to the telomere lengths of lymphoid cell population, especially, the 
CD8+ T cells (Spyridopoulos et al., 2009). Analysis of 749 peripheral blood samples by 
Spyridopoulos research group in 2016, of octogenarians revealed interesting results. CMV 
seropositive participants were more prone to ischemic heart disease. There were also profound 
changes to the T cell pool: CD4/CD8 ratio was lower with the increased presence of CD4 and 
CD8 TEMRA cells. There was a significant association between CMV seropositivity and 
cardiovascular mortality in participant cohort. In addition, CD4+CD45RO+CD28-CD27-cells 
(senescent-like) and CD8+CD27+ (non-senescent) cells were also associated with 
cardiovascular mortality. Consistent with Spyridopoulos et al., 2016; in elderly participants 
(age above 65), median life expectancy in CMV seropositive population was also lower than 
in CMV seronegative population CMV seropositivity was associated with 40% mortality.  In 
addition, cardiovascular death was the most common cause of mortality among CMV 
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seropositive participants and mortality from other causes did not correlate with CMV 
seropositivity. Thus, CMV seropositivity in individuals above the age of 65 is strongly 
associated with cardiovascular mortality (Savva et al., 2013). 
In conclusion, studies have shown that the homing of immune cells, particularly EM T cells, 
to the damaged myocardium, contribute to injury during, and following, myocardial infarction 
and reperfusion. CMV positivity enhances the numbers of EM T cells and induces their chronic 
stimulation and proliferation leading to premature aging of the cells (immune senescence) 
together with immune dysregulation in the form of chronic inflammation through cytokine 
secretion.  
1.9 Chronic Fatigue Syndrome (CFS) 
 
Early research into CFS was typified by the presence of numerous definitions for CFS used by 
research groups, the use of incorrect medical tests to diagnose CFS patients, and the lack of 
subgrouping for cohort populations, making it difficult for comparative studies to be 
conducted. Thus, Fukuda et al., in 1994 designed a conceptual framework that eliminated all 
the above-mentioned negatives. According to the framework, only persistent fatigue lasting 
more than 6 months would be classified as ‘chronic fatigue’ and diagnosis of CFS would only 
be made after a comprehensive mental, physical and laboratory examination. Patients with 
depression-related conditions such as bi-polar disorder, schizophrenia, alcohol and or drug 
abuse, and medical conditions that have chronic fatigue as a major symptom, such as untreated 
hyperthyroidism, can be classified as having chronic fatigue. However, patients with conditions 
such as fibromyalgia and anxiety disorders that cannot be confirmed by laboratory tests, or any 
condition for which there is definitive treatment options, require further diagnosis to be 
classified as having chronic fatigue. Severe fatigue is a symptom that is associated with a wide 
variety of disorders such as sleep disorders, infections, immunopathology, autoimmunity, 
cancer, and endocrine and metabolic disorders. CFS may be associated with pathogenic 
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signalling pathways that converge at the neurological axis (Jones et al., 2009) and is most often 
associated with chronic inflammation. In most cases fatigue is idiopathic i.e. the cause of 
fatigue in patients with CFS/ME is unknown and cannot be identified by conventional lab tests 
(Holgate et al., 2011). Extensive research points to CFS as a condition that occurs after an 
infection by a pathogen, thus testing immune responses of CFS patients against a wide range 
of implicated pathogens such as Influenza, Cytomegalovirus, Epstein-Barr virus, Human 
herpes virus 6, 7, and mycoplasma is warranted (Cameron et al., 2010). Chapenko et al., in 
2012 used the 1994 CDC criteria to diagnose CFS patients and used the fatigue severity scale 
(FSS) to measure fatigue in patients. They measured the frequency of HHV-6, HHV-7 and 
parvovirus B19 viral transcripts in CFS patients. CFS patients and healthy controls had a high 
seroprevalence as well as comparable levels of HHV-6 and B19 IgG and IgM antibodies. 
However, there was a significant increase in active HH6, HHV-7 and B19 viral infection in 
CFS patients compared to healthy controls. In disagreement with Chapenko group, Oakes et 
al., (2013) found using qPCR that viral copy numbers of HHV-6 and HHV-7 did not differ 
between healthy controls and chronic fatigue syndrome patients. Furthermore, they also 
showed that the viral copy numbers of human endogenous retroviruses (HERV) did not differ 
between the two groups. Thus, analysis of viral influence in CFS patients revealed contrasting 
results. Treatment of patients with valacyclovir and valganciclovir, in response to elevated 
serum levels of EBV, HHV 6, 7 and CMV, led to improvements related to immunologic and 
neurological functioning. The use of Isoprinosine, an immunostimulatory drug, increased NK 
cell activity and increased levels of CD4+ T cells. In addition, the clinical trial involving the 
use of Rintatolimod led to the production of type 1 interferon and led to the reduction of fatigue 
symptoms in patients. Thus, the successful action of these drugs indicates a role of microbial 
pathogens in contributing chronic fatigue in patients. However, the action of acyclovir had no 
effect on CFS patients. Moreover, a research report by the Reeves research group in 2000 and 
50 
 
Burbelo et al., in 2012 identified no associations between viral infections and CFS. Therefore, 
it is possible that the presence and active replication of EBV, HHV 6, 7 and CMV will be due 
to underlying conditions rather than active involvement with CFS. The use of different disease 
classifications and use of different analytical methods might also play a vital role in the 
contrasting results. There is also emerging evidence to suggest CFS might have an autoimmune 
component. Rituximab is usually used to treat rheumatoid arthritis, but it was used by Fluge 
group to show disturbances in the immune system of CFS patients. Navaneetharaja, et al., 2016 
suggested that intestinal microbiota might be a trigger for CFS and identification of biomarkers 
would add to the understanding of CFS as well as help in generating therapeutics to treat 
patients through alteration of this microbiota. An intestinal dysfunction is supported by the 
research by Fremont et al., (2013) who used high throughput 16S rRNA sequencing to test for 
changes in intestinal microbiota in CFS patients from Belgium and Norway. It was found that 
the levels of genera Lactonifactor and Asaccharobacter were significantly higher and lower 
respectively in Belgian CFS patients. Genera Roseburia and Holdemania showed a significant 
increase in Norwegian CFS patients whereas genera Bacteroides, Alistipes, Barnesiella, 
Parabacteroides and Prevotella were significantly reduced when compared to levels in 
Norwegian controls. 
The innate arm of the immune system is non-specific and elicits the same magnitude of 
response when encountered with a second bout of infection as the first, whereas the adaptive 
arm of the immune system is highly specific and elicits a stronger immune response when the 
same pathogen is encountered again. Innate immune cells such as macrophages express TLRs 
which recognize common molecules on invading pathogens and release an assortment of 
cytokines which attracts other immune cells to the site of infection. In contrast, immune cells 
of adaptive immune system such as T cells have cell surface T cell receptors that are highly 
specific for a complementary molecule of a pathogen. The T cells of the Th1 phenotype release 
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IFN-γ to combat intracellular pathogens, Th2 cells produce cytokines like IL-4, IL-5 to combat 
worms, and Th17 cells produce IL-17 to fight extracellular pathogens. Once the pathogen is 
neutralized, the inflammation is resolved by regulatory T cells (Tregs) which produce IL-10 and 
TGF-β to dampen the immune response. In a normally functional immune system, a 
homeostatic balance is maintained between inflammation-causing and inflammation-resolving 
immune cells. Chronic inflammation is caused by an over-reactive immune system due to the 
presence of persistent pathogens like CMV, which is also associated with immune senescence, 
accelerated immune ageing and increased mortality among the elderly population (Macaulay 
et al., 2013).  
Limited studies have attempted to define the immunology behind CFS that could throw a light 
on the mechanism of disease and act as biomarkers and therapeutic targets (Lorusso et al., 
2009; Klimas et al., (2012). From a wide variety of published results, consistent markers 
observed have been increased inflammatory cytokines such as IFN-γ, TNF-α, IL-1, IL-12 in 
blood (Kerr et al., 2008) and serum, and upregulation of related receptors and signalling 
pathway molecules (NF-κB, JAK-STAT) which strongly suggest increased inflammation in 
individuals with CFS/ME. Persistent viruses such as EBV and CMV are also thought to play 
an important role in the exacerbation of fatigue in patients. Studies have also suggested 
increased Th2 responses in CFS patients (Skowera et al., 2004). CFS patients who are 
seropositive for Epstein-Barr virus had lower levels of NKH1 T3- cells compared to healthy 
controls. Consequently, NK cells of CFS patients also showed reduced cytotoxic activity. 
Infusion of recombinant IL-2 increased the cytotoxic activity of NK cells against K562 cells; 
however, despite the infusion of IL-2, NK cells of patients could not lyse EBV infected B cells 
(Caligiuri et al., 1987). There is also a suggestion that CFS may be an autoimmune disease 
(Elfaitouri et al., 2013), where the immune system attacks healthy tissue. Some studies have 
researched targeted therapies for CFS including the use of antivirals (Lerner et al., 2007) and 
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B cell-depleting antibodies [rituximab] (Fluge et al., 2011). Thus, a more comprehensive 
investigation into the immunology behind CFS will expand our knowledge and help us 
understand the pathology of chronic fatigue.   
Nakatomi et al in 2014 showed through positron emission tomography (PET) scanning that 
11C-(R) -(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carboxamide (11C-
(R)-PK11195) bound to translocator protein (TSPO) 45% to 199% higher in CFS than in 
healthy controls. 11C-(R)-PK11195 is a ligand for TSPO. The presence of higher percentage 
of TSPO suggests activated astrocytes, microglia and glial cells indicating neuro-inflammation. 
The non-displaceable binding potential values (BPND) (affinity of a ligand to its receptor) 
values of this motif positively correlated with pain score, cognitive impairment score and 
depression score, thus strongly supporting a neuronal link to CFS. However, one drawback of 
this study was the small sample size, only 9 CFS patients and 10 healthy controls were used. 
As for treatment options for CFS, cognitive behaviour therapy (CBT) and graded exercise 
therapy (GET) are more likely to lead to recovery from CFS than specialist medical care alone 
(SMC) and adaptive pacing therapy (APT) (White et al., 2013). Thus, a more comprehensive 
research approach encompassing both the immune system and nervous system must be taken 
to understand CFS. 
1.9.1 Characterization of CFS:  Fatigue Impact Scale (FIS) 
 
The fatigue impact scale (FIS) was created to measure a patient’s perception of functional 
limitations that they attribute to the symptoms of fatigue. The foundation of the FIS is laid on 
two pillars, questionnaires and interviews. The FIS is determined on the cognitive, physical 
and psychosocial functioning of patients. Along with fatigue impact scale, the sickness impact 
profile (SIP) was also generated to decipher the link between chronic fatigue and general 
health. One of the most important findings of the study by Fisk et al., 1994 was that the FIS 
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was able to clearly distinguish between CFS patients and multiple sclerosis (MS) patients 
although fatigue is a common factor in both ailments. 
Flachenecker et al., (2002) concluded that fatigue was influenced by numerous factors and felt 
the necessity for developing a clear definition for CFS as well as develop more reliable tools 
to conclusively measure fatigue in patients. Fatigue severity scale (FSS) and modified fatigue 
impact scale (MFIS) were better tools to measure fatigue than the visual analog scale (VAS) 
or multiple sclerosis specific-FSS. FSS and MFIS, nevertheless had wide variations amongst 
themselves thus necessitating the requirement for a better understanding of fatigue in patients 
with MS so that wide variations could be reduced to a minimum. This process could also help 
measure accurate fatigue levels in patients with chronic fatigue. Tellez et al., (2005) showed 
that cognitive and psychosocial aspects of fatigue were better measured by MFIS than FSS. 
The physical subscale of MFIS correlated strongly with FSS and the linear regression analysis 
of the physical subscale of MFIS was the only independent predictor of the FSS. Thus, the 
authors suggested that while the physical subscale of MFIS correlated with FSS, the cognitive 
and psychosocial aspects of fatigue are better analysed by MFIS.  
Despite the establishment of numerous fatigue scales, the FIS still remains invaluable, robust 
and widely used among researchers and doctors (Newton & Frith, 2010). 
1.9.2 Innate & Adaptive Immune Responses in CFS 
 
1.9.2.1 Innate Immune cells in CFS 
 
Hardcastle et al., (2015) conducted experiments that measured the activation markers CD80 
and CD86 on DCs but found no significant differences between healthy controls and patient 
cohorts. There were also no significant differences in the phagocytic potential determined by 
calculating the ‘respiratory burst’ of neutrophils and monocytes which did not differ between 
the healthy controls, moderately affected patient and severely affected patients. The expression 
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of lytic proteins such as perforin and granzyme B also showed no significant correlations 
between the participating groups. However, in a contrasting report, Brenu et al., (2010) 
reported reduced neutrophil function in CFS patients. The ‘respiratory burst’ of neutrophils 
was decreased in patients when compared to healthy controls. It was suggested that decrease 
in neutrophil functions was due to the increase in levels of apoptotic neutrophils which impair 
immune monitoring activities of neutrophils. It is, however, important to mention only 10 
patients and 10 healthy controls were used for this study. CD177, a cell surface molecule of 
neutrophils, used for migration into inflamed tissues, was reduced in patient samples compared 
to healthy controls which may indicate impaired migration of neutrophils to sites of infection 
or reduced CD177 expressing neutrophils in the periphery (Brenu et al., 2013). Thus, sub-par 
respiratory burst of neutrophils along with reduced CD177 expression seem to have a negative 
effect on CFS patients and so more research is required to understand the role of neutrophils in 
CFS patients. 
NK cells showed reduced cytotoxic capabilities in the CFS patient group compared to healthy 
controls (Brenu et al., 2013). Type I IFN is also known to activate NK cells (Siegal et al., 
1999). Reduced NK cytotoxicity in CFS patients occurs despite the possible increase in serum 
type I IFN-α level, indicating that other factors might contribute to the reduced NK cell 
cytotoxicity. Tregs are known to have immunomodulatory and immunosuppressive effects 
during acute or chronic infections and the increased cell percentages of Tregs in patients may 
explain the reduced NK cell cytotoxicity. It is interesting to note that while NK cell cytotoxicity 
was reduced, the NK degranulation levels remained high suggesting NK cells, despite being in 
an activated state, are not functionally able to combat pathogens, which might be due to NK 
cell anergy. Brenu et al., in 2010 once again demonstrated the changes in NK cell phenotype. 
CD56brightCD16- NK cells were lower in the patient cohort, and NK cells as a whole showed 
reduced cytotoxic potential in CFS patients. However, in a contrasting report, the Curriu 
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research group in 2013 reported that although NK cell percentages and cytotoxicity did not 
statistically differ between patients and healthy controls, the expression levels of activation 
markers CD69 and NKp46 in NK cells were higher and CD25 levels were lower for CFS 
patients when compared to healthy controls. 
Hardcastle et al., in 2015 compared the moderately and severely affected CFS patients for 
irregularities in immune function. NK cells showed increased expression levels of CD150 
(SLAM receptors) and NKp46 in moderately affected patients compared to severely affected 
patients. NKp46 is a member of the cytotoxicity activating receptor family of NK cells (Pessino 
et al., 1998). The low levels of expression of NKp46 in severely affected patients may be one 
of the factors that leads to low NK cytotoxicity levels. The paucity of SLAM expression in 
severely affected patients may indicate a lack of immune regulation, thus leading to immune 
dysregulation. 
1.9.2.2 Adaptive Immune system in CFS 
 
 Few comprehensive investigations into the role played by the innate and adaptive immune 
cells have been conducted in CFS. Plasmacytoid DC (pDCs) and immature B cells showed a 
decrease in cell numbers, and NK cells showed reduced cytotoxic capabilities in the CFS 
patient group compared to the healthy controls. Tregs and CD4
+CD73+CD39- T cells were 
elevated in the CFS patient group (Brenu et al., 2013). The higher expression of CD73 leads to 
the increase in adenosine levels which further increases the immune supressing capabilities of 
Tregs, thus dampening the pro-inflammatory immune responses (Kobie et al., 2006).  
Disturbances in T cell homeostasis were prevalent in CFS patients. The cell percentages of Tregs 
were elevated in CFS patients, while the proliferative potential of CD4+ T cells was lower in 
patients evidenced by the low expression of Ki67 marker. Also, the CD38 marker was reduced 
in the CD45RO+ memory T cell compartment. CD5 marker was highly expressed on patient 
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CD8+ T cells (Curriu et al., (2013). CD5 expression is associated with self-antigen tolerance 
of T cells whereby they are unable to mount an immune response to antigen in-vivo (Hawiger 
et al., 2004) thereby indicating CD8+ T cell anergy. 
The decrease in naïve or immature B cell numbers and increase in memory B cells in CFS 
patients suggests a lack of homeostatic balance in CFS patients that is similarly observed in 
patients with rheumatoid arthritis (Fekete et al., 2007) and patients with multiple sclerosis 
(Hartung & Keiseier, 2010). Thus, CFS may have an autoimmune component to pathogenesis.  
As previously mentioned, the research by Fluge et al., (2011) showed that depleting B cells 
using the anti-CD20 antibody rituximab improved clinical response of CFS patients. However, 
contrastingly, studies on B cell phenotypes and cell numbers by Curriu et al., (2013) showed 
that there were no significant changes in absolute B cell numbers within Transitional, Marginal 
zone and Plasma/ Plasmablast populations, as did Hardcastle et al., (2015) who reported no 
significant differences in B cell receptor levels and regulatory B cells levels (Bregs) between 
moderately and severely affected patients 
1.9.3 Cytokine Signatures in CFS 
 
Landi et al., in 2016, using patient serum samples approved from the “Solve ME/CFS 
biobank”, found significant differences in levels of cytokines and chemokines between the 
patients and healthy controls.  Levels of IL-6, IL-7, VEGF-A, CX3CL1 and CXCL9 all showed 
reductions in patient samples, whereas only levels of eotaxin-2 (CCL24) increased. Maes et 
al., (2012) used the fibromyalgia and chronic fatigue syndrome (FF) scale to measure fatigue 
in patients. The patient groups were ME/CFS and CF (patients with fatigue for more than 6 
months but not satisfying all diagnostic criteria as entailed by Fukuda et al., in 1994). Serum 
levels of IL-1, TNF-α, neopterin, lysozyme and PMN-elastase in ME/CFS were significantly 
higher than in CF patients and healthy controls. Hardcastle et al., (2015) found increased levels 
of IL-1β and RANTES in moderately affected patients while severely affected patients had 
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higher levels of IL-7, IL-8 and IFN-γ. No associations were found for VEGF, TNF-α, IL-2, IL-
4, IL-5, IL-10, IP-10, GM-CSF, IL-13, IL-17, IL-1ra, IL-6, IL-9, IL-12p70, FGF, eotaxin, G-
CSF and PDGF-BB. So, increase and decrease in serum cytokine and chemokine levels are due 
to the disturbances in the homeostasis of the immune system. Brenu et al., in 2012 conducted 
a longitudinal analysis of cytokine levels of 65 CFS patients at T0 (baseline), T6 (after 
6months) and T12 (after 12 months). The blood samples of test subjects were collected at the 
time of CFS diagnosis (T0) and at 6 months and 12 months after diagnosis. It was interesting 
to note that cytokine levels were different at different time points. IL-10, IFN-γ and TNF-α 
were significantly higher in CFS patients at T0, but at T6, there was a significant drop in IL-
10 and IL-17A levels in CFS patients. At T12 only IL-2 showed a significant increase in CFS 
patients. Thus, the increase and decrease in cytokine levels at different time points follow a 
pro-inflammatory trend. The drop in IL-10 levels from T0 to T6 showed a drop in anti-
inflammatory functioning whereas the increase in IL-2 at T12 pointed to a pro-inflammatory 
trend. Thus, to summarize, CFS patients show a significant increase in pro-inflammatory 
cytokines which suggests that CFS is characterized by chronic inflammation. 
Different research groups, using different fatigue scales to measure fatigue in patients, have 
found contrasting results when the immune measurements and the fatigue scale scores were 
checked for correlations. This was underlined in the research by Brenu et al., in 2013, who 
reported different levels of expression of NK killer immunoglobulin receptors and NKG2D in 
patients diagnosed by 1994 CDC (Centre for Disease Control) and ICC (International 
Consensus Criteria) CFS criteria. The ICC patients had higher KIR2DL1, KIR3DL1, NK2G2D 
and KIR2DL2. This complicates arriving at a definite immunological explanation to chronic 
fatigue. A consensus must be achieved to have a comprehensive yet universal fatigue scale 
scoring system to better define immunology of CFS patients. This might lead to therapeutic 
treatments at a much faster rate than the present scenario. 
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Overall conclusion to literature review 
 
Immune dysregulation, due in part to unresolved immune responses to persistent microbes such 
as CMV and EBV, are believed to be central to the immunopathology at the centre of 1. 
myocardial damage associated with reperfusion treatment for MI; and 2. cytokine-induced 
sickness behaviour which is a major part of CFS.  Hence this thesis examines both diseases for 
discernible differences in immune responses from healthy individuals, and how the magnitude 
of such responses associate with disease parameters.  
Hypothesis of this work 
 
The overall hypothesis of this work is that, in two disease states (MI+R & CFS), immune 
responses can be measured and characterised that are associated with the disease process with 
clinical parameters, or that can discern diseases for non-diseased state. 
Aims 
To identify immune characteristics that are indicative of disease and could enlighten disease 
aetiology and serve as disease biomarkers. 
Objectives 
1). Measure features of T cells, particularly reactivity against herpes viruses and other 
microbes, in patients undergoing MI+R or in patients with CFS. 
2). Look for relationships of immune measurements with disease parameters or compare 
responses between diseased and non-diseased groups. 
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2.0 CHAPTER TWO 
 
Materials & Methods 
 
2.1 Patient Cohort data in this thesis 
 
2.1.1 Myocardial Infarction patient group 
 
Professor Ioakim Spyridopoulos (MD) at the Institute of Genetic Medicine, Newcastle 
University and Dr. Stephen Boag (Newcastle University) recruited 59 patients with AMI for 
the study. Only patients with chest pain within 6 hours of ST-elevation myocardial infarction 
(STEMI) were included. Patients with chronic infection, autoimmune disorders, active 
infection and previous MI were excluded. Local NHS Health Research Authority Ethical 
committee (HRA) (REC 12/NE/0322) (Appendix) and the ethical committee of Northumbria 
University (RE-HLS-13-140219-53048a) approved this study. The attending physicians 
obtained written informed consent from the patients taking part in the study. Whole heparinized 
blood from the peripheral veins of patients was collected from the clinicians at the Freeman 
Hospital at 0 minutes (before reperfusion), 90 minutes after PPCI, 24 hours after PPCI, and at 
3 months after PPCI. 
2.1.2 Chronic Fatigue Syndrome patient group 
 
For the CFS project, Prof. Wan Fai Ng and Prof. Julia Newton of the Institute of Cellular 
Medicine, Newcastle University, and Newcastle Hospitals NHS Foundation Trust, Newcastle 
upon Tyne, UK provided access to their patients. Dr. Gavin Spickett, consultant Immunologist 
and Ms Victoria Hindmarsh, Phlebotomist at the Royal Victoria Infirmary, Newcastle Upon 
Tyne, UK recruited a total of 50 CFS patients for this study. The local NHS Research Ethics 
Committee (12/NE/0225) and ethical committee of Northumbria University (RE-HLS-13-
140219-53048a) approved the study. The Fukuda Criteria was used to diagnose all patients 
giving each patient a Fatigue Impact Score (FIS) value. Whole heparinized blood samples of 
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patients were obtained from the clinicians at the Clinics for Research and Service in Themed 
Assessments (CRESTA) clinic at the General Hospital, Newcastle upon Tyne and the Royal 
Victoria Infirmary (RVI). The non-fatigued healthy controls were recruited at the clinical site. 
Furthermore, it is important to mention that the number of healthy controls did not match with 
the CFS patient number, and healthy controls were not age and sex matched with CFS patients. 
2.2 Isolation of PBMC from Whole Blood & Cell counting 
All handling of blood and cells was carried out under sterile conditions within a laminar flow 
hood (Telstar Bio-II-A). 
 
Figure 2.1 PBMC isolation from whole blood. A. Heparinized blood is carefully layered onto 
Lymphoprep in the Leucosep tubes containing the filter (left), B. A typical image after separation of 
whole blood (right). a). plasma layer, b). Interface between the plasma layer and PBMC layer, c). PBMC 
layer, d). High grade polyethylene barrier, e). Lymphoprep, f). Granulocytes and Erythrocytes.  
Whole, heparinised blood was layered on to Lymphoprep (Axis-Shield, Norway), a density 
gradient medium, in Leucosep tubes (Greiner Bio-one, Stonehouse, UK) which contains a high-
grade polyethylene filter, which makes sure the blood and lymphoprep do not mix. The tubes 
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with the blood were spun in a Megafuge16 (Thermo scientific, Loughborough, UK) at 2100 
rpm for 12 minutes with brake at zero. It is important to put the brake at zero to make sure the 
Plasma and PBMCs layers do not mix after separation. The plasma obtained was stored at -
200C for future use. The PBMCs were washed with RPMI-1640 medium (R0) (Sigma, Dorset, 
UK) supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), L-glutamine (2mM) 
(Invitrogen, Paisley, UK) and centrifuged (Megafuge 16) at 1700 rpm for 10 minutes with the 
brake on. The PBMC pellet obtained was resuspended in freezing medium (90%FCS, 10% 
DMSO (Sigma Aldrich, Poole, UK) and stored at -800C in Mr Frosty to ensure slow freezing 
and then further stored at -1500C (Revco freezer, Thermo). For immediate use, cells were 
resuspended in R0 medium supplemented with 10% v/v heat inactivated Fetal Calf serum 
(BioSera, Sussex, UK) (i.e. R10 medium). 
2.2.1 Cell counting using CASY cell counter 
 
The PBMCs obtained from different study participants were counted using the CASY cell 
counter (Roche diagnostics, GmbH, Manheim, Germany). 10µl of cells was added to 10 ml of 
CASYTON solution in a CASY counting tube and placed in the machine containing the probe. 
After the appropriate command (‘START’) was initiated, the cell count was displayed on the 
cell counter display screen. All cell counts were adjusted to 8x106cells/ml to obtain optimal 
immune responses and maintain uniformity among samples (as previously established by Prof. 
Stephen Todryk). The CASY clean solution was used to clean the cell counter system before 
and after each patient sample run. The CASY counter was set up to measure cell size ranges 
for lymphocytes of 5.4µm-9.2µm and monocytes 9.3µm-20µm. The CASY count settings were 
validated by flow cytometric separation of lymphocytes and monocytes. 
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2.3 Ex-vivo and Cultured ELIspot 
 
Figure 2.2 The ELIspot assay principle. A.  Cytokine produced by PBMCs is bound to capture 
antibody and then to detector antibody.  The addition of alkaline phosphatase to the streptavidin-biotin-
labelled detector antibody follows. Addition of substrate reveals ‘spots’ B. Typical formation of spots 
depicting production of cytokines by T cells, each spot represents a T cell that has produced a cytokine. 
The size of the spot indicates the amount of cytokine produced by the cells. C. ELIspot plate with varied 
spot profile when PBMCs get stimulated with a wide variety of selected peptides and non-specific 
stimulants.   
Enzyme-linked Immunospot assay (ELIspot) was performed to measure T cell responses in 
study participants. Capture antibody (CAP-Ab) for the desired cytokine was diluted in 
bicarbonate buffer. 50µl of capture-antibody (CAP-Ab)-Bicarbonate buffer mixture was added 
to each well on the ELIspot plate (Millipore, Watford, UK), a day before the assay and 
incubated at 40C overnight. The ELIspot plates were then washed three times with sterile 
phosphate buffer saline (PBS) and blocked with R10 for 1-4 hours.  Cryopreserved PBMC 
were quickly thawed by gentle shaking of the cell vials in a 370C water bath, washed with R0 
solution and resuspended in R10 medium.  Fresh or cryopreserved PBMC were set up for ex-
vivo ELIspot at 8x106cells/ml. After the blocking solution was flicked off, 50µl of antigenic 
stimulus and 50µl of cells were added to the plates and incubated in the 5% CO2 incubator 
(Thermo Scientific). The length of incubation ranges from 18-20 hours for IFN-γ and 36-48 
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hours for other cytokines being tested (See table). ELIspot kits were purchased from Mabtech 
(Nacka, Sweden). After incubation, the contents of the plate were flicked off and the plate was 
washed 6 times with PBS. 50µl detector antibody-Biotin complex was added to each well and 
incubated for 1 hour at room temperature. The plates were then washed 6 times with PBS and 
50µl of streptavidin-alkaline phosphatase (SA-ALP) (Mabtech) (5µl in 5ml of PBS) was added 
and the plate, incubated for 1 hour at room temperature. The strong bond formation between 
biotin and streptavidin is crucial for successful plate development. The contents of the plates 
were once again flicked off and 50µl of the substrate solution (see appendix) was added to each 
well and incubated at room temperature for 5-15 minutes following which the plates were 
washed in tap water and allowed to dry. The ELIspot plates were then read using ELIspot plate 
reader.  
For cultured ELIspot, on day 0, PBMCs were placed in a 24 well corning plate. 500µl each of 
patient PBMC (1M/ml) along with 500µl of CD4+ and CD8+ specific CMV peptide pool and 
EBV CD4+ and CD8+ specific peptide pool in separate wells (1000µl in total for each sample). 
On day 3, 500µl of cell culture supernatant was carefully removed and 500µl of 100U/ml IL-2 
solution (previously optimized by Todryk et al., 2009) was added. The same process was then 
repeated on day 7. On day 9, the cells were gently scraped from the wells, washed 3 times with 
2ml of R0, resuspended in 1 ml of R10 in 5ml round bottomed polystyrene tubes. The tubes 
with cells were left overnight in a CO2 incubator at 37
0C. The lids on the tubes were not tightly 
closed to maintain neutral pH and proper air circulation. ELIspot plates were also coated and 
kept at 40C. On day 10 (next day), cells were counted using the CASY counter. The cells were 
washed with 2ml of R10, resuspended in 1ml of R10 and the ‘protocol for the ex-vivo ELIspot’ 
was followed, i.e. the CMV and EBV antigens were added to the ELIspot wells followed by 
the cells in the round bottomed polystyrene tubes. The ELIspot plates containing the mixture 
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of antigen and cells were incubated overnight in the CO2 incubator. The plates were then 
developed the following day.  
For the NK cell assay, PBMCs of healthy controls were stimulated with K562 cells (American 
type culture collection ATCC, Middlesex, UK) to measure baseline IFN-γ spot forming 
cells/M. 
2.3.1 ELIspot coating and detection antibody concentrations and setting up ELIspot 
reader  
 
Carbonate-bicarbonate buffer capsule was added to 100ml of sterile H2O. The sterile water was 
then taken in a BD Plastipak 10ml syringe attached to a sterile filter and collected in a 50ml 
falcon tube. The process was repeated until all the coating buffer was collected. The coating 
antibodies were then mixed with bicarbonate coating buffer and added to the ELIspot wells. 
The coating concentration for coating antibodies for IFN-γ and IL-5 was 1 in 100.  Coating 
concentration for IL-17 was 1 in 500. Coating concentration for IL-2 was 1 in 50. The detector 
antibody concentration for IFN-γ and IL-5 was 1 in 1000, 1 in 500 for IL-17 and 1 in 60 for 
IL-2. The detector antibody solution was prepared by mixing antibody with PBS. R10 medium 
only was used for the unstimulated background. The CMV and EBV viral antigenic stimuli 
used were pools of known CD8 epitope peptides (10 mg/ml) for CD8 responses and pools of 
known CD4 epitope peptides (10 mg/ml) plus viral lysates for CD4 responses. 
Phytohaemagglutinin (PHA, 5 µg/ml) and α-CD3 (1 in 200) were used as positive controls in 
all assays. Measurement of polyclonal secretion of IL-5, IL-17 and IL-2 was carried out using 
PHA as the stimulus, and ELISPOT reagents from Mabtech (IL-5), eBioscience (IL-17), or 
R&D Systems (IL-2). Data analysis involved the use of spot forming cells/106 PBMC (net 
antigen-stimulated spots minus medium). The Spots were read using ELIspot plate reader 
(Autoimmun Diagnostika, GmBh, Strassberg, Germany). The thresholds for spot counting 
were as follows: 
65 
 
  Intensity Size Gradient 
MIN 4 3 1 
MAX 255 500 90 
 
Emphasis: Tiny 
Speed of reading = maximum 
The protocol underwent minor changes for the CFS project. All experiments were performed 
with fresh PBMCs. Peptides and lysates belonging to a wide variety of pathogens were tested 
at optimal concentrations. Apart from PHA, other positive controls used were pokeweed 
mitogen (PWM), Phorbol 12-myristate 13-acetate with ionomycin (PMAi) and α-CD3. 
Measurement of polyclonal secretion of IL-5 and IL-17, but not IL-2 was carried out with α-
CD3 as the positive control. K562 cell line was cultured and used as a “stimulus” to test IFN-
γ production by NK cells. 
2.3.2 Calculation of ELIspot result 
 
The ELIspot plate was read and printout containing the ‘spot count’ was obtained. The spot 
counts for negative control (medium only) were subtracted from spots counts obtained from 
antigenic stimulus and positive controls (PWM, PMAi, PHA and α-CD3). The response to 
positive controls were used to determine initial experimental success. All cell counts were 
adjusted for 50µl of cells from the starting concentration of 8M/ml. To obtain spot forming 
cells/106, we divided 106 by the cell count for 50µl of cells added (4 Million). Thus, we 
obtained a multiplication factor of 2.5 for all stimulants except the positive controls. The 
multiplication factor for PWM, PHA and α-CD3 was 12.5 since only 10µl of cell were added 
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(for 50µl of cells, the multiplication factor is 2.5 and so for 10µl of cells, the multiplication 
factor would become 12.5(2.5 times 5)). The multiplication factor for PMAi was 62.5 since 
only 2µl of cell were added. The volume of cells added for positive controls were lower than 
other stimulants to obtain countable results and avoid obtaining a ‘blackout’ due to high levels 
of cytokine production by the cells. The number of spots obtained for each stimulant was 
multiplied with the respective multiplication factor to obtain spot forming cells /Million.   
2.4 Enzyme linked immunosorbent assay (ELISA) 
 
Figure 2.3 ELISA principle. Addition of Plasma or Serum to the ELISA plate coated with antigen allows 
the plasma to best tested for the presence of antibodies. The biotin-labelled detection antibody binds 
to immunoglobulin produced. Streptavidin-horse radish peroxidase (HRP) binds to biotin forming a 
strong bond. The addition of substrate leads to colour change, which is measured by ELISA plate reader 
at 490nm.                
2.4.1 EuroImmun ELISA 
 
Euroimmun ELISA kits were used to quantify the CMV (IgG, IgM) and EBV (IgG, IgA) 
specific antibody responses. The presence of IgG in patient sera indicated established immunity 
to CMV and EBV whereas IgM antibody titres indicate recent infection to CMV. The IgA 
antibody titre was used as an indicator of primary EBV infection.  The CMV antigen used in 
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ELISA was obtained from the inactivated cell lysates of MRC-5 cells infected with AD169 
strain of cytomegalovirus while the EBV antigen used was obtained from inactivated cell 
lysates of human B cells infected with P3HR1 strain of EBV. The results obtained from using 
these ELISA kits were used to determine the viral serology of the CFS patients. The 
Euroimmun plates are pre-coated with the antigen of interest. 100µl of calibrators along with 
patient samples and positive and negative controls were added to the well and incubated for 30 
minutes at room temperature. The plates were washed 3 times with the kit specified wash buffer 
(dilution to 1X from 10X is necessary).  100µL of the secondary antibody-enzyme conjugate 
was added and the plates incubated for 30 minutes at room temperature. The plates were then 
washed again. 100µl of substrate solution was added and incubated for 15 minutes at RT 
following which 100µL of stop solution was added to stop the reaction. The plates were finally 
read at 450nm to measure the absorbance (EL808, Bio-Tek Vermont, USA). 
2.4.2 Meso Scale Discovery (MSD) 
 
Figure 2.4 Principle of MSD with a typical profile of MULTI-SPOT MSD plate. Each well in the MSD 
plate consist of 10 spots with each spot coding for a specific cytokine. The analyte produced from serum 
samples of study participants is added to detector antibody labelled with electro-chemiluminescent 
SULPHO-TAG. Upon the application of electricity at the carbon electrodes, the tags emit light. The 
intensity of light is directly proportional to the amount of analyte produced.    
Quantification of cytokine levels in patient sera or cell culture supernatants was determined by 
a highly sensitive multiplex cytokine assay. MSD uses an electro-chemiluminescent principle, 
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which leads to the production of light when samples containing the analyte are stimulated with 
electricity. In MSD, carbon electrodes that have 10 times higher binding capacity to reagents 
than polystyrene are used. The detection antibody is conjugated with SULPHO tags, which are 
electro-chemiluminescent and produce light once electricity is applied at the carbon electrodes. 
The intensity of the light generated is directly proportional to the quantity of analyte in the cell 
culture supernatant. Unlike ELISA, MSD can quantify multiple analytes in a single well with 
low background. The labels used are non-radioactive, stable and bind to biological molecules 
with ease. Multiple excitation levels of labels allow increased sensitivity of the assay. Labelling 
reporters with ruthenium complexes (tris (bipyridine) ruthenium (II); [Ru (bipy) 3]2+), which 
are stimulated to produce photons when a small electrical charge is applied. The electrically 
excited complex emits light at 620 nm as it falls back to its resting state. Output is regenerated 
in the presence of TPA (Tripopylamine) which allows repeated triggering of the output signal, 
improving sensitivity. This stimulation and regeneration occurs at the solid–liquid interface at 
the binding surface of the MSD plate.   
We used three multispot 96 well plates and quantified the cytokines and chemokines of interest 
(see Appendix 7). A proinflammatory panel, a cytokine panel as well as a chemokine panel 
were tested. These three 10-plex panels were a part of the “V-PLEX human cytokine 30-Plex 
kit”. 1000µl of assay diluent (diluent 2) was added into the calibrator bottle. 100µl of the 
mixture was added to seven Eppendorf tubes each containing 300µl of assay diluent by 
doubling dilution. The proinflammatory panel and the cytokine panel had different calibrators 
and thus two standard curves were generated. The detector antibody solution was prepared 
using the diluent 3 solution in the MSD kit. 60µl of the desired detector antibody was added to 
2400µl of diluent solution to generate a 1X working solution from a 50X detector antibody 
solution. The wash buffer was prepared by adding 15ml of wash buffer in 285ml of distilled 
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water. 10ml of read buffer (4X) was added to 10ml of distilled water to generate a working 
solution of the read buffer (2X). 
Both plates were washed 3 times with 150µl of wash buffer and 50µl of doubly diluted 
calibrators and patient samples were added to the appropriate wells and sealed with the 
adhesive tape. The plates were then incubated with shaking for 2 hours at room temperature. 
The plates were washed again with 150µl of wash buffer and 25µl of detector antibody solution 
was added to each well. The plates were covered with an adhesive tape and incubated at room 
temperature for 2 hours with shaking. The plates were washed with 150µl of wash buffer and 
150µl of read buffer was added to the well and read on the MSD plate reader at 620nm (Meso 
Scale Discovery, Rockville, MD, USA). The concentration (ng/ml) of cytokines in the patient 
samples was calculated using the standard curve. 
2.5 Flow Cytometry 
 
All FACS analysis was performed on an 8 colour FACS Canto II flow cytometer with FACS 
Diva software. A minimum of 10,000 events for a population of interest were recorded for each 
sample. The 8 fluorochromes used for the experiments are as follows: FITC, PE, PerCP-Cy5.5, 
PE-Cy-7, APC, APC-Cy7, BV421 and BV510. Further details on the fluorochromes are 
furnished in Table 2.5. 
Cell surface markers on PBMCs that are indicative of infection, antigen-specific responses, 
immune senescence and regulation were determined by flow cytometry. A panel containing 
antibodies against a wide range of cell surface markers specific for T cells, NK cells, Treg and 
B cells bound to fluorochromes was used to stain the PBMCs, which were then analysed using 
the flow cytometer. 
Cryopreserved patient PBMCs were thawed and 300µl of 1x106 cells were washed with PBS 
and the supernatant poured off. The master mix antibody for FACS was made in an Eppendorf 
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tube (2µl Ab/sample +50µl brilliant stain buffer/sample). 66µl of the master mix was added to 
designate FACS tubes, 50 µl of cells was also added, and tubes kept at 4oC for 30 minutes in 
the dark. 2ml of PBS was then added to each FACS tube and centrifuged at 1500 revolutions 
per minute (RPM) for 5 minutes and cells resuspended in 300 µl of PBS and acquired by the 
Flow cytometer and the results were analysed. The panel of markers tested for the MI and CFS 
project are described in table 2.2 and table 2.3. Measurement of CMV specific CD8+ T cells in 
eight patient PBMCs were done by tetramer analysis. HLA typing database (performed by our 
research collaborators) of patient cohort were used to identify the specific HLA typing for each 
patient sample. HLA type A*0101, A*0201 and A*0301 were used. 
2.5.1 Setting up the Flow Cytometer 
 
FACS tubes were labelled for each fluorochrome to be tested and 2µl of each antibody was 
added to the appropriate FACS tube. Only negative compensation beads were added to the tube 
marked ‘negative control’. To optimize compensation, one drop of negative compensation 
beads and one drop of anti-mouse Ig, κ positive compensation beads (BDTM CompBeads, BD 
Biosciences, Oxford, UK) was added to each tube. This was done to help distinguish positive 
and negative background for analysis of data. The BDTM CompBeads anti-mouse Ig κ particles 
bind to κ light chain Ig whilst negative compensation beads do not bind to antibodies. Tubes 
were vortexed and incubated for 15 minutes in the dark at RT or incubated for 30 minutes at 
40C. 2ml of PBS was then added to each tube and the tubes were centrifuged at 1500rpm for 5 
minutes. The supernatants from all tubes were discarded and the beads were re-suspended in 
300µl of PBS. The beads were then acquired on BD FACScantoTM II Flow cytometer (BD 
Biosciences, Oxford, UK), using automated compensation program, which is a part of the BD 
FACSDivaTM software to measure the spectral overlap. The gating strategy used for the CFS 
project is shown in detail in section 4.7 of chapter 4). 
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2.5.2 Tetramer analysis of patient PBMCs 
 
HLA typing of patients were carried out by NHS blood and transplant, Newcastle upon Tyne 
and the HLA typing results were obtained from our research collaborators at Newcastle 
University. CMV-specific T cells were identified in PBMCs samples using a CMV tetramer 
kit (Immudex, Denmark). The kit consisted of 8 CMV-specific tetramers that were conjugated 
to PE. The alleles used for main sub-group-B were A*0101, A*0201, A*0301, A*2402, 
B*0702, B*0801 and B*3501. Before staining process with tetramers, PBMCs were thawed 
quickly in a water bath at 370C for 1-2 minutes. PBMC samples were then washed twice in a 
PBS buffer containing 5% fetal calf serum (PBS-5 % FCS). The cells were then resuspended 
in PBS-5 % FCS. The viability of Vi-CELL Cell Viability Analyser (Beckman Coulter). 1x106 
cells were resuspended in a total volume of 50μl PBS/5%FBS and incubated with 10μl 
appropriate MHC dextramer in the dark at room temperature. After a 10-minute incubation, 
appropriate amounts of CD3-FITC, CD27-APC, CD8-APC-H7, CD45RA-PacificBlue 
monoclonal antibodies were added to the sample and incubated for at least 20 minutes at room 
temperature. Finally, cells were washed twice with PBS/5%FBS and assessed by 
multiparametric FCS (BD FACS Canto II). The same procedure was carried out for cohort C. 
the alleles used for cohort C were A*0101, A*0201 and A*0301. The monoclonal antibodies 
used for testing cohort C were CX3CR1-PE-Cy7, S1PR1-APC, C-met-FITC, CXCR3-PerCP-
Cy5.5, CCR5-APC-Cy7 and CCR4-BV421. The experiment was performed to test three 
measurements. 1). CD8+ Tetramer cells, 2). CD8+ non-tetramer cells and 3). CD8+ non-
tetramer T cells within the CX3CR1 population. 
2.6 Production of Bacterial lysates for Antigens 
 
We grew Pseudomonoas aeruginosa in 10ml of broth and placed in an orbital shaker at 200 
rpm and incubated overnight at 370C. The following day, 1 ml of culture was transferred into 
a 200ml flask containing nutrient broth. The flask was placed on an orbital shaker at 200rpm 
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at 37oC for 2 hours. The flasks were kept in incubation until an optical density of 0.8 (mid-log 
of the growth phase) was reached. Bacterial culture was transferred into 50ml centrifuge tubes 
and centrifuged at 4000 RPM for 5 minutes at 4oC, and the supernatant discarded. The bacterial 
cell pellets were resuspended and washed with PBS 3 times and finally resuspended in 5ml of 
PBS.  Bacterial cells in PBS were sonicated (Soniprep 150, Henderson Biomedical, UK) at 
high intensity for 10 seconds with 10 second intervals. This process was carried out three times. 
The sonicated bacterial cells were transferred into Eppendorf tubes and centrifuged at 13000 
RPM for 20 minutes at 4oC to remove unwanted cell debris. Desired number of aliquots were 
made by carefully removing the supernatant from the Eppendorf tubes and stored at -200C for 
future use. The resulting pellet was discarded. 
2.7 Determination of Protein Concentration by Bradford Assay 
 
100µl of the original bacterial lysate was diluted in PBS in 10-fold steps and incubated for 30 
minutes at room temperature. 5 µl of each concentration were added to labelled 96 well ELISA 
plate in duplicate. To produce the standard curve, 10 dilutions of BSA (Bovine serum albumin) 
in 500 µl of deionised water were made ranging from 0.1–1.4 mg/ml. 5 µl of these samples 
were added to the plate. Subsequently, 250 µl of Bradford Dye Reagents was added to each 
well. The plate was incubated for 30-45 minutes at room temperature and read on ELISA Plate 
Reader (EL808, Bio-Tek Vermont, USA) at 595 nm. The concentration of unknowns was 
calculated from the standard curve. 
2.8 Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Two glass plates were placed on top of each other and clamped at the edges. The two glass 
plates were then placed on a casting tray.  A 12% separating gel was prepared and mixed well 
albeit gently (refer appendix for contents). The separating gel was carefully layered into the 
space between the clamped glass plates and care was taken to make sure the top layer of the 
stacking gel was horizontal and not slanted (a layer of distilled water was added to the top layer 
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of stacking gel to ensure horizontal layer was achieved). Furthermore, addition of the water 
layer also aids in proper polymerization of the gel protecting it from oxidation. The casting tray 
with separating gel was kept aside for polymerization. After 45 minutes, the water at top was 
removed by gently inserting a filter paper without affecting the separating gel. The stacking 
gel was then gently layered onto the space between the glass plates until overflow. A comb 
was inserted gently into the glass plates avoiding air bubbles. The stacking gel with the comb 
was allowed to polymerize for another 45 minutes. The Comb was gently taken out to reveal 
the wells. The glass plates were removed from the casting tray and placed in an electrophoresis 
buffer dam. The electrophoresis buffer was poured into the dam until an overflow (buffer level 
higher near the glass plates than on the outside).  20µl of samples was mixed with 5µl of loading 
buffer and placed in boiling water for 5 minutes. The samples were pipetted into the wells 
carefully and care was taken to avoid overflow of samples. The first well was reserved for the 
molecular weight maker. Power supply and voltage were set at 120 mA and 150V respectively. 
The apparatus was run for 45 minutes. After sufficient protein migration, the power supply was 
switched off. The gel was carefully removed from the glass plates and placed inside a container 
with coomassie brilliant blue stain for 10 minutes (with gently shaking). The gel was then, 
placed in a different container with destaining solution overnight (with gentle shaking). The 
gels were photographed using Bio-Rad Gel Doc2000 gel documentation system using Quantity 
One software. Hard copies of the gel photographs were printed using a Mitsubishi video copy 
processor attached to the gel documentation apparatus (see chapter 4, section 4.2.4). 
2.9 Lipopolysaccharide (LPS) assay 
 
The presence of endotoxins in antigenic stimulus was tested using the Pierce LAL chromogenic 
endotoxin quantitation kit (Thermo Scientific, Rockford, USA). The presence of LPS in 
antigenic peptides catalyses the production of proenzymes of Limulus Amebocyte Lysate 
(LAL). The catalysed proenzyme then proceeds to catalyse the cleavage of p-nitroaniline 
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(pNA) of the substrate. Higher the presence of endotoxin in the sample, the higher is the colour 
intensity of the reaction. The standard curve was plotted by preparing standard stock solution 
of LPS (Refer Chapter 3). 50µl of samples to be tested was added to the microplate along with 
50µl of LAL reconstituted in endotoxin free water. Endotoxin free water alone was used as the 
blank. The microplate was then incubated at 370C for 10 minutes following which 100µl of 
substrate was added to the plate. The plate was then gently rocked and incubated for 6 minutes. 
50µl of 25% acetic acid was added to all the wells to stop the reaction. The microplate was 
read at 410 nm in plate reader (EL808, Bio-Tek Vermont, USA) to measure the absorbance. 
The blank absorbance values were subtracted from the absorbance values of the samples tested. 
The net absorbance values were inserted into the standard curve to obtain the concentration of 
endotoxin present in the test samples (EU/ml).   
2.9.1 Preparation of Stock solution and generation of standard curve 
 
The endotoxin present in the kit was added to 1ml of endotoxin free water to make 26EU/ml 
stock. 0.05ml of this stock was then added to 1.25 ml of endotoxin free water to produce 
1EU/ml stock solution (Taken from instruction sheet obtained within the kit)   
Table 2.1 Dilutions for preparing the endotoxin standard stock solutions 
Vial number Endotoxin free water added(ml) Final stock concentration(EU/ml) 
1 1.25 1 
2 0.25 0.5 
3 0.75 0.25 
4 0.9 0.1 
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Standard concentration of 1EU/ml of was prepared by the addition of 0.05ml of the standard 
stock to 1.25ml of endotoxin free water. To prepare 0.5EU/ml stock solution, 0.25ml of 
endotoxin free water was added to 0.25 ml of 1EU/ml stock solution. 0.25EU/ml stock solution 
was prepared by the addition 0.25 ml of 1EU/ml stock to 0.75ml of endotoxin free water. 
0.1EU/ml stock was prepared by the addition of 0.1ml of 1EU/ml of stock solution to 0.9ml of 
endotoxin free water. (Table 2.1). The standard curve generated for the assay was used to 
measure the endotoxin levels of test antigens (refer Figure 4.2.1).  
The limulus Amebocyte lysate was reconstituted with 1.4ml of endotoxin free water. 
Furthermore, the chromogenic substrate in the kit was reconstituted with 6.5ml of endotoxin 
free water to make up a final concentration of 2mM. The complete list of antigens tested in the 
LPS assay and their endotoxin levels is listed in Table 4.2. 
2.10 Statistical analysis 
 
All statistical analysis was performed using IBM SPSS statistics version 24, Graphpad prism 
version 6 and Graphpad prism version 7. For the CFS project, normality tests such as the 
D’Agostino-Pearson omnibus K2 test was performed to assess whether the datasets were 
parametric or non-parametric. Thus, correlations were analysed by Spearman’s correlation 
analysis as well as Pearson’s correlation analysis. Non–parametric Mann-Whitney U test and 
parametric unpaired t test with welch correction were used to determine the relationship 
between two unpaired or independent groups and Wilcoxon signed rank test or paired t test 
was used to determine the relationship between two paired or dependant groups. Kruskal-
Wallis test with Dunn’s multiple comparison test or a one-way ANOVA with Tukey posthoc 
test was performed to test the relationship between three or more unrelated samples. Friedman 
test was performed to test the relationship between 3 or more matched groups. P values lower 
than 0.05 (p<0.05) were considered significant. Data was presented as median with the 
inclusion of upper and lower quartiles unless otherwise indicated. The data on column graphs 
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were presented as mean+SEM. For the cultured ELIspot data analysis, the ‘zero’ values in the 
data sets were reassigned with a minimum value of ‘1’. This change did not affect the result of 
the statistical analysis and the logarithmic scale for the data sets were then obtained. 
Table 2.2 Panel of Cell Surface markers used for MI project (Flow Cytometry) 
CELL SURFACE 
MARKER 
NAME FUNCTION in MI FLUROCHROME 
CD11a Integrin αL Lymphocyte adhesion 
and migration 
FITC 
CCR5 C-C chemokine receptor 
5 
Regulates homing of 
CD4+T cell into 
inflamed tissues 
PE 
CXCR3 C-X-C chemokine 
receptor 3 
Recruitment of Th1 
cells to site of 
inflammation binding to 
IP10 
PerCP-Cy5.5 
CX3CR1 CX3 C chemokine 
receptor 1 
Fractalkine signalling 
plays an important role 
in increasing MVO 
PE 
CD107a Lysosome associated 
membrane glycoprotein 
1 
Measurement of 
cytotoxic activity of 
CD8+ T cells 
PE-Cy7 
PD-1 Programmed cell death 
ligand-1 
Apoptosis of activated T 
cells expressing high 
levels of PD-1 
APC 
c-MET Hepatocyte growth 
factor 
T cell recruitment to the 
myocardium 
FITC 
CD69 Early activation antigen 
69 
Marker of lymphocyte 
activation 
BV421 
CD8 T cell surface 
glycoprotein α 
T cell killing of infected 
cells by binding to MHC 
class-I molecules on 
APCs. 
BV510 
CD4 T cell surface 
glycoprotein 
Binds to MHC class-II 
molecules on APCs and 
causes immune 
activation. 
APC-Cy7 
CD45RA Src kinase Expressed on naïve as 
well as terminally 
differentiated T cells  
PerCP-Cy5.5 
CD27 T cell activation antigen Identification of effector 
memory T cells. 
PE-Cy7 
CCR7 C-C chemokine receptor 
type7 
Homing of T cell and 
DCs to lymph nodes 
BV421 
S1PR1 Sphingosine1-phosphate 
receptor 1 
 
Cell migration and 
trafficking from lymph 
nodes. 
APC 
 
77 
 
Table 2.3 Panel of cell surface markers used for CFS project (Flow Cytometry) 
CELL 
SURFACE 
MARKER 
NAME FUNCTION FLUROCHROME 
CD57 Human Natural 
Killer-1 
CD57+ NK cells exhibit 
potent cytotoxic capabilities 
FITC 
CD161 Killer cell lectin-
like receptor 
subfamily B 
member 1 
Inhibits NK cell cytotoxicity PE 
TCR Vα24-
Jα18 
Invariant T cell 
receptor α chain 
NKT cells use iTCR to bind 
to antigens presented by 
CD1d. 
PE-Cy7 
TCR Vα7.2 Semi-invariant T 
cell Receptor 
Bind to antigens expressed 
on MHC molecule MR1. 
APC 
CD16 FcγIIIb Receptor. Antibody dependant cell 
mediated cytotoxicity by NK 
cells 
APC-Cy7 
CD56 Neural cell 
adhesion molecule 
Identification of Natural 
Killer cells 
BV421 
CD3 T cell surface 
glycoprotein 
Activation of T cells and 
used to differentiate T cells 
from B cells. 
FITC, BV510 
CD95 Tumour necrosis 
factor receptor 
superfamily 
member 6 
Apoptosis of Immune cells PE-Cy7 
TCRγδ T cell receptor with 
γδ chains 
Bind to CD1d molecule 
containing 
αGalactosylceramide. 
 
FITC 
CD25 Interleukin 2 
receptor subunit α 
IL-2 binds to CD25 and 
causes a myriad of immune 
functions 
PE 
CD19 B cell antigen Enhances B cell-antigen 
interactions. 
PerCP-Cy5.5 
CD127 IL-7 Receptor IL-7 is important for B cell 
development 
APC 
CD38 ADP ribosyl 
cyclase 
Marker of B cell activation BV421 
The following cell surface markers CD45RA, PD-1, CD4, CD8, CCR7, CD27, and CD69 are 
common for both studies. 
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Table 2.4 Chemokine receptors tested for the MI project by flow cytometry 
Cytokine Name Role in MI 
CCR4 Chemokine 
receptor 4 
T cell trafficking of Th2 cells, and regulatory T cells 
(Nakagawa et al., 2014)  
CCR5 Chemokine 
receptor 5 
Homing of CCR5+ T cells into atherosclerotic lesions by 
binding to CCL5 (Li & Ley, 2015).  
C-met Hepatocyte growth 
factor 
T cell recruitment to the myocardium (Komarowska et 
al.,2015) 
CX3CR1 Fractalkine receptor Involved the depletion of T cells from circulation and 
into the myocardium (Boag et al., 2015)  
CCR7 Chemokine 
receptor 7 
Priming of naïve T cells and T cell migration. 
CXCR3 CXC Chemokine 
receptor 3 
T cells trafficking into sites of inflammation (Groom & 
Luster, 2011).   
 
Table 2.5 Fluorochromes and their emission spectra used in flow cytometry experiments 
Fluorochromes Name Excitation/Emission 
Spectra(nm) 
FITC Fluorescein Isothiocyanate 494/520 
PE Phycoerythrin 496-578 
PerCp-Cy5.5 Peridinin Chlorophyll protein with 
cyanine5.5  
482/695 
APC Allophycocyanin  650/660 
APC-Cy7 Allophycocyanin with cyanine7 650/785 
BV421 Brilliant violet 421 407/421 
BV510 Brilliant violet 510 405/510 
Data obtained from BD Biosciences Fluorochrome/Laser Reference Poster 
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CHAPTER THREE 
 
The significance of anti-viral T cells and cytokines in 
patients with acute myocardial infarction (AMI) 
receiving reperfusion (R) treatment (AMI+R) 
 
Abstract 
 
Background  
The sudden rupture of an atherosclerotic plaque leads to myocardial infarction (MI) and 
ischemia. Such coronary occlusion and reduced oxygen provision results in death of 
cardiomyocytes. Inflammatory responses follow, with the release of cytokines which play a 
crucial role in cardiac repair (Nah & Rhee, 2009). The reopening of blocked artery by PPCI is 
vital for survival. However, the restoration of blood flow causes reperfusion injury due to the 
influx of leukocytes, particularly T cells, into the cardiac tissue causing microvascular 
obstruction (MVO). MVO has been linked with improper left ventricular remodelling, 
increased infarct size and generation of oxygen free radicals (Hoffmann et al., 2012). CMV 
seropositivity is shown to be associated with mortality due to myocardial ischemia (MI). Thus, 
the focus of this chapter is on the role of anti-viral T cells in myocardial ischemia and 
reperfusion injury.    
Aims  
The aim of this chapter was to investigate T cell immune responses, T cell populations, and 
serum cytokine concentrations, in cytomegalovirus (CMV) seropositive and seronegative, as 
well as Epstein-Barr virus (EBV) seropositive and seronegative, AMI patients during 
reperfusion (+R) treatment (AMI+R). The expression of chemokine receptors involved in the 
migration of T cells was also studied. 
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Methods  
Techniques used included ex-vivo and cultured ELIspot to measure T cell responses in AMI 
patients before and after reperfusion treatment. Stimuli for T cells comprised CMV and EBV 
antigenic peptides and lysates, as well as positive controls. Multiplex assay was used to 
measure serum cytokine levels in patients. Flow cytometric analysis was carried out to identify 
the expression of chemokine receptors on patient T cells. Statistical tests involved testing data 
for normality followed by parametric or non-parametric analysis performed to test for 
correlations and significance. Comparison of two unrelated groups was performed using Mann-
Whitney U test or the unpaired t test and paired t test or Wilcoxon signed rank test for related 
groups. Comparison of three or more groups were performed by one-way ANOVA followed 
by Tukey’s post hoc test or the Friedman test. P values below 0.05 were considered significant. 
Results  
Polyclonal activation of T cells with PHA in ELIspot showed increased Th1 (IFN-γ) responses 
in CMV seropositive patients. The serum concentrations of IFN-γ, IL-10 and IP-10 in CMV 
seropositive patients was higher than in CMV seronegative patients after reperfusion. The 
ELIspot results did not correlate with total ischemic time. Studies involving flow cytometric 
analysis of programmed death ligand 1(PD-1) revealed the permanent depletion of terminally 
activated PD-1+ memory CD8+ T cells from circulation during MI+R. Furthermore, a 
significant drop in cell numbers at 90 minute time point in fractalkine receptor+ population of 
CD8+ T cells (p=0.001) was seen. No correlations were seen between MVO, a measure of 
reperfusion-induced disease, and CMV specific ex-vivo ELIspot immune responses. There 
were, however, correlations of MVO with CMV specific cultured ELIspot responses, along 
with EBV-specific ex-vivo and cultured ELIspot. 
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Conclusion   
The results of this study suggest a chronic activation of the pro-inflammatory Th1 arm of the 
immune system together with the loss of CMV-specific terminally differentiated effector 
memory PD-1+ CD8+ T cells, likely via fractalkine-mediated homing to the myocardium. This 
might help explain the link between heart disease, CMV and immunosenescence. 
Introduction 
 
Myocardial infarction (MI) is one of the major causes of morbidity and mortality and across 
the world, although treatment and management of patients has improved considerably 
(Thygesen et al., 2012). MI usually follows the rupture of an atherosclerotic plaque which 
blocks the coronary artery. Myocardial cell death or necrosis due to prolonged ischemia (lack 
of oxygen supply to the heart tissue) causes myocardial infarction MI, which can be identified 
by electrocardiograph (ECG), increase in levels of biomarkers associated with myocardial 
necrosis (e.g. Troponin), and by imaging (Thygesen et al., 2012). Boag et al., in 2015 used 
cardiac MRI to detect microvascular obstruction in MI patients. Some of the prominent cardiac 
biomarkers that are released from dead cells are cardiac troponin, myoglobin, creatine kinase 
and C reactive protein.  Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are considered 
reliable indicators of MI (Fathil et al., 2015). Both subunits of troponin are released from 2-4 
hours from the onset of MI and persist in the blood from 10-14 days after MI (Bahadir & 
Sezginturk, 2015). Hoffmann et al., in 2015 also used initial and peak troponin levels in two 
patient cohorts for their study. Primary percutaneous coronary intervention (PPCI) using intra-
arterial catheter/stent is considered the most effective procedure to remove blockages, 
widening the narrow arterial walls and restoring the blood supply to the heart (Reperfusion). 
Unfortunately, this results in reperfusion injury, characterized by the influx of leukocytes such 
as T cells and neutrophils which cause microvascular obstruction (MVO) and initiate 
inflammatory reaction in response to dead cells, damaged tissue and clot components 
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(Hoffmann et al., 2012). Thus, elevated levels of troponin indicate the onset of MI and the 
extent of reperfusion injury after PPCI. In this research, the focus is mainly on the role of T 
cells in MI and reperfusion injury and the contribution of cytomegalovirus specificity of T 
cells. The main premise to the study is that T cells contribute significantly to heart disease 
generally, and to cardiac reperfusion injury, by homing to injured heart tissue during 
reperfusion. Furthermore, pro-inflammatory T cell subsets, particularly those specific for 
persistent viruses such as CMV, are abundant in the circulation of seropositive patients and 
home to the heart to contribute to immunopathology. 
 
Figure 3.1 Migration of T cell through the myocardium. T cell migration and circulation from the 
blood stream into myocardium passing through the lymph node occurs periodically at steady state 
condition. During inflammatory conditions lymphocytes, mainly CMV-specific T cells are recruited into 
the myocardium and exacerbate disease conditions. (Image taken and modified from Hofmann & 
Frantz, 2015). 
Naïve T cells and memory T cells circulate in the blood stream during steady state conditions. 
In the case of MI, the migration of T cells to the heart, and their retention, is controlled by 
chemokines and their receptors. 
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Several studies have shown the role of T cells in MI. RAG-1 KO mice which lack T cells were 
shown to have lower infarct size than the infarct size in control mice in an MI model (Yang et 
al., 2006). It was also found that the depletion of CD4+ and not CD8+ led to the decrease in 
infarct size in mice. Further, the adoptive transfer of CD4+ T cells led to the loss in protection 
from the depletion of these cells. This strongly indicates an important role for CD4 T cells in 
the onset of MI. It was extremely interesting to note that the adoptive transfer of CD4+ T cells 
from IFN- KO mice did not abolish the protection which strongly suggest a critical role for 
IFN- produced by Th1 cells in the exacerbation of inflammatory damage. (Yang et al., 2006). 
Hoffmann et al., in 2012 showed a shift in CD4+ T cell population 24 hours after PPCI, where 
there was a drop in cell numbers of the terminally differentiated effector memory T cells 
expressing CD45RA (TEMRA). The depleted cell populations were CCR7
+, suggesting the role 
for CCR7 in the migration of T cells into the heart tissue. Ammirati et al., in 2012 showed that 
effector memory T cells (TEM) were significantly increased in patients with acute MI providing 
more cells with heart-homing potential. The central memory T cells (TCM) express CCR7 but 
lack CD45RA, whereas effector memory T cells (TEM) lack both CCR7 and CD45RA. Naïve 
T cells express both CCR7 and CD45RA (Ammirati et al., (2012)).  The TEMRA express 
CD45RA but lack CCR7. Yu et al., in 2015 performed a study to characterize the CD8+ CD57+ 
T cells subset in AMI patients and showed that these cells contributed to the pathology of AMI. 
It was found that the levels of CD57+ CD4+ and CD8+ T cells were significantly higher in the 
patient group that suffered cardiovascular mortality. When other factors such as left ventricular 
ejection fraction, age and gender were considered, cardiovascular mortality was associated with 
the CD8+ T cells compartment. In addition to the high expression of CD57, these cells also 
expressed high levels of PD-1, FasL, CCR5 and CX3CR1. Thus, these cells exhibited 
hallmarks of hyper-activation, senescence, and with capacity to home to the target tissue. The 
authors also studied the functionality of these cells. The frequency IFN-+ TNF-+ cells were 
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significantly higher in the CD8+CD57+ T cell compartment, and this was accompanied by the 
high expression of cytotoxic granules such as perforin and granzyme B.  
The role of other chemokines in MI have also been investigated. Komarowska et al., in 2015 
investigated the role of c-met, CCR4 and CXCR3 in the migration of T cells to the myocardium. 
It was found that the binding of hepatocyte growth factor receptor (HGFR=c-met) to 
myocardium-specific HGF during priming of naïve T cells in the lymph nodes imprints ‘T cell 
cardiotropism’. This binding also results in the engagement of CCR5 with CCR5 ligand 
(released in an autocrine manner due to the binding of HGFR-HGF). Zamilpa et al., (2011) 
showed that the deletion of CCR5 in macrophages results in impaired left-ventricular 
remodelling post-MI in a mouse model. In addition, only during inflammatory conditions and 
not during steady state conditions, are CCR4 and CXCR3 required for the recruitment of T 
cells to the myocardium (Komarowska et al., 2015). Boag et al., in 2015 showed that the drop 
in T cell counts correlated with the expression of fractalkine receptor (CX3CR1) on T cells. 
The amount of fractalkine in the serum of patients peaked at 90 minutes after reperfusion 
coinciding with the drop in T cell count at the same time period. Boag et al., 2015 suggested 
fractalkine-mediated migration of lymphocytes to the myocardium could affect the extent of 
microvascular obstruction (MVO) in patients. So, studying the phenotype, migration and 
specificity of T cells will give better insights into the role of T cells in MI patients.  
Thus, the aim of this study was to examine T cell phenotype and functionality, particularly in 
relation to CMV specificity, in MI patients before and after their reperfusion treatment. These 
findings may provide targets for treatment of T cell-mediated reperfusion injury as well as 
identifying patients who could benefit from T cell targeting therapies. 
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RESULTS 
 
3.1 Patient demographics in acute myocardial infarction patients 
 
The main cohort of patients was divided into three sub groups for investigation: initial sub 
group A (n=28), main sub group B (n=52) and tetramer sub group C (n=8) based on availability 
of patient samples, patient data and project chronology. The main subgroup B represents an 
addition of patient numbers to the initial sub group A. The sub group C was selected based on 
the presence of PBMCs from patients that were MHC-typed and matched the available 
tetramers. It was decided to test these remaining patient samples for cell surface receptors 
involved in the migration of T cells into the myocardium. 
Baseline Characteristics of sub-group A 
The sub group A patient cohort included 28 patients suffering from acute myocardial infarction 
and were divided according to CMV serostatus. 14 patients were CMV seropositive and 14 
patients were CMV seronegative. All the patients were male and the mean age for CMV 
seronegative patients was 57.9 and for CMV seropositive patients, it was 57.2. There were no 
other significant differences between CMV seropositive and CMV seronegative patient 
population in other clinical parameters, including blood lipids, BMI, troponin levels and 
ischemic time (Onset to balloon). Total ischemic time is the total time the myocardium is 
deprived of oxygen supply. (Table 3.1). 
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Parameters  Cytomegalovirus seronegative 
patients 
Median (Q1; Q3) 
Cytomegalovirus seropositive 
patients 
Median (Q1; Q3) 
P 
value 
Number of patients 14 14  
Age median range 57.2(52;61) 57.9(50;60) 0.87 
Previous incidence of MI 
(%) 
0 7 0.33 
Number of Vessel disease, 
1/2/3 
11/2/1 7/5/2 0.29 
Serum Creatinine 
(µmol/L) 
94(88;100) 92(88;103) 0.96 
HDL cholesterol 
(mmol/L) 
1.1 (0.9;1.2) 1.1 (1.0;1.3) 0.44 
LDL Cholesterol 
(mmol/L) 
4.1 (3.5;4.8) 3.9 (3.5;4.3) 0.52 
Triglycerides, (mmol/L) 1.3(0.9;2.0) 1.4(0.9;2.4) 0.98 
BMI 28(26;31) 27(25;34) 0.92 
Hypertension (%) 21 21 1 
Active smokers (%) 50 50 1 
Statin Treatment (%) 7 29 0.16 
Initial troponin I (ng/L) 0.5(0.2;11.8) 1.0(0.1;1.8) 0.66 
Peak Troponin I (ng/L) 50(28;50) 40(19;50) 0.18 
Onset-to-balloon time 
(min) 
153(96;240) 113(102;272) 0.68 
Door to balloon time 
(min) 
25(17;35) 19(16;29) 0.42   
Sex (Male/Female) 14/0 14/0 1 
Table 3.1. Baseline characteristics of sub group A.   All p values were determined by non-parametric 
t test. AMI indicates acute myocardial infarction; HDL, high density lipoprotein; LDL, low density 
lipoprotein; BMI, Body mass index; Q1-first quartile, Q3- third quartile. 
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3.2 Higher IFN-γ response in CMV seropositive AMI patients   
 
In order to address the aims of this study, the first objective was to find out if there were 
differences in the main Th subtype responses between CMV seropositive and CMV 
seronegative patients. Patient PBMCs were examined before reperfusion/ PPCI by stimulation 
with PHA (a polyclonal activator of T cells) to look for global reactions. It was found that 
CMV seropositive patients had significantly higher Th1 (IFN-γ secreting cells) than CMV 
seronegative patients. Th2 (IL-5 secreting) cells were lower in CMV seropositive patients, 
though not significantly so, and no differences were found in Th17 (IL-17 secreting) responses 
(Figure 3.2.1). Although IL-4 was our preferred Th2 cytokine to be tested, the lack of 
optimized response in ELIspot experiments forced us to test IL-5, another Th2 cytokine.  
 
Figure 3.2.1 Polyclonal T cell activation in patients PBMC with PHA.  A. There were more IFN-γ 
secreting Th1 cells in CMV seropositive patients than CMV seronegative patients (p=0.0072). B. There 
were no significant differences in T cells secreting IL-5 (p=0.606) and C. IL-17 (p=0.670), Th2 and Th17 
cells, respectively, between CMV seropositive and CMV seronegative groups. Th1, T helper 1 cells; 
Th2, T helper 2 cells; Th17, T helper 17 cells. ns- Not significant. The bars indicate standard error of 
mean (+SEM), n=28. Mann-Whitney U test was carried out to test for significance between the two 
groups. 
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Next, we wanted to find out whether there was increased IFN-γ serum levels in a subset of 
patient samples shortly after the reperfusion process. Examination of patient serum samples by 
MSD, a multiplex cytokine assay, revealed CMV seropositive patients had higher levels of 
IFN-γ at 30 minutes post PPCI (Figure 3.2.2). There were no significant changes at the 15 
minute and 90 minute time points. We found no other significant changes in the levels of other 
cytokines. 
                                 
Figure 3.2.2 IFN-γ levels in patient serum samples. CMV seropositive patients had higher levels of 
IFN-γ at 30 minutes after reperfusion (p<0.01). However, there were no changes between CMV 
seropositive and CMV seronegative groups at 15 and 90 minute time points. pg/ml, picograms/millilitre. 
The serum levels were measured by MSD. n=12 at 15 minutes, n=14 at 30 minutes and n=14 at 90 
minutes. Unpaired t test was used to test for significance between the two groups. 
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3.3 Relationship between Total ischemic time and CMV serology in patients 
 
The next step was to investigate the association between CMV seropositivity and the total 
ischemic time. The total ischemic times for the patients were obtained from our clinical 
collaborators and indicate the total time the heart is deprived of oxygen supply. In medical 
terminology, ‘door (onset of heart attack) to balloon (insertion of stent to remove blockage)’ is 
considered as total ischemic time. Total ischemic time may reflect the degree of atherosclerotic 
plaque blockage of the coronary artery, which may be dependent on a pre-existing 
inflammatory state, or may be simply the logistical time to deliver treatment. Just like we 
predicted, it was found that there was no significant difference in ischemic time between CMV+ 
and CMV- serology. Thus, as expected, speed of treatment from the onset of heart attack 
determines the total ischemic time, and the presence or absence of cytomegalovirus does cause 
any changes in the total ischemic time.  
Next, we decided to ascertain whether there were associations between total ischemic time and 
IFN-γ production by T lymphocytes in CMV seropositive and CMV seronegative patients. We 
decided to focus on IFN-γ as it is the main Th1 cytokine and high Th1 responses have been 
implicated in the progression of MI. It was found that the magnitude of Th1 response, 
evidenced by IFN-γ spot forming cells/106 PBMC in response to PHA showed a positive 
correlation with total ischemic time (p=0.0006, R= 0.84) in CMV-seronegative patients. No 
correlations, however, were seen between magnitude of T cell response (IFN-γ spot forming 
cells/106 PBMC in response to PHA) in CMV-seropositive patients (p=0.47, R= 0.17). Thus, 
it is entirely possible that T cells in CMV seropositive patients are highly activated and present 
in high numbers and has nothing to with total ischemic time. 
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Figure 3.3.1 Relationship between CMV serology and IFN- levels with ischemic time. A. There 
was no association between CMV serology and total ischemic time. Total ischemic time indicates the 
total time the myocardium was deprived of oxygen supply. ns, not significant. n=28. B.  The production 
of IFN-γ in CMV-seronegative patients was lower and correlated with ischemic time, n=12; C. The 
production of IFN-γ in CMV-seropositive patients was much higher and showed no correlation with total 
ischemic time, n=19. p-significance value; R, Spearman correlation coefficient. Patient PBMCs were 
stimulated with PHA. 
Keeping in view of the above results, we hypothesize that the longer the myocardium remains 
deprived of oxygen supply, the more significant is the damage to the heart tissue. In CMV 
seronegative patients, we suggest the migration of T cells away from the heart tissues causes 
less damage. In CMV seropositive patients, the presence of high numbers of CMV-specific T 
cells indicate a lack of migration away from the heart tissues, consequently causing increased 
damage. This will be covered in more detail in the discussion section.   
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3.4 Tetramer analysis of CD8+ T cells before and after reperfusion 
 
On examining absolute counts of leukocytes before reperfusion, we found that only CD8+ T 
cell compartment showed a significant increase in number in CMV seropositive patients. So, 
tetramer analysis of CD8+ T cells was one of the approaches carried out to examine the CD8+ 
T cell population in greater detail, since tetramers identify T cells with a CMV-specific TcR. 
In order to do this, we initially measured the percentage of CMV-specific CD8+ T cells present 
in patients PBMCs before PPCI. We found that there was considerable variability in the 
percentage of CMV-specific CD8 T cells (Figure 3.4.1). The percentages of tetramer+ T cells 
ranged from 0.2 to 18% for HLA specific tetramers. 
Next, we focussed on the numbers of tetramer+ CD8+ T cells at 0 minutes, 90 minutes, 24 hours 
and 3 months after reperfusion. It was found that there was a significant decrease in CMV-
specific T cells at the 90 minute time point compared to 0 minute time point (p<0.0001) (Figure 
3.4.1). Whilst the percentage of T cells was increased at 24 hours, they were still significantly 
decreased compared to T cell percentage at 0 minutes (p<0.05). Whilst levels remained reduced 
at the 3 month time point, this did not reach significance. 
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Figure 3.4.1 Percentage of CMV-specific T cells before and after reperfusion therapy. A. Tetramer 
analysis using HLA specific epitopes revealed considerable variability in CMV-specific CD8+ T cells in 
patients. The data for blood samples collected before PPCI was performed on the patient group. n=19. 
B. The highlighted sections on flow cytometric scatter plots show the CMV-specific tetramer+ CD8+ T 
cells at 0 minute, 90 minute and 24 hours post PPCI. There is clearly a decrease at the 90 minute time 
point.  This is representative data for one patient. C. Compared to the relative proportion of T cells 
before reperfusion, there was significant decline to 24 % at 90 minutes after PPCI (P<0.0001), 53% at 
24 hours (p<0.05) and 54% at 3 months (p=0.05). n=10. Friedman test was carried out to test for 
significant associations. 
These results indicate the homing of T cells to the heart, possibly, via the sphingosine-1 
phosphate receptor pathway into lymph nodes and to site of inflammation (myocardium). In 
addition, the loss of circulating CMV-specific T cells may lead to reactivation of latent CMV, 
thus causing long lasting low-grade inflammation.  
A 
C 
B 
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It was then decided to investigate associations between tetramer-determined CMV-specific 
CD8+ T cells and functional CMV-specific CD8+ measured by ELIspot. Interestingly, there 
was a negative correlation between ELIspot CMV-specific CD8+ T cells and tetramer CMV-
specific CD8+ T cells (r=-0.79, p=0.006) (Figure 3.4.2). 
  
Figure 3.4.2 Relationship between ELIspot and tetramer+ CMV-specific CD8+ T cells. An inverse 
relationship was found between ELIspot and tetramer CMV specific CD8+ T cells. Higher the percentage 
of tetramer CMV specific T cells lower was the ELIspot CMV specific T cells. p value indicates value of 
significance; r-Spearman correlation coefficient.  
The functionality of CMV specific tetramer CD8+ T cells before reperfusion is decreased as 
shown by the decrease in number of CMV specific CD8+ T cells measured by ELIspot. This 
suggests that the CMV-specific T cells are over-stimulated and have become anergic. 
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3.5 Depletion of PD-1+ terminally differentiated CD8+ effector memory T cells (TEMRA)  
 
The next step was to identify the CD8+ T cell subset that accounted for the drop at the 90 minute 
time point and also to find out whether there was a permanent loss of CD8+ T cells since CD8+ 
T cells at the 24 hours and at the 3 month time point do not recover from the drop at 90 minutes 
to the levels immediately after reperfusion. It is also possible that the cells homed away from 
the myocardium and were anergic and not permanently lost. 
We first identified the percentage of activated CD8+ T cell subsets before reperfusion.  The 
expression of CD69 was used as an indicator of T cell activation. It was found that only the 
effector memory (TEM) and terminally differentiated effector memory CD8
+ T cells (TEMRA) 
showed the highest activation levels of CD69 (Figure 3.5.1). In addition, there was a 
significant difference in the activation levels of naïve CD8+ T cells and TEMRA population 
(p=0.016).  
PD-1 is expressed on activated memory T cells to dampen T cell activity, thus it made sense to 
examine the loss of PD-1+ CD8+ TEMRA cells after reperfusion. Interestingly it was found that 
at 90 minutes after reperfusion there was significant drop in PD-1+ CD8+ TEMRA cells (Figure 
3.5.1). The 15 minute time point was one of the time points included in this pilot experiment 
to determine the time point at which the most significant drop in T cell count occurred. 
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Figure 3.5.1 Percentage of activated CD8+ T cell subsets before reperfusion and Drop in PD-1+ 
CD8+ TEMRA cells. A. Staining of CD8+ T cells for memory (CD45RA/RO) and activation (CD69) 
markers revealed the activation levels of CD8+ T cell subsets before reperfusion. There was a significant 
difference between the activation levels of naïve CD8+ and TEMRA CD8+ T cells (p=0.016). p value 
indicated significance. It must also be noted that the activated levels of effector memory cells (EM) and 
TEMRA were higher than naïve and central memory cells (CM). There was no significant relationship 
between the other T cell subsets. n=28. One-way ANOVA followed by Tukey’s post hoc test was carried 
out to test for significant associations. B. Compared to baseline CD8+ TEMRA, the PD-1 expressing 
CD8+ TEMRA showed a significant drop at 90 minutes after reperfusion (p=0.016). There was, however, 
no significance at the 15 minute time point. n=28. Wilcoxon signed rank test was carried out to test for 
significant associations. 
The next aim was to measure PD-1+ CD8+ TEMRA cell levels at 24 hours after reperfusion. The 
percentages of effector memory (TEM) and TEMRA cells were higher than naïve and central 
memory (TCM) cells in both CMV seronegative and seropositive patients (Figure 3.5.2). In 
addition, in CMV seropositive patients, the percentages of PD-1+ CD8+ TEMRA cells were 
significantly lower than PD-1+ CD8+ TEM cells (p=0.017). The level of PD-1
+ CD8+ TEMRA in 
CMV-seropositive patients was significantly lower than the same population in CMV-
seronegative patients (p=0.04). 
A B 
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Figure 3.5.2 PD-1+ CD8+ T cell subsets in CMV seropositive and seronegative patients. In both 
CMV seropositive and CMV seronegative patient groups the effector memory cells and terminally 
differentiated effector memory cells were higher than naïve and central memory cells. The TEMRA in 
CMV seropositive patients after 24 hours was significantly lower than TEMRA in CMV seronegative 
patients (p=0.04). The TEMRA population in CMV seropositive patients were also significantly lower than 
effector memory cells. CM, Central memory; EM, effector memory; TEMRA, terminally differentiated 
effector memory cells; PD-1, programmed cell death ligand-1. p value indicates significance value. 
n=28. One-way ANOVA followed by Tukey’s post hoc test was carried out to test for significant 
associations. 
The presence of PD-1 on highly activated T cells prepares the cells for apoptosis, thus, it was 
decided to test the level of spontaneous and induced early; (Annexin V+) and late (7-AAD+ & 
Annexin V+) apoptosis on CD8+ T cells. For spontaneous apoptosis, uncultured patient PBMCs 
stained with Annexin V and 7-AAD were analysed by flow cytometry. The CD8+ T cells were 
split into PD-1 negative, PD-1 dim and PD-1 high cells. (Figure 3.5.3A). PD-1 negative cells 
showed only early apoptosis and no late apoptosis, whereas PD-1 dim and PD-1 high cells 
showed early and late spontaneous apoptosis (Figure 3.5.3B). 
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Figure 3.5.3 PD-1 expression levels and spontaneous apoptosis in activated CD8+ T cells. A. PD-
1 high cells and PD-1 dim cells were more numerous than PD-1 negative cells. B. There was no late 
apoptosis in PD-1 negative cells indicated by the lack of presence of 7-AAD staining, whereas PD-1 
high and PD-1 dim cells showed both early and late spontaneous apoptosis. A representative set of 
FACS data for one patient is shown. PD-1, Programmed cell death ligand-1; 7-AAD, 7- 
Aminoactinomycin D. n=28. 
3.5.1 Gating strategy for different levels of PD-1 expression 
 
The lymphocyte population was first gated by plotting forward scatter against side scatter; the 
gated lymphocyte population were further gated by plotting forward scatter (height) vs forward 
scatter (area) to exclude all doublet cells and include only singlet cells. Next, only the CD3 
population were gated from singlet cells by creating FSC-A vs CD3 dotplot. The CD8+ T cell 
population was obtained from the CD3 population and the PD-1 expression was investigated 
in CD8+ T cells.  
The high, dim and ‘negative’ expression levels of PD-1 were discriminated. We used a contour 
plot to identify PD-1 CD8+ T cells. We used a combination of statistics as well as fluorescent 
minus one (FMO) samples to make sure that the gating procedure is accurate and appropriate. 
The FMO sample was used to determine the negative control for the experiment. Next, we used 
statistics to split the positive population into high and dim populations. The PD-1+ cells above 
98 
 
the median were classified as ‘high’ whereas all the positive population below the median were 
classified as ‘dim’. 
We also measured the extent of induced early and late apoptosis in these cells. PD-1 negative 
cells and PD-1 dim cells showed higher percentage of early apoptosis compared to PD-1 high 
cells (Figure 3.5.4). The percentage of early apoptosis of PD-1 dim cells was significantly 
higher than PD-1 negative cells (p<0.05) and PD-1 high cells (p<0.01). There were changes 
during late apoptosis where the PD-1 high cells showed significantly higher apoptosis 
compared to negative and dim cells. Furthermore, the percentage of live cells expressing high 
levels of PD-1 was significantly lower than live PD-1 negative cells (p<0.0001). 
To confirm the role of PD-1 in the permanent loss of activated CD8+ T cells, we decided to test 
the level of apoptosis of T cells in the presence of PD-1-blocking monoclonal antibody. The 
loss of cell membrane integrity during cell death allows the intake of propidium iodide (PI) 
which can be detected by flow cytometric analysis. Interestingly, the percentage of late 
apoptosis in stimulated T cells incubated with the anti-PD-1-monoclonal antibody showed 
significantly lower apoptosis than cells with no blocking antibody (Figure3.5.4).  
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Figure 3.5.4 Induced early and late apoptosis in PD-1 negative, PD-1 dim and PD-1 high and 
Apoptosis in anti-CD3 stimulated T cells. A. The percentage of early apoptosis in PD-1 dim cells 
was significantly higher than PD-1 negative (p<0.05) and PD-1 high cells (p<0.01), B. The percentage 
of late apoptosis was significantly higher in PD-1 high cells than in PD-1 negative cells(p<0.001) and 
PD-1 dim cells (p<0.05). C. concurrently, the percentage of live cells expressing high levels of PD-1 is 
significantly lower than PD-1 dim and PD-1 negative cells.  D. PD-1 high cells underwent a much higher 
percentage of apoptosis than dim (p<0.05) and negative cells (p<0.001). C). The percentage of live 
cells (7AAD-) expressing high levels of PD-1 was lower than live cells with no PD-1 and less PD-1.  
Sample size, n=10. B). Cells stimulated with anti-CD3 showed a significantly higher percentage of late 
apoptosis compared to cells incubated with anti-PD-1 monoclonal antibody. PI, Propidium Iodide. 
p=0.03. n=6. One-way ANOVA followed by Tukey’s post hoc test was carried out to test for significant 
associations between the three groups (A, B, C) and the unpaired t test was carried out to compare the 
two groups (D). 
Thus, it was shown that the expression of PD-1, predominantly in CD8+ TEMRA cells, led to 
increased late apoptosis and was responsible for the permanent loss of CD8+ TEMRA from 
circulation. The analysis of cells incubated and stained with anti-PD-1 monoclonal antibody, 
propidium iodine and 7-AAD confirmed this hypothesis. 
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3.6 Baseline characteristics of main sub group B 
 
52 patients comprised the main sub-group B of the study. 29 patients were CMV seropositive 
and 23 patients were CMV seronegative. The CMV seropositive patients were significantly 
older than CMV seronegative patients (p=0.033). Moreover, there were more males than 
females (p=0.016).  More CMV seropositive patients were EBV seropositive compared to 
CMV seronegative patients (p=0.04). The patient sub group did not vary in other parameters 
based on CMV-seropositivity. 
Parameters CMV-seropositive (n=29) CMV-seronegative (n=23) P value 
Age 62 (54; 72) 56 (47; 63) 0.033 
Sex: male/female 18 / 11 21 / 2 0.016 
EBV-seropositive 28 (96.5%) 18 (78.3%) 0.040 
White Blood Cells, (cells/μl) 11520 (9500; 14155) 12540 (10938; 14903) 0.392 
Lymphocytes, (cells/μl) 2000 (1400; 3110) 1915 (1413; 2730) 0.669 
Monocytes, (cells/μl) 800 (545; 910) 635 (463; 833) 0.278 
Neutrophils, (cells/μl) 9220 (6800; 10615) 9240 (7775; 10865) 0.530 
Eosinophils, (cells/μl) 100 (60; 170) 160 (65; 310) 0.397 
Platelets, (x103/μl)  239 (204; 311) 240 (225; 326) 0.482 
Serum Creatinine, (µmol/L) 77 (65; 88) 81 (69; 95) 0.190 
HDL cholesterol, (mmol/L) 1.2 (1.0; 1.4) 1.2 (1.0; 1.4) 0.795 
Serum cholesterol, (mmol/L) 5.1 (4.5; 5.8) 5.0 (4.5; 6.1) 0.699 
Glucose, (mmol/L) 7.9 (6.1; 9.2) 8.1 (7.3; 9.4) 0.161 
Triglycerides (mmol/L) 1.3 (0.9; 2.4) 1.9 (1.1; 2.7) 0.483 
Troponin, 12h sample (ng/L) 4800 (2274; 8461) 5098 (2102; 8238) 0.934 
Table 3.2 Baseline characteristics of main sub group B.  Continuous variables are represented as 
median (25% quartile; 75% quartile) and compared by Mann-Whitney test; categorical variables are 
compared by chi-square test. Listed parameters represent measurements before reperfusion, except 
for troponin levels (12h after reperfusion). HDL, high density lipoprotein; EBV, Epstein-Barr virus. 
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3.7 Cytokine production by CD8+ and CD4+ T cells in CMV and EBV seropositive AMI 
patients 
 
One of the main objectives of this part of the study was to investigate antigen-specific cytokine 
production by patient PBMC using the ex-vivo ELIspot assay. We first analysed IFN-γ 
production by CD4+ and CD8+ T cells in CMV seropositive patients. There were no changes 
in the CD8+ T cell compartment across all time points whereas IFN-γ production in CD4+ T 
cells showed a significant reduction at the 90 minute time point after reperfusion (p=0.002) 
before recovering at 24 hours (p=0.003). 
 
Figure 3.7.1 IFN-γ production by CMV-specific CD4+ and CD8+ T cells by ex-vivo ELIspot. A. 
Production of IFN-γ by CD8+ T cells across all time points after reperfusion did not show any significant 
changes. B. There was, however, a significant drop in the production of IFN-γ by CD4+ T cells at the 90 
minute time point (p=0.002), but at 24 hours IFN-γ production had recovered (p=0.003). The y axis is 
shown as logarithmic scale (10). 90 min, 24h and 3 months indicate time points after reperfusion. The 
data sets include median with interquartile range. n=20 (before PPCI), n=19 (90 minutes), n=19 (24 
hours) and n=9 (3 months) for CD8+ T cells. n= 20 (before PPCI), n= 19(90 minutes), n= 19 (24 hours) 
and n=8 (3 months) for CD4+ T cells. Wilcoxon singed rank test was performed to identify associations 
between each of the time points. 
Performing cultured ELIspot is an indicator and measure of the memory T cell response. In 
contrast to ex-vivo ELIspot CD4+ T cell response, no changes were found across all time points 
in cultured CD4+ T cell response (Figure 3.7.2). The CD8+ T cell compartment showed some 
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changes by cultured ELIspot. IFN-γ production in CD8+ T cells showed no changes at 90 
minute time point compared to baseline levels. However, IFN-γ levels at 24 hours was 
significantly higher compared to baseline levels (p=0.0074). (Figure 3.7.2) 
 
Figure 3.7.2 IFN-γ production by CMV specific CD4+ and CD8+ T cell by Cultured ELIspot.  A. 
IFN-γ production in CD4+ T cells showed no changes at any time point. B. The cytokine production in 
CD8+ T cells was significantly higher 24 hours after PPCI compared to the secretion of IFN-γ before 
PPCI (p=0.0074). However, there were no further changes. The y axis is shown as a logarithmic scale. 
Data sets include median with interquartile range. n=35 (before PPCI), n=32 (90 minutes), n=34 (24 
hours) and n=14 (3 months) for CD8+ T cells. n= 35 (before PPCI), n= 32 (90 minutes), n= 34 (24 hours) 
and n=15 (3 months) for CD4+ T cells. Wilcoxon singed rank test was performed to identify associations 
between each of the time points. 
The focus then shifted to IFN-γ production by EBV specific CD4+ and CD8+ T cells (Figure 
3.7.3). EBV has no known role in MI and thus testing EBV responses would give a control 
response against CMV response. Release of IFN-γ at 24 hours was significantly higher than 
the levels before PCCI (p=0.026) and at 90 minutes (p<0.001). The CD4+ T cell compartment 
showed a significant dip at 90 minutes (p=0.008) which recovered at 24 hours (p=0.02).  
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Figure 3.7.3 IFN-γ production by EBV-specific CD4+ and CD8+ T cells by ex-vivo ELISPOT. A. 
There was a dip in CD8+ T cell responses at 90 minutes but was not significant. However, there was 
significant increase at 24 hours (p<0.01). B. There was, however, a significant drop in the production of 
IFN-γ by CD4+ T cells at the 90 minute time point (p=0.008), but at 24 hours IFN-γ production had 
recovered (p=0.002). The y axis is shown as logarithmic scale (10). 90 min, 24h and 3 months indicate 
time point after reperfusion. The data sets include median with interquartile range. n=29 (before PPCI), 
n=28 (90 minutes), n=27 (24 hours) and n=11 (3 months) for CD4+ T cells. n=29 (before PPCI), n=28 
(90 minutes), n=27 (24 hours) and n=11 (3 months) for CD8+ T cells. Wilcoxon singed rank test was 
performed to identify associations between each of the time points. 
Next, the cultured ELIspot responses for EBV were examined. IFN-γ production by EBV-
specific CD4+ T cells at 24 hours was significantly higher than the production before PPCI 
(p=0.0027) with no changes at 90 minutes. In the CD8+ T cell compartment, IFN-γ production 
at 24 hours was significantly higher than the production before PPCI (p=0.0010) and the levels 
at 24 hours were also significantly higher than the levels at 90 minutes (p=0.0001) (Figure 
3.7.4). 
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Figure 3.7.4 IFN-γ production by EBV specific CD4+ and CD8+ T cells by Cultured ELIspot. A.   
IFN-γ production in both CD4+ T cells showed an increase at 24 hours compared to baseline level, but 
no difference was seen at 90 minutes. B. IFN-γ production in both CD8+ T cells also showed an increase 
at 24 hours compared to baseline levels, but no difference was seen at 90 minutes. The y axis is shown 
as a logarithmic scale (log10). Data sets include median with interquartile range. n=36 (before PPCI), 
n=32 (90 minutes), n=34 (24 hours) and n=16 (3 months) for CD4+ T cells. n= 34 (before PPCI), n= 32 
(90 minutes), n= 33 (24 hours) and n=16 (3 months) for CD8+ T cells. Wilcoxon singed rank test was 
performed to identify associations between each of the time points. 
It was then decided to measure non-specific T cell activation and other cytokine levels in 
patient PBMCs. Non-specific IFN-γ production in response to PHA stimulation was higher in 
CMV seropositive patients than in CMV seronegative patients (Figure 3.7.5). In addition, in 
CMV seropositive patients, there was a significant decrease in IFNγ production at 90 minutes 
(p=0.009) followed by an increase at 24 hours after PPCI (p=0.0329). A similar trend was seen 
for CMV seronegative patients. There was significant decrease at 90 minutes (p=0.048) 
followed by a significant increase at 24 hours (p=0.0067). There was a significant drop in IL-
2 production in response to PHA stimulation at 90 minutes after PPCI (p=0.008). However, no 
changes were seen at 24 hours and 3 months after PPCI. IL-5 production in response to PHA 
stimulation at 24 hours after PPCI was significantly higher than at 90 minutes after PPCI. There 
were no changes at any other time points (Before PPCI and 3 months after PPCI). IL-17 
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production was significantly increased at 24 hours after PPCI compared to production before 
PPCI. There was no relationship at other time points (Figure 3.7.5). 
 
Figure 3.7.5 Measurement of cytokine levels and non-specific activation of PBMCs with PHA. A. 
Production of IL-2(n=40 before PPCI, n= 39 at 90minutes, n=39 at 24 hours and n=6 at 3 months); B. 
Production of IL-5 (n=40 before PPCI, n= 38 at 90minutes, n=38 at 24 hours and n= 6 at 3 months); C. 
Production of IL-17(n=40 before PPCI, n= 39 at 90minutes, n=38 at 24 hours and n=6 at 3 months); 
and D. Production of IFN-γ in responses to 24 h PHA-stimulation by ex-vivo ELIspot in CMV-
seropositive and seronegative patients; D. For CMV seropositive patients, n =23 before PPCI, n=22 at 
90 minutes, n=23 at 24 hours and n=11 at 3 months. For CMV seronegative patients, n=18 before PPCI, 
n=17 at 90 minutes, n=17 at 24 hours and n=6 at 3 months. P values are provided separately for CMV 
seropositive individuals (red), CMV-seronegative individuals (blue) otherwise, CMV-seropositive and 
seronegative individuals are given together (black). Data sets include median with interquartile range. 
IL-2, interleukin-2; IL-5, interleukin-5; IL-17, interleukin-17; PHA, phytohaemagglutinin. Y axis is shown 
as a logarithmic scale (log10). Due to the suboptimal performance in the use of IL-4 in our ELIspot 
experiment, we used IL-5, another Th2 cytokine. Wilcoxon signed rank test was used to identify 
associations between each of the time points.  
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The inflammatory process connected to myocardial infarction and reperfusion injury may be 
mediated through lymphocyte migration controlled by several cytokines that will manifest in 
the patient circulation/serum. So next, MSD was used to measure the levels of serum cytokines 
in patients. 11 different serum cytokines in CMV seropositive and CMV seronegative patients 
were tested using MSD. MSD was the preferred electrochemiluminescence multiplex platform 
owing to its minimum background levels, the use of carbon electrode plate that offers 10 times 
the binding capacity compared to normal polystyrene plates, the use of non-radioactive labels, 
signal amplification caused by multiples excitation levels allow for highly enhanced sensitivity. 
Among the 11, only IP-10 and IL-16 showed significant changes. The levels of IP-10, in CMV 
seropositive patients, at all times points after PPCI were higher than the level before PPCI 
(Figure 3.7.6 A, B). In contrast, IL-16 levels were lower than IL-16 levels for CMV 
seronegative patients.  Also, the levels of IL-16 oscillated across all time points before and 
after PPCI.  (n=25, 14-CMV seronegative, 11-CMV seropositive). Interestingly, IL-16 levels 
at 90 minutes had an inverse relationship with CD4+ T cells levels at 90 minute time point 
(Figure 3.7.6 C). 
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Figure 3.7.6 Serum cytokine levels in patient samples. A. Apart from the 24 hour time point after 
PPCI, the IP-10 levels in CMV seropositive patients were significantly higher than in CMV seronegative 
patients. n=25 at 0 minutes, n=22 at 15 minutes, n=24 at 30 minutes, n=24 at 90 minutes, n=23 at 24 
hours and n=3 at 3 months. B. The IL-16 levels in CMV seropositive patients were significantly lower 
than the levels in CMV seronegative patients. n=25 at 0 minutes, n=22 at 15 minutes, n=24 at 30 
minutes, n=24 at 90 minutes, n=23 at 24 hours and n=3 at 3 months. C. The percentage of CD4+ T cells 
at 90 minutes had an inverse association with IL-16 levels at the same time point. The drop in CD4+ T 
cell count was accompanied by the reduction in IL-16 levels, n=24. Boxplots represent median, upper 
and lower quartiles along with minimum and maximum values. P values were calculated using Wilcoxon 
signed rank test. For Figure C, Spearman analysis was used to test for correlation between the two 
variables.  
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3.8 Analysis of the relationship between Microvascular obstruction with Ex-Vivo and 
Cultured ELIspot  
 
Microvascular obstruction (MVO), or no-reflow phenomenon, occurs in a proportion of 
patients after PPCI. MVO is characterised by structural and functional changes to the 
myocardium such as endothelial destruction, emboli of neutrophils and platelets, and release 
of free radicals, and is an indication of reperfusion-induced injury (Ito, 2009). So next, it was 
decided to test for association between MVO levels in patients and T cell responses in patients 
measured by ELIspot. The values of MVO were provided by our clinical collaborators at 
Freeman Hospital. MVO was quantified and detected on late gadolinium enhancement (LGE) 
cardiac MRI images as an area of hypoenhancement within the infarct core (Boag et al., 2015). 
These values were then used to identify correlations between ELIspot and MVO levels in 
patients. Spot forming cells/106 PBMC obtained by ex-vivo ELIspot and cultured ELIspot for 
patient cohorts were compared to microvascular obstruction (MVO) and peak troponin levels 
by Spearman analysis to identify significant correlations. CMV-specific cultured ELIspot 
CD8+ T cell response at 24 hour point (p=0.044 for MVO volume, p=0.042 for MVO mass) 
and EBV-specific CD4+ T cells at 24 hour time point (p=0.026 for MVO volume, p=0.025 for 
MVO mass) showed a positive correlation with both MVO volume and MVO mass which was 
significant (Figure 3.8.1). No ex-vivo ELIspot responses correlated with either MVO volume 
or MVO mass. Furthermore, CMV-specific CD4+ T cell responses at 24 hours was just outside 
significance (p=0.071 for MVO volume, p=0.069 for MVO mass) and EBV specific CD4+ T 
cell response at 3 months after PPCI was just outside significance as well (p=0.05 for both 
MVO volume and MVO mass). For peak troponin levels, both CMV specific CD4+ T cell 
response at 0 minute time point (p=0.006) and CMV specific cultured CD8+ T cell response at 
24 hours post PPCI showed a negative correlation (p=0.042).  
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Figure 3.8.1 Associations between MVO mass and cultured ELIspot EBV and CMV-specific T 
cells 24 hours after PPCI. A. Cultured ELIspot CMV-specific CD8+ T cell response 24 hours after PPCI 
positively correlated with MVO mass (r=0.326, p=0.042); B. Cultured ELIspot EBV specific CD4+ T cell 
response 24 hours after PPCI correlated with MVO mass (r=0.361, p=0.025). PPCI-Primary 
percutaneous coronary intervention. Correlations were obtained using Spearman analysis. n=33 for A. 
and n= 35 for B. 
In addition to the above analysis, the MVO mass in patients were split into ‘high’, ‘low’ and 
‘none’ as in the research article by Boag et al., 2015. These MVO levels were then analysed 
with ELIspot data at various time points. Patients were divided into the three groups depending 
upon the extent of MVO. Patients with MVO levels 3.5 and above were classified as high, 
patients with MVO levels higher than 0 but lower than 3.5 were classified as low and patients 
with MVO levels of 0 were classified as none.  There were 9 patients classified as ‘high’, 7 
patients classified as ‘low’ and 12 patients were classified as ‘none’. We first investigated the 
relationship between CMV-specific CD4+ and CD8+ T cells, at different time points with 
MVO. We found no associations between MVO and CMV-specific CD4+ and CD8+ T cell 
response.  
We then performed the same analysis for EBV-specific T cells. Interestingly, the production 
of IFN-γ by EBV-specific CD4+ T cells at baseline levels (before PPCI) were significantly 
higher in the ‘none’ MVO patient group (p=0.03978). The trend continued at 90 minutes after 
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PPCI, the ‘none’ MVO patient group still had higher (but not significant) IFN-γ spot forming 
cells/M than patients with ‘high’ MVO (p=0.05), although this was lost at 24 hours after 
reperfusion (data not shown) (Figure 3.8.2) Moreover, for EBV specific CD8+ T cells, the IFN-
γ production by ‘none’ MVO group significantly exceeded the high MVO group before PPCI 
(p=0.0082), however, this trend was lost at 24 hours (p=0.092). We also found that at 24 hours, 
the ‘none’ MVO group had significantly higher IFN-γ production compared to low MVO 
group.  
 
Figure 3.8.2 Relationship between MVO and EBV-specific T cells. A. Secretion of IFN-γ by EBV-
specific CD4+ T cells before PPCI; B. Secretion of IFN-γ by EBV-specific CD4+ T cells at 90 minutes 
after PPCI; C. Secretion of IFN-γ by EBV-specific CD8+ T cells before PPCI; D. Secretion of IFN-γ by 
EBV-specific CD8+ T cells at 24 hours after PPCI. ns- Not significant. The y axis is shown as a 
logarithmic scale and the x axis indicates the extent of MVO (high, low or none) in the patients group. 
Blue-high MVO; red-low MVO; green-no MVO. n=9 for ‘high’, n=7 for ‘low’ and n= 12 for ‘high’. Kruskal-
Wallis test with Dunn’s multiple comparisons test was used to compare the three groups. 
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Next, the cultured ELIspot responses for CMV and EBV were tested. We hoped this might 
offer insights into the relationship of MVO with ex-vivo as well as cultured ELIspot. For both 
CMV specific and EBV specific CD4+ T cells and CD8+ T cells, we found no associations 
between the extent of MVO in patients and level of IFN-γ produced by these cells.  
After testing MVO levels against pathogen specific T cells, patient lymphocytes were also non-
specifically activated by Phytohaemagglutinin (PHA) to test the production of IL-2, IL-5, IL-
17 and IFN-γ.  IL-5 and IL-17 are signature cytokine of Th2 and Th17 cells respectively, so it 
was interesting to test the relationship between different T cell subtypes with the extent of 
MVO in patients. We found IL-2, IL-5, IL-17 and IFN-γ production in response to PHA did 
not differ in all three MVO groups at all three time points. 
There was no association between the different MVO patient groups and non-specific 
production of cytokines at all the three time points.  
Apart from looking for correlations between MVO and ELIspot, associations between peak 
troponin levels and ELIspot responses (both Ex-Vivo & Cultured) were also studied. Spearman 
correlation analysis revealed both CMV-specific CD4+ cultured T cell response at 0 minute 
time point (p=0.003) and CMV-specific cultured CD8+ T cell response at 24 hours post PPCI 
showed a negative correlation (p=0.042) with peak troponin levels (Figure 3.8.3). Apart from 
these correlations, EBV-specific CD4+ and CD8+ T cell response at 0 minutes after PPCI was 
just outside significance (p=0.066 and p=0.064), respectively. In addition, cultured CD8+ T cell 
response at 0 minutes after PPCI was also just outside significance (p=0.056). 
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Figure 3.8.3 Relationship between Peak Troponin levels and ELIspot responses. A. Correlation 
between cultured CMV-specific CD4+ T cell response before PPCI and peak troponin (R=-0.455, 
p=0.003). B. Correlation between Peak Troponin and cultured CMV-specific CD8+ T cell response at 
24 hours after PPCI (R=-0.300, p= 0.042); p value indicates value of significance. Correlations were 
obtained using Spearman analysis. n=35 for A. and n=34 for B.  
Peak Troponin is considered a prognosticator of MI disease level before reperfusion, and 
Microvascular obstruction (MVO) is an indicator of reperfusion injury after PPCI. We clearly 
show that these two measurements are unrelated in our patient cohort. Therefore, identifying 
associations between MVO, Peak Troponin level and ELIspot responses gave an interesting 
insight into the influence of the immune response, especially by T cells.  
3.9 Flow cytometric Analysis of Tetramer and Non-Tetramer CD8+ T cells  
 
Boag et al., in 2015 revealed that the increase in levels of fractalkine (CX3CR1) was strongly 
associated with the T cell drop in STEMI patients following PPCI/Reperfusion. Thus, it was 
decided to study the role of fractalkine in more detail. To this end, all remaining patient PBMC 
samples were surveyed to identify if PBMC samples were available at all time points. 8 patient 
PBMC samples (sub-group C) were selected and flow cytometric analysis of tetramer, non-
tetramer and fractalkine positive CD8+ was performed on them. As well as fractalkine, it was 
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decided to test various other cell surface receptors implicated in myocardial injury such as 
CCR4, CCR5, CXCR3, CX3CR1, SIP1R and C-met. 
3.9.1 Gating Strategy used for tetramer analysis of CD8+ T cells 
 
A typical gating strategy to identify, measure and depict the levels of expression of cell surface 
receptors of tetramer CD8+ T cells is shown. Similar gating strategies were adopted to analyse 
non-tetramer CD8+ T cells and CX3CR1+ CD8+ T cells in patient samples. Each sample was 
analysed on a BD FACS Canto II cytometer with BD FACSDiva acquisition software. The 
samples were run until 10000 T cell events had been acquired, or until just before the sample 
ran dry in cases with low T cell numbers. Similar gating strategy was adopted for analysing 
levels of cell surface markers on non-tetramer CD8+ T cells as well as within CD8+ CX3CR1+ 
T cells. 
1) Lymphocytes were gated according to their typical forward and side scatter 
characteristics (Figure 3.9.1 A). 
2) Singlet cells were further analysed for CD3 expression focussing only on the T cell 
population. From the CD4+ and CD8+ T cell populations, the CD8+ T cell population 
was further analysed to measure tetramer PE recognition (Figure 3.9.1 A). 
3) CD8+ T-BV510 cells were gated with tetramer-PE and only CD8+ T cell populations 
that recognized tetramer was taken for further analysis (Figure 3.9.1 A). 
4) Cell surface markers such as CX3CR1, S1PR1, c-met, CCR5, CCR4 and CXCR3 were 
plotted against side scatter to ascertain the level of expression of these cell surface 
molecules in tetramer CD8+ T cells (Figure 3.9.1 B).  
114 
 
 
 
Figure 3.9.1 Gating strategy for tetramer CD8+ T cells. A. Lymphocytes were gating according to 
their forward and side scatter characteristics. Next, the lymphocytes were gated FSC-A against FSC-H 
to identify the singlets. The singlets were then gated on to identify CD3+ T lymphocytes. The CD4+ and 
CD8+ T cell populations were identified from the CD3+ population. The CD8+ T cell population was gated 
with tetramer-PE and double positive CD8+ T cell populations were considered for further analysis. B. 
All the cell surface markers shown were plotted against side scatter to measure the levels of these 
markers in CD8+ T cell tetramer population. This gating strategy is representative for a single patient 
sample and the similar process was performed all patient samples at all time points. 
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Figure 3.9.2 CD8+ Tetramer+ cells and various receptor positive cells within CD8+ Tetramer+ cells. 
There were no significant changes in the CD8+ T cells before PPCI and 90 minutes, 24 hours and 3 
months after PPCI except for CXCR3 tetramer+ T cells (p=0.0391). CX3CR1-fractakine receptor; 
S1PR1- Sphingosine -1 phosphate receptor; C-met- Hepatocyte growth factor receptor; CCR5- C-C 
chemokine receptor 5; CCR4- C-C chemokine receptor 4; CXCR3- G protein coupled receptor 9. p- 
value of significance. Y axis indicates cell/μl; PPCI- primary percutaneous coronary intervention. (n=8 
for 0, 90, 24 hour time points) and n=3 for 3 months post PPCI). Wilcoxon signed rank test was used 
to test for significance between two time points. 
The CD8+ tetramer+ T cells showed no correlation before PPCI/Reperfusion and 90 minutes 
after PPCI/Reperfusion (p=0.1250). Moreover, the levels of other chemokine receptors also 
did not show significant associations between ‘before PPCI’ and 90 minutes, 24 hours and 3 
months after PPCI except for CXCR3+ tetramer+ cells which showed a significant drop at 90 
minutes from pre-PPCI levels (p=0.039) (Figure 3.9.2). 
In contrast to CD8+ Tetramer cells, the non-tetramer CD8+ T cells showed a significant drop in 
T cell count at 90 minutes after PPCI (p=0.0010) but by 24 hours and 3 months, had returned 
to pre-PPCI levels. CX3CR1+ cells within non-tetramer CD8+ cells also showed a significant 
drop at 90 minutes (p=0.0010). Furthermore, CXCR3+ (p=0.012), CCR4+ (p=0.008), CCR5+ 
(p=0.033) cells also showed a significant loss at 90 minutes before recovering at 24 hours. The 
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other cell surface receptors did not show any significant difference between the different time 
points. 
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Figure 3.9.3 CD8+ Non-Tetramer cells and various receptor positive cells within CD8+ Non-
Tetramer cells. A. CD8+ non-tetramer cells; B. CX3CR1+ non-tetramer cells; C. S1PR1+ non-tetramer 
cells; D. c-met+ non-tetramer cells; E. CCR4+ non-tetramer cells; F. CCR5+ non-tetramer cells; G. 
CXCR3+ non-tetramer cells. CX3CR1-fractakine receptor; S1PR1-Sphingosine -1 phosphate receptor; 
C-met-Hepatocyte growth factor receptor; CCR5-C-C chemokine receptor 5; CCR4- C-C chemokine 
receptor 4; CXCR3-G protein coupled receptor 9. p- Value of significance. Y axis indicates cell/μl; PPCI- 
primary percutaneous coronary intervention. (n=8 for 0, 90, 24 hour time points) and n=6 for 3 months 
post PPCI). Wilcoxon signed rank test was used to test for significance between two time points. 
Next, it was decided to test the presence of these cell surface receptors within the CX3CR1 
positive cells since this population was found to be important previously (Boag et al., 2015) 
and in agreement with Boag et al., 2015, we found some interesting results (Figure 3.9.4). 
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Figure 3.9.4 Presence of cell surface receptors within fractalkine-positive non-tetramer cells. A. 
CX3CR1+ cells; B. S1PR1+ cells. CX3CR1-fractakine receptor; S1PR1-Sphingosine -1 phosphate 
receptor; p- Value of significance. Y axis indicates cell/μl; PPCI- primary percutaneous coronary 
intervention. (n=8 for 0, 90, 24 hour time points) and n=3 for 3 months post PPCI). Wilcoxon matched 
signed rank test was used to compare the two time points. 
 CD8+ T cells within the CX3CR1+ population also showed a drop in T cell numbers at the 90 
minute (p=0.0078) time point before recovering at 24 hours. Naturally, CX3CR1+ cells also 
show a significant drop at 90 minutes before recovering at 24 hours. Amongst other cell surface 
receptors within CX3CR1 positive cells, only S1PR1 showed a significant drop in count at the 
90 minute time point and recovered at 24 hours. Only S1PR1+ (p=0.0195) apart from CX3CR1+ 
(p=0.0078) showed a significant correlation between the 0 and 90 minutes. (n=8 for before 
PPCI, 90 minutes after PPCI and 24 hours after PPCI and n=3 for 3 months after PPCI). 
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DISCUSSION 
 
Higher IFN-γ Responses in CMV-seropositive patient PBMCs 
 
In response to PHA (non-specific polyclonal activator) stimulation, the CMV-seropositive 
STEMI patients’ PBMCs produced higher levels of IFN-γ (Th1 cytokine) compared to CMV- 
seronegative STEMI patients immediately before reperfusion, whereas the levels of IL-5 (Th2 
cytokine) and IL-17 (Th17 cytokine) (Figure 3.2.1) showed no differences between groups 
suggesting that Th1 cells are more dominant in CMV-seropositive patients during 
inflammatory conditions. Thus, there is greater potential in the events leading up to ischemia 
for Th1 cells to infiltrate the myocardium. Cheng et al., in 2005 showed that acute MI patients 
had higher numbers of IFN-γ (Th1 cytokine) producing cells compared to patients with 
unstable and stable angina. The high production of IFN-γ was evident at even one month after 
ischemic attack. There was however, no differences in the production of IL-4 (a Th2 cytokine) 
among the three groups. This suggests a preference towards a Th1 phenotype rather than a Th2 
phenotype during acute myocardial ischemia. The Cheng research group, however, did not 
investigate the role of Th17 cytokines. De Boer et al., in 2010 showed the presence of IL-17A, 
IL-17F and neutrophils in thrombus specimens suggesting a role for IL-17 in the growth and 
stabilization of thrombus after myocardial ischemia. Eid et al., in 2009 showed that IFN-γ and 
IL-17 were produced in high amounts by T cells within the coronary arteries, suggesting both 
these cytokines act synergistically to induce a pro-inflammatory response. However, the 
presence or absence of CMV-specific T cells in patients was not addressed by both research 
groups. Simon et al., in 2012 found that acute MI patients with low amounts of IL-17 in serum 
were strongly linked to worse prognosis and increased levels of IL-17 was associated with 
better outcomes in MI patients. We, however, did not find any difference between CMV-
seropositive patients and CMV-seronegative patients in their production of IL-17 by T cells in 
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response to stimulation with PHA. A more comprehensive investigation is required to identify 
a role for Th17 cells in myocardial infarction.   
Release of cytokines in patient serum supernatants 
 
Subsequent to the elevated levels of IFN-γ before PPCI detected by ELIspot, there was also an 
increase in serum IFN-γ levels in CMV-seropositive patients after PPCI. The levels of IFN-γ 
in serum samples of patients 30 minutes after reperfusion were significantly higher in CMV 
seropositive patients than in CMV seronegative patients. Although not significant, the levels 
of IFN-γ in CMV-seropositive patients at 15 minutes and 90 minutes after reperfusion/PPCI 
were also higher than the levels in CMV-seronegative patients. Although increase in IFN- 
levels in patients is in agreement with most research groups and is one of the main focus in the 
thesis, it will also be interesting to study the levels of other pro-inflammatory cytokines 
released in much more detail. 
Haider et al., in 2015 showed that IFN-γ levels in CMV seropositive MI patients was much 
higher than the levels in CMV seronegative MI patients. Furthermore, Liang et al., in 2017 
found that patients with coronary artery disease had significantly higher serum levels of 
CD40L, monokine induced IFN-γ/CXCL9 (MIG) and IFN-γ than the control group. Moreover, 
severe Coronary Artery Disease (CAD) patients had higher levels of MIG than moderately 
affected CAD patients indicating that MIG might play a role in the development of 
atherosclerosis as well as promote the increase in size of coronary artery lesions.    
Expression of other cytokines such as TNF- and IL-1 are also associated with myocardial 
infarction. The role of TNF- in myocardial infarction is pleotropic. Despite being associated 
with promoting cardiac injury and chemokine synthesis in the myocardium, they also protect 
cardiomyocytes from apoptosis. IL-1 is actively involved the recruitment of leukocytes into 
the myocardium (Frangogiannis, 2004).  
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Relationship between Total ischemic time and CMV serology in patients 
 
Total ischemic time is the total time from the onset of ischemia to medical contact, otherwise 
known as door to balloon time. We tried to find any relationship between total ischemic time 
and CMV serology of patients (Figure 3.3.1). We found CMV-seropositivity or CMV-
seronegativity of patients had no impact on the total ischemic time. This clearly indicates that 
‘speed of treatment’ rather CMV seropositivity determines the extent of damage in the 
myocardium after MI. Thus, longer ischemic time equals more damage to the heart tissue. 
IFN-γ spot forming cells/M in CMV-seronegative patients in response to PHA stimulation was 
lower and positively correlated with total ischemic time whereas in CMV-seropositive patients, 
IFN-γ spot forming cells/M was much higher and did not correlate with total ischemic time. A 
possible explanation for this phenomenon would be that in CMV-seronegative patients, the 
homing of T cells away from the myocardium will ease the extent of damage to the heart tissue. 
In CMV-seropositive patients, the homing of T cell into the heart tissue causes the increase in 
the release of IFN-γ by CMV-specific T cells which causes more damage to the heart tissue. 
This might explain the high production of IFN-γ in CMV-seropositive patients.  
Tetramer analysis of CD8+ T cell population before and after PPCI/Reperfusion 
 
We analysed monocyte, CD3+ T cell, CD4+ T cell and CD8+ T cell population in CMV-
seronegative and CMV-seropositive patients before PPCI/Reperfusion. Only CD8+ T cells were 
increased in CMV-seropositive patients whereas other cell population showed no difference 
between CMV-seropositive and CMV-seronegative groups, suggesting increased circulation 
of CD8+ T cells with ability to circulate into and out of the myocardium prior to and during 
ischemic attack. CMV-specific CD8+ T cells as a percentage of total CD8+ T cells, determined 
through HLA type 1 specific tetramer analysis ranged from 0.2 to 18%. The next step was to 
check the levels of CD8+ T cell levels after reperfusion. Flow cytometric analysis of HLA 
specific tetramers (See chapter 2, section 2.5.2) revealed a significant drop in CD8+ T cell count 
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at 90 minutes after reperfusion. Although CD8+ T cell count increased at 24 hours after 
reperfusion, they were still significantly lower than the levels before reperfusion. Forteza et al., 
2018 noticed a significant drop in both CD4+ and CD8+ T cell count 24 hours after PPCI and 
this level was restored to pre-PPCI levels at day 4. Interestingly, Th1 cells and not Th2 showed 
the drop which is yet another strong indicator of T cell homing to the myocardium.    
Hoffmann et al., 2015 suggested that CD8+ T cells were temporarily directed away from 
circulation to the myocardium through either the sphingosine pathway or the fractalkine 
pathway. Sphingosine-1-phosphate is a lipid messenger that uses G-protein coupled receptor 
for signalling purposes (Matloubian et al., 2004). Matloubian research group generated       
S1P1-/- mouse chimeras by transferring fetal liver cells from S1P1 knockout mice. These mouse 
chimeras showed a near complete absence of peripheral T cells. Moreover, T cells were also 
absent from the spleen, lymph nodes as well as Peyer’s patches. There were however, increased 
numbers of single positive CD4+ and single positive CD8+ thymocytes. The presence of these 
cells in the thymus but absence in secondary lymphoid organs and in circulation show the lack 
of egress of T cells from the thymus in the absence of S1P1. To investigate the role and 
importance of S1P1 in the circulation of T cells in the peripheral blood, thymocytes from the 
S1P1-/- and control thymocytes were transferred into wild-type recipient mice. It was found, 
unlike control thymocytes which were present in peripheral blood, lymph and secondary 
lymphoid organs, the S1P1-/- thymocytes were absent from the blood and lymph but were 
present in the secondary lymphoid organs suggesting S1P1 is vital for the egress of T cells 
from peripheral blood and lymph to the secondary lymphoid organs. In addition, only highly 
matured single positive thymocytes (CD4+ and CD8+) are capable of strong chemotactic 
responses to S1P1. Thus, S1P1R plays an important role in lymphocyte migration. The role of 
S1P in Myocardial infarction and ischemic injury was investigated by Means et al., (2007). 
S1P3 and S1P2 deficient mice had a larger infarct size than wild-type mice in artificially induced 
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I/R injury which suggests that S1P has a protective function in ischemic reperfusion injury. 
Knapp et al., in 2009 found that the levels of S1P in plasma with myocardial infarction was 
lower immediately after reperfusion. They suggested that the loss of S1P from plasma causes 
a reduction in the protective effect of S1P in myocardial infarction patients. So, it is possible 
that at 90 minutes after reperfusion, coupled with permanent loss of S1P1r+ CD8+ T cells, there 
is also migration of anergic S1P1r+ CD8+ T cells to the myocardium. The second pathway 
mentioned by Hoffmann et al., (2015) was the pathway that involves fractalkine (CX3CL1) 
(Please refer to ‘Flow cytometric Analysis of tetramer and non-tetramer CD8+ T cells section’). 
Depletion of PD-1+ terminally differentiated CD8+ effector memory T cells (TEMRA)  
 
The drop in percentage of CD8+ T cells at 90 minutes after PPCI/Reperfusion was intriguing. 
We wanted to find out which subset of CD8+ T cells was responsible for the drop.  Prior to 
reperfusion, the percentages of activated terminally differentiated effector memory CD8+ T 
cells (TEMRA) was significantly higher than the percentage of naïve CD8
+ T cells (Figure 
3.5.1A). Thus, it made sense to focus on TEMRA cells (after PPCI/Reperfusion) which expressed 
high levels of PD-1. Coinciding with the drop in CD8+ T cells at 90 minutes, we found there 
was a permanent drop in PD-1 expressing TEMRA cells at 90 minutes post reperfusion compared 
to baseline levels (Figure 3.5.1B). 
Zajac et al., in 1998 reported that persistent antigenic presence decreases the responsiveness of 
anti-viral CD8+ T cells of mice chronically infected with lymphocytic choriomeningitis virus 
(LCMV) and suggested that the unresponsiveness of CD8+ T cells could be further exacerbated 
in the absence of CD4+ T cells and professional antigen presenting cells. Barber et al., in 2006 
using genome wide microarray analysis, found the presence of PD-1 mRNA in exhausted CD8+ 
T cells of mice infected with LCMV whereas functional CD8+ T cells expressed very low levels 
of PD-1. Kinetic studies on PD-1 expression by the Barber research group also showed that 
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PD-1 expression during acute infection is rapidly downregulated whereas in a chronic 
infectious setting, the expression of PD-1 is increased and sustained for a long period of time.  
In humans, Cytomegalovirus (CMV) causes low grade persistent infection and elicits very 
strong memory T cell responses in CMV-seropositive healthy individuals. However, as time 
progresses, CMV slowly dominates the entire T cell repertoire and thus impairs T cell 
functioning against other pathogenic antigens.  Most CMV-specific CD8+ T cells have effector 
memory T cell phenotype (TEM) (Klenerman & Hill, 2005). Interestingly, we found that the 
percentage of PD-1 expressing TEMRA cells in CMV-seropositive patients is significantly lower 
than the percentage in CMV-seronegative patients at 24 hours after PPCI/Reperfusion (figure 
3.5.3). This might indicate that the presence of CMV causes a persistent activation of TEMRA 
cells leading to their eventual depletion. In addition, in CMV-seropositive patients, the 
percentages of PD-1+ TEMRA cells were significantly lower than effector memory T cells (TEM ) 
suggesting that these cells are the most affected after reperfusion.   
The high expression of PD-1 on T cells makes them more sensitive to apoptosis and thus we 
wanted to determine early and late apoptosis in PD-1+ T cells before reperfusion. The presence 
of annexin V only indicated early or spontaneous apoptosis whereas the presence of both 
annexin V and 7-AAD indicated late apoptosis.  As expected CD8+ T cells expressing high 
levels of PD-1 and medium levels of PD-1 were more numerous than PD-1 negative cells. PD-
1 negative T cells showed only early or spontaneous apoptosis whereas PD-1dim and PD-1high 
cells showed both early and late apoptosis. The percentages of early apoptosis were higher in 
PD-1 negative and PD-1dim cells whereas the percentage of late apoptosis was much higher in 
PD-1high cells. This suggests that T cells expressing medium and high levels of PD-1 are more 
prone to apoptosis and cell death. This was corroborated by the fact that PD-1high cells were 
present in least numbers compared to PD-1negative and PD-1dim cells among the total percentage 
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of live cells. Thus, the loss of CD8+ T cell due to high expression of PD-1 diminishes CD8+ T 
cell mediated immunity.  
Barber et al., in 2006 also used PD-L1 blocking antibody in LCMV specific CD8+ T cells in 
mice. The virus-specific T cells showed improvement qualitatively (functionality) as well as 
quantitatively. Petrovas et al., in 2006 also reported the increase in proliferative capacity of 
HIV- and CMV-specific CD8+ T cells obtained from PBMCs of HIV positive and HIV negative 
volunteers. So, we decided to find out if the loss of cells could be salvaged. To achieve this, 
we wanted to see the difference in the percentage of late apoptosis in T cells stimulated with 
CD3, a polyclonal activator of T cells, and the addition of PD-1 blocking antibody. We found 
the percentage of late apoptosis was significantly lower in CMV-specific T cells with PD-1 
blocking antibody than with T cells with no blocking antibody. Our results indicate a strong 
connection between increased expression of PD-1 and the exhaustion/ loss of CMV-specific T 
cells and TEMRA cells.  
Cytokine production by CD8+ and CD4+ T cells in CMV and EBV seropositive AMI 
patients 
 
In the next study group (group B), by carrying out ex-vivo ELIspot experiments, we found 
CMV-specific CD4+ T cells show a drop in production of IFN-γ at 90 minutes after 
PPCI/reperfusion and recover by 24 hours. However, there were no changes in the CD8+ T cell 
compartment, i.e. the production of IFN-γ remained stable throughout all time points. Cultured 
ELIspot responses, in contrast, did not show any significant changes across any time point for 
the CD4+ T cell compartment. The cultured CD8+ T cell responses showed a significant 
increase at 24 hours compared to pre-reperfusion levels. The sustained production of IFN-γ by 
effector CD8+ T cells (ex-vivo ELIspot), memory CD8+ T cells (Cultured ELIspot) and memory 
CD4+ T cell response, might suggest a lack of self-termination mechanisms and might lead to 
exacerbation of inflammation in CMV-seropositive MI patients. This result also indicates that 
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the memory T cells seem to be the primary cell type behind the sustained release of IFN- 
which could eventually lead to increased apoptosis of these cells.  
The focus then shifted to ex-vivo ELIspot and cultured ELIspot EBV-specific CD4+ T cell and 
CD8+ T cell responses. Ex-vivo ELIspot EBV-specific CD4+ T cell response showed a drop at 
90 minutes after PPCI which recovered at 24 hours.  EBV-specific CD4+ T cell Cultured 
ELIspot response, however showed no changes before PPCI and 90 minutes after PPCI and 
production of IFN-γ remained stable. There was however, significant increase in production of 
IFN-γ at 24 hours after PPCI. Ex-vivo ELIspot EBV-specific CD8+ T cell response showed no 
changes before PPCI and 90 minutes after PPCI and production of IFN-γ remained stable. 
There was however, significant increase in production of IFN-γ at 24 hours after PPCI. EBV-
specific CD8+ T cell cultured ELIspot response, showed a dip at 90 minutes (non-significant) 
before recovering at 24 hours. It was noted that T cell responses to CMV in ex-vivo ELIspot 
were much higher compared to T cell responses to EBV. 
Non-specific activation of patients’ PBMCs with PHA also gave interesting results. Cytokines 
such as IL-5 and IL-17 which represent Th2 and Th17 cells, respectively, showed no difference 
across all time points in CMV-seropositive and CMV-seronegative patients. However, there 
was decline in production of IFN-γ and IL-2 at 90 minutes after reperfusion. This indicates that 
Th1 but not Th2 and Th17 cells are predominantly in AMI patients and Th1 cells could home 
to the myocardium. The current understanding is that the immune system limits the magnitude 
of the effector functions of T cells to make sure excessive inflammatory reactions and 
autoimmune reactions are minimized. This exhaustion or anergy of T cells occurs due to the 
chronic exposure of T cells to viral antigens (in this study CMV and EBV) (Vigano et al., 
2012).  Thus, the apparent loss in effector T cell responses is most probably due to functional 
anergy and their subsequent trafficking from circulation and into inflamed tissues, including 
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the heart tissue. Research by Pasqui et al., in 2005 found increased levels of IFN- in AMI and 
patients with unstable angina. They isolated lymphocytes from peripheral blood and stimulated 
them with PHA and LPS to test the release of pro-inflammatory cytokines. Liuzzo research 
group in 2007 reported on the expansion of a CD4+CD28null T cell subset in unstable angina 
patients. These cells were also present in the plaque regions and associated with increased 
levels of C-reactive protein and myocardial infarction. This subset is considered to have Th1 
functionality and is strongly associated with the exacerbation of chronic inflammatory diseases. 
These cells are resistant to apoptosis as well as resistant to the influence of Tregs and secrete 
high amounts of IFN- and TNF- (Dumitriu, 2015). In the previous section, we described the 
permanent loss of the PD-1 expressing CD8+ TEMRA. We believe the constant activation of 
CMV-specific T cells will eventually lead to PD-1 mediated apoptosis as well as functional 
anergy and exhaustion. Thus, it is possible that in AMI patients the combination of TEMRA cells 
and CD4+CD28null T cells account for the production of high amounts of IFN- production. 
However, while terminally differentiated effector memory CD8+ are prone to PD-1 mediated 
apoptosis, the CD4+CD28null T cells continue their potent inflammatory action due to them 
being resistant to apoptosis. This could explain the sustained and stable IFN- secretion as 
shown in figure 3.7.2 and figure 3.7.4.   
Among the 11 cytokines tested by meso scale discovery, we found levels of IL-16 were 
decreased in CMV-seropositive patients and increased in CMV-seronegative patients. In 
addition, we also found that the drop in IL-16 levels at 90 minutes after PCCI correlated with 
the CD4+ T cell count at the same time point (Figure 3.7.6 C). IL-16 is a chemoattractant for 
CD4+ T cells and is involved in the migration of Th1 cells in the presence of CCR5.  Through 
the action of IL-16 on its receptor, CD4 elicits a greater migratory response in Th1 subset 
compared to Th2 subset. Also, the presence of CCR5 strengthens the binding capacity of IL-
16 to CD4 receptor. The presence of CCR5 could lead to the recruitment of T cells into sites 
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of inflammation (Lynch et al., 2003). This could explain the temporary drop in T cell numbers 
at 90 minutes after PPCI.  
Analysis of the relationship between Microvascular obstruction with Ex-Vivo and 
Cultured ELIspot 
  
To our best knowledge, we are the first group to identify correlations between microvascular 
obstruction and ELIspot responses. Microvascular obstruction (MVO), or no-reflow 
phenomenon, occurs in patients after PPCI. MVO is characterised by the structural and 
functional changes to the myocardium such as endothelial destruction, emboli of neutrophils 
and platelets, and release of free radicals. The extent of MVO is a good indicator of reperfusion 
injury.  Only CMV-specific cultured ELIspot CD8+ T cell response at 24 hour time point and 
cultured EBV-specific CD4+ T cells at 24 hour time point showed a positive association with 
MVO. No ex-vivo ELIspot response correlated with MVO. Thus, memory T cell responses 
rather than effector T cell responses seem to influence the extent of MVO in STEMI patients. 
IFN-γ production by cultured CMV-specific CD8+ T cells and by cultured EBV-specific CD4+ 
T cells at 24 hours after PPCI was the highest compared to all other time points. The extent of 
MVO was also highest at this time point. Our hypothesis suggests that increased production of 
Th1 cytokine, IFN-γ, by memory T cells causes increased inflammation which might lead to 
increased microvascular obstruction. While MVO is a good indicator of post-MI reperfusion 
injury, peak troponin levels is a good indicator of infarct size and pre-MI diseased condition. 
Cultured CMV-specific CD4+ T cell response before PPCI (0 minute time point) negatively 
correlated with peak troponin levels as did Cultured CMV-specific CD8+ T cell response at 24 
hours after PPCI. There were no other correlations between troponin levels and ELIspot 
responses. 
We also found no meaningful differences between ex-vivo CMV-specific CD4+ and CD8+ T 
cell responses and MVO levels (high, low and none) i.e. there was no difference in MVO levels 
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before and after reperfusion. In contrast, ex-vivo EBV-specific CD8+ T cell responses were 
higher in the ‘none’ MVO group compared to ‘high’ and ‘low’ MVO group at all-time points. 
Ex-vivo EBV-specific CD4+ T cell responses were also higher in the ‘none’ MVO group 
compared to ‘high’ and ‘low’ MVO groups. Among cultured ELIspot responses, the release of 
IFN-γ from CMV-specific CD4+ T cells was higher in ‘none’ MVO group. There were no 
differences among the MVO groups for CMV-specific CD8+ T cell responses. There were no 
meaningful correlations between MVO groups and cultured EBV ELIspot responses. Release 
of IFN-γ by non-specific activation of T cells with PHA also did not show any significant 
results. IL-5 and IL-17 production at 24 hours after PPCI were significantly higher in the ‘none’ 
MVO group compared to the ‘low’ group. The production of IL-2 before PPCI and at 90 
minutes after PPCI was higher in the ‘none’ MVO group. It is plausible that unequal numbers 
of patient samples 12 for ‘high’ MVO, 10 for ‘low’ MVO and 15 for ‘none’ MVO may be the 
reason for lack of differences between T cell response and cytokine production with the extent 
of MVO in patients. 
Flow cytometric Analysis of tetramer+ and non-tetramer+ CD8+ T cells 
 
Within CD8+ tetramer+ cells, only CXCR3+ cells showed a significant drop at 90 minutes after 
PPCI. Levels of other receptors such as CX3CR1, S1PR1, C-met, CCR5 and CCR4 remained 
unchanged. In contrast, within non-tetramer CD8+ T cells, levels of CX3CR1, CCR5, CCR4 
and CXCR3 showed a significant drop at 90 minutes before recovering at 24 hours after PPCI. 
The difference between the tetramer+ and non-tetramer+ cells might be due to limited number 
of MHC complexes tested in tetrameric T cells and also due to the low cell count in tetramer 
samples. CXCR3, is a chemokine receptor that plays an important role in antiviral immunity. 
CD8+ T cells upregulate this receptor in responses to viral infections and CXCR3 signalling is 
involved in T cell recruitment into virus-infected and inflamed tissues. In a vaccinia virus 
model, it was found that CD8 T cells in Cxcr3-/- mice were characterized by reduced capacity 
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to locate and destroy virus infected cells. The adoptive transfer of wildtype CD8+ T cells 
restored viral clearance in Cxcr3-/- mice (Hickman et al., 2015). 
The presence of other cell surface receptors within CX3CR1+ non-tetrameric CD8+ T cells was 
also carried out. Only CX3CR1 and S1PR1 showed a significant drop at 90 minutes after PPCI. 
This might indicate the combined action of S1PR1 and CX3CR1 in the migration of CD8+ T 
cells away from circulation. The role of CX3CR1 or fractalkine in the depletion or trafficking 
of T cells was investigated by Boag et al., (2015). They found a strong correlation between the 
level of expression of fractalkine on T cells and the drop in T cell count.  The expression of 
CX3CR1 on effector CD8+ T cells lacking in CCR7 was the highest. Gene transcription studies 
also showed the varied changes in fractalkine levels before PPCI, at 24 hours and at 3 months 
after reperfusion. Moreover, the increase in serum fractalkine levels coincided with the drop in 
CD8+ T cells at 90 minutes after PPCI. Boag’s research suggested that the drop in CX3CR1 
expressing T cells could be due the downregulation of fractalkine at 90 minutes, or the 
trafficking of CD8+ T cells from the blood stream into the heart tissue or the binding of serum 
fractalkine with T cells. Ikejima et al., (2010) showed that patients with coronary artery disease 
(stable and unstable angina) had significantly higher levels of serum fractalkine levels as well 
as CD3+ CX3CR1+ T lymphocytes compared to healthy controls. They concluded that the 
elevated levels of serum fractalkine combined with CD3+ CX3CR1+ T lymphocytes and CD3- 
CX3CR1+ monocytes contribute to plaque rupture and the eventual MI. Damas et al., in 2005 
showed significantly elevated levels of serum CX3CR1 and CX3CR1+ CD8+ T cells in patients 
with myocardial infarction than in healthy controls.  The percentage of CX3CR1+ CD4+ T cells, 
however, showed no changes in patient group compared to healthy controls. The elevated levels 
of fractalkine and CX3CR1+ CD8+ T cells dropped 6 months after treatment with atorvastatin. 
Thus, they suggested that the use of atorvastatin may help in the reduction of fractalkine-
mediated T cell recruitment and reduce inflammation. The administration of atorvastatin led to 
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the decrease in lipid levels in plasma. Atorvastatin also reduced the levels of CX3CR1 and 
CX3CL1, reducing fractalkine related inflammatory response in coronary artery disease 
patients. In AMI patients who died, immunohistochemistry analysis was performed. It was 
found that T cells in the lesion expressed high levels of CX3CR1 indicating infiltration of these 
cells via a fractalkine-mediated mechanism. In addition, it was also shown how CX3CR1 
genotypes affect Th1 cell recruitment. The I249 allele of CX3CR1 correlated with decreased 
recruitment of Th1 cells and lower IFN- production. Thus, the authors suggested the use of 
fractalkine genotype as a marker to stratify population suffering from AMI (Pucci et al., 2013). 
 
CONCLUSION 
 
In overall conclusion, CMV+ MI patients have higher Th1-mediated chronic inflammatory 
responses (IFN) than CMV- patients. CD8+ T cells with TEMRA PD-1+ phenotype, in which 
CMV-specific T cells reside, are reduced during myocardial reperfusion, likely via fractalkine-
mediated homing to the myocardium. This reveals mechanistic insight and suggests a treatment 
option in MI+R injury of targeting these cells and associated molecules, possibly with 
monoclonal antibodies that block or neutralize IFN and fractalkine. 
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CHAPTER 4 
Immune Responses in Chronic 
Fatigue Syndrome (CFS) 
Abstract 
 
Background  
CFS is a disease that affects the central nervous system and the immune system and is 
characterised by other comorbidities such as gastrointestinal infection and cognitive 
impairment. Although CFS can affect people of all ages and genders, women are most affected. 
Despite being an idiopathic disease, dysfunction of the immune system is widely reported in 
CFS patients, with changes in the T cell, B cell and NK cell compartments in particular.  Herpes 
viruses such as EBV are considered to be one of the viral triggers that leads to the onset of 
CFS. Apart from EBV, immune responses against various microbes have been proposed as a 
causative link. This study aims to utilize various immunological phenotypic assays to compare 
the immune responses of CFS patients to healthy controls, and potentially identify changes that 
could serve as a biomarker of pathogenesis and offer therapeutic insights.   
Aims  
The aim of this study was to measure and compare immune responses, particularly those direct 
against microbes, in patients suffering from CFS, and in healthy controls. The identification of 
immune parameters and any immune abnormalities in CFS patients will help in better 
understanding of the CFS disease aetiology and suggest diagnostics and treatments. 
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Methods  
CFS patients were recruited by our clinical collaborators at the Royal Victoria Infirmary (RVI) 
as well as the CRESTA clinic at the old General Hospital site. The Fatigue Impact Scale (FIS) 
was used by our clinical collaborators to measure the fatigue levels in patients. ELIspot was 
used to test cytokine production by stimulating PBMCs with antigenic stimuli including CMV 
and EBV. ELISA was performed to test for antigen-specific antibodies in serum samples of 
patients and healthy controls. Multiplex cytokine analysis was performed to test for the release 
of cytokines in cell culture supernatants of patient samples. Flow cytometry was used to analyse 
T cell, B cell and NK cell populations and their subsets including mucosal associated invariant 
T cells (MAIT), natural killer T cells (NKT) and gamma delta T cells (TCRγδ). 
Results  
There was a negative correlation between percentages of NK cells and FIS score (p=0.04), and 
severely affected patients had lower NK cell numbers than mild or moderately affected CFS 
patients. Moreover, the percentage of NK cells, and CD57+ NK cells, were significantly lower 
in CFS patients than in healthy controls. Furthermore, the percentages of CD3+ MAIT and 
CD4+ T cells were significantly higher in CFS patients than in healthy controls whereas the 
percentages of CD8+ T cells were significantly lower in CFS patients compared to healthy 
controls. No correlations were found in antibody and cytokine analyses with FIS scores.  
Surprisingly only PMAi, a positive control used in ELIspot, positively correlated with FIS 
score. 
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Conclusion  
The results suggest abnormalities in the immune system in individuals with chronic fatigue, 
including raised non-specific IFNsecretion. The NK cells seem to be the most affected, as 
reported widely in research reports on CFS. 
Introduction 
 
CFS is defined as the onset of debilitating fatigue for a period of 6 months or more, 
characterized by at least short-term memory loss, sore throat, tender cervical and auxiliary 
lymph nodes, headaches, joint pain and lack of proper sleep. Conditions such as bipolar 
disorder, eating disorders, substance abuses, depression and psychosis are typically excluded 
from patient diagnosis of CFS (Brenu et al., 2010). CFS is considered a nervous system 
disorder caused by changes in the immune system due to microbial infections, and 
heterogeneity among patient groups suggests CFS is a multifactorial condition. Unfortunately, 
CFS still lacks defined biomarkers or clinical signs that would confirm the condition. It is 
believed that through the study of the immune system in CFS patients, suitable biomarkers may 
be discovered (Lorusso et al., 2009). CFS is categorized by the FIS which had 
recommendations made by Fukuda et al., in 1994. Some of the important recommendations 
that were made were diagnosis of people with prolonged fatigue (longer than 1 month) 
accompanied by clinical and laboratory evaluation to include or exclude other ailments that a 
fatigued patient might have. In addition, a thorough psychiatric and physical examination was 
also included as a recommendation to ensure all physical and mental information about patients 
are known. 
Numerous research studies have shown discrepancies in immune responses in CFS patients. 
Fluge et al., (2011) showed that the depletion of B cells using rituximab (anti-CD20) in patients 
with CFS decreased the chronic fatigue in 3 patients who were all able to return to normal life. 
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Thus, they suggested that CFS might be an autoimmune-related disease. Curriu et al., (2013) 
in contrast found no changes in the B cell compartment of CFS and healthy control group. 
Although the expression of CD69 and NKp46 was higher in NK cells of CFS patients, no 
significant correlations were found in the NK cell compartment. However, the level of 
regulatory T cells in CFS patients was increased. Furthermore, increased expression levels of 
CD5 and decreased levels of CD38 were also reported. Brenu et al., in 2010 showed a 
decreased ability of NK cells of CFS patients to lyse K562 target cells in addition to reporting 
dysfunction of neutrophil function. Brenu et al., (2013) showed significant changes in the 
immune cells of CFS patients. Elevated levels of regulatory T cells were shown in agreement 
with Curriu et al., (2013). In addition, decrease in Plasmacytoid DCs, immature B cells, but 
increase in memory B cells was also reported. They also reported that reduced NK cell 
cytotoxic function, as the ability of NK cells of CFS patients to lyse K562 cells, was 
significantly lower.  Maes et al., (2012) showed that plasma of CFS patients showed elevated 
levels of interleukin-1, TNF-α, neopterin, lysozyme and PMN-elastase. This might suggest the 
existence of low grade inflammation in CFS patients. It is to be noted that the Maes group used 
Fibromyalgia and Chronic fatigue syndrome rating scale (FF) which is different from the FIS. 
Navaneetharaja et al., in 2016, in their review, suggested that CFS might be an autoimmune 
disease.  Germ-free animal models have been shown to have minimal or no sign of autoimmune 
disease suggesting that intestinal microbiota might be a contributing factor or trigger in CFS. 
The co-existence of CFS along with gastrointestinal conditions such as irritable bowel 
syndrome also point to the role of intestinal microbiota in the exacerbation of CFS. Apart from 
intestinal microbiota, Carding group also suggested that viruses, including bacteriophages, 
might also play a role in the onset of CFS in people. The gut microbiota could possibly also 
influence the central nervous system (CNS), thus creating an immune system-nervous system 
axis in CFS. Cameron et al., (2010) studied the role of human herpes virus 6, cytomegalovirus 
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(CMV) and Epstein-Barr virus (EBV). Although, they did not find any significant results, it is 
still an interesting prospect to study the role of these viruses in CFS patients. The research of 
this study into CFS, hopes to find consistencies with the data obtained from other prominent 
research groups as well as identify novel immunological changes that will help us better 
understand CFS. 
In our experiments, we tested CFS patient PBMCs and serum for immune reactivity of 
lymphocytes and antibodies, respectively, against a wide variety of pathogens to identify links 
between the Fatigue Impact Scale and immune measurements. The comparison of patient data 
with healthy control data may give new insights into the immune dysfunction in CFS patients. 
The identification of suitable diagnostic markers or biomarkers is the prime aim of researchers 
in chronic fatigue. To achieve this, it was vital to establish assays and set up parameters for 
experiments to ensure optimum and measurable immune responses from patient and control 
groups, with a main focus on T cell responses to bacterial and viral pathogens. T cell epitope 
peptides of selected pathogens were obtained to produce antigen panels. Appropriate 
concentrations of pathogenic antigenic peptides, and positive controls, were prepared to ensure 
optimal and measurable T cell responses. The ELIspot plate reader was set up in such a way so 
as to capture all ‘spots’ that represents all cytokine secreting cells and remove false positives. 
Experiments with blackout were repeated after cell concentration was diluted. The K562 cell 
line was used to determine natural killer cell response. Using different volumes and cell 
concentrations of PBMCs allows for the determination of the maximum NK cell response.  The 
coating concentrations of in-house ELISA was determined as the coating concentrations of 
pathogens is vital to obtain optimum antibody response. In order to remove false positive 
results, the pathogenic antigens were also endotoxin tested. Finally, gating strategies and 
spectral overlap (Flow Cytometry) for cell phenotypes was determined. 
The aims of this study were as follows: 
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1) To study antimicrobial T cell responses in chronic fatigue syndrome patients and compare 
them with immune responses of healthy controls, including testing cell culture supernatants for 
the release of cytokines using cytokine multiplex assays. furthermore, FIS scores and immune 
parameters were investigated for association. 
2) To test the production of antibodies for CFS patients and healthy controls against CMV and 
EBV by propriety ELISA, as marker of exposure. 
3) To perform flow cytometric analysis to measure the levels of T cells, B cells and NK cells 
in patients and healthy controls, to identify immune dysregulation. 
4.1 Patient demographics for the CFS study 
 
A total of 50 CFS patients were recruited by consultants Prof. Julia Newton, Prof. Fai Ng and 
Dr Gavin Spickett, and clinician Victoria Hindmarsh at the CRESTA (Clinics for Research and 
Service in Themed Assessments) and at the Royal Victoria Infirmary (RVI). Under the NHS 
guidelines, apart from Age and Sex, all other information about patients have been classified, 
considering the sensitive nature of chronic fatigue in patients. FIS scores were generated using 
the Fukuda criteria. FIS questionnaire, used to determine the FIS score by doctors, is shown in 
appendix 2. Female CFS patients far exceeded male CFS patients. Only 5 patients were male 
and the remaining 45 were females. Patients belong to a wide age group ranging from 17 to 70. 
Based on the FIS score, patients were further divided into two sub groups: patients with FIS 
scores below 100 have been classified mild or moderately affected, and patients with FIS scores 
above 100 have been classified severely affected. For statistical analysis, the mild/moderately 
affected patients are designated as group 0 and severely affected patients as group 1. The age 
and sex of patients along with their FIS scores is shown in table 4.1. 
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CFS patient identification Number Age Sex FIS score (maximum score 160) 
61 39 F 50 
63 17 F 75 
64 47 F 122 
66 57 F 88 
73 53 F 140 
80 45 F 60 
82 49 F 117 
83 26 F 110 
84 21 F 111 
86 44 F 73 
89 35 F 111 
90 42 F 85 
92 27 F 74 
93 30 F 140 
94 21 F 106 
95 45 F 80 
96 67 M 52 
101 20 M 121 
104 24 F 90 
106 48 F 125 
108 20 F 130 
110 61 M 101 
111 61 F 149 
112 62 M 146 
113 70 F 108 
116 33 F 93 
118 46 F 113 
119 43 F 102 
123 52 F 60 
124 65 F 139 
130 60 F 71 
131 26 F 57 
132 34 F 98 
133 56 F 143 
134 61 F 153 
135 47 F 96 
136 38 M 102 
138 38 F 70 
139 43 F 132 
143 21 F 91 
144 40 F 120 
145 36 F 110 
149 42 F 101 
152 21 F 94 
153 65 F 113 
154 29 F 92 
155 42 F 126 
156 28 F 99 
157 50 F 128 
158 25 F 123 
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Table 4.1 Age, Sex and FIS score of patients with Chronic Fatigue Syndrome. The details on the 
age and sex of CFS patients were obtained from our clinical collaborators at Newcastle upon Tyne 
Hospital Trust and at Newcastle University. CFS patients were given a unique identification code which 
were allocated by our clinical collaborators. The FIS score was calculated by the clinicians. 
We first decided to establish the relationship between FIS score and age to see if age played a 
role in the onset of chronic fatigue in patients. There was however no correlation between FIS 
scores of patients and their age. (Figure 4.1.1) 
 
Figure 4.1.1 Relationship between Age of CFS patients and FIS score. Pearson correlation analysis 
revealed no significant association between age of CFS patients and the fatigue impact scale score. 
R=0.099, p=0.2450. n=50. 
4.2 Bacterial Growth Curve & Lipopolysaccharide assay  
 
Maes research group in 2007, found IgA (p=0.01) levels against LPS of Pseudomonas 
aeruginosa in chronic fatigue syndrome patients was significantly higher than in patients with 
partial CFS and healthy controls, whereas the IgM response was outside significance. The 
diagnosis of the CFS patients were made using the Fibro Fatigue Scale. Thus, we decided to 
use Pseudomonas aeruginosa for our ELIspot and ELISA experiments. We proceeded to 
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produce antigen from the bacterium. In order to achieve this, the bacterial cells were grown in 
the appropriate growth medium and harvested at the middle-log growth phase where the 
bacterial cell growth is without any cell death.  
The LPS assay was used to identify the presence of endotoxins in antigenic solutions. The 
protocol for the LPS assay as well as the generation of standard curve is described in chapter 2 
(Methods). It was important to test some of the antigens for endotoxin presence before further 
use. The results are shown in Table 4.2. 
  
Figure 4.2.1 Standard Curve for the LPS assay. The endotoxin was added to the endotoxin free 
water to make a stock solution of 1EU/ml, a series of four dilutions were made from the stock solution. 
The Y axis indicates absorbance. The X axis indicates stock concentration of endotoxin. R2=0.9538. 
The endotoxin levels in antigen samples are shown in table 4.2. 
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Table 4.2 Endotoxin Levels in antigen samples 
Identification Code Pathogen tested LPS Concentration 
(ng/ml) 
Protein 
Concentration 
(mg/ml) 
PSA Pseudomonas 
aeruginosa (NCTC) 
0 16.2 
STY Salmonella 
typhimurium 
0.2 29.44 
MYCO Mycoplasma 0 1.0 
 
4.2.3 Bradford Assay 
 
The protein concentration of each bacterial antigen was measured by Bradford assay as 
described in section 2.7 of chapter 2 (Methods). Figure 4.2.2 shows the standard curve used to 
obtain the protein concentrations. The amount of protein (in µg/ml) in unknown samples was 
calculated using the equation shown in the standard curve. The concentration obtained from 
the curve was multiplied by the dilution factors of the samples. The results are shown in Table 
4.2. 
 
Figure 4.2.2 Standard curve for the Bio-Rad Bradford protein assay. The curve is produced by the 
addition of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1 mg/ml BSA in 500 μl of PBS to 250 μl of 
Bradford dye reagents. 
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4.2.4 Determination of protein content of bacterial lysates using SDS-PAGE 
 
SDS-PAGE was performed to separate proteins from lysates from different species of bacteria: 
Moraxella catarrhalis, Bordetella pertussis, Salmonella typhimurium, Pseudomonas 
aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Pseudomonas intermedia, 
all of which were considered candidate microbes to be studied. 
 
Figure 4.2.3 Visualization of protein bands of bacterial lysates. 12% SDS-PAGE was performed to 
separate proteins from the lysates of various bacteria. Lane 1-molecular weight ladder, Lane 2- 
Moraxella catarrhalis, Lane 3- Pseudomonas intermedia, Lane 4- Pseudomonas aeruginosa, Lane 5- 
Pseudomonas aeruginosa, Lane6- Pseudomonas aeruginosa (NCTC), Lane 7- Salmonella 
typhimurium control, Lane 8- Staphylococcus aureus, Lane 9- Streptococcus pneumoniae. 20 µl of 
samples were loaded into the wells. The gels were stained with Coomassie blue solution and then de-
stained with de-staining buffer. 
We found that all samples showed clear bands indicating that they are made up of proteins and 
were thus suitable to be included in our research experiments. Table 4.3 shows the antigens 
that were finally selected for use in the study. 
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4.2.5 Construction of peptide panels for microbes (CFS) 
 
Numerous peptides belonging to a wide variety of chosen microbes were chosen and used in 
our experimental study. These peptide panels were obtained through an epitope database (refer 
appendix 8). We decided to choose pathogens that were persistent and pathogens that were 
implicated or tested in CFS in other studies. Furthermore, we looked for T cell epitopes that 
could be synthesised. We tested the peptides of the following microorganisms:  
1. Cytomegalovirus (Cameron et al., 2010; Beqaj et al., 2008)) 
2. Epstein-Barr Virus (Loebel et al., 2014 ; Fremont et al., 2009)) 
3. Coxsackie virus (Schutzer et al., 2011) 
4. Human herpes virus 6,7 (Fremont et al., 2009 ; Chapenko et al., 2012)) 
5. Respiratory Syncytial virus + Rhinovirus 
6. Parvovirus (Fremont et al., 2009) 
7. Adenovirus (Buchwald et al., 1996) 
8. Pseudomonas aeruginosa (Maes et al., 2007, 2012) 
9. Purified protein derivative (PPD) of Mycobacterium tuberculosis 
10. Chlamydia (Komaroff et al., 1992 ; Chia & Chia, 1999) 
11. Salmonella typhimurium 
12. Mycoplasma (Nijs et al., 2002) 
13. Influenza (Prinsen et al., 2012 ; Magnus et al., 2015)  
 
Apart from testing peptides from the above chosen microorganisms, we included positive 
controls such as anti-CD3, phytohaemagglutinin (PHA), pokeweed mitogen (PWM) and 
Phorbol 12-myristate 13-acetate (PMA) with ionomycin. 
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4.3 Antibody Responses in CFS 
 
4.3.1 Antibody responses to CMV and EBV by propriety ELISA 
 
We used ELISA kits from Euroimmun to test IgG, IgM responses against CMV, and IgG and 
IgA responses against EBV. The immunoglobulin responses did not correlate with FIS scores. 
However, CMV-specific IgG response was just outside significance (p=0.057). 
 
 
Figure 4.3.1 Immunoglobulin responses to CMV and EBV. ELISA kits obtained from Euroimmun 
were used to measure CMV and EBV specific immunoglobulin responses. There were however, no 
correlations between Ig responses and FIS scores. A. CMV-specific IgG response (R=0.226, p=0.057); 
B. EBV-specific IgG response (R=0.049, p= 0.366); C. CMV-specific IgM response (R=-0.047, 
p=0.371); D. EBV-specific IgA response (R=0.107, p=0.229). Spearman or Pearson analysis was 
performed to obtain the above results. n=50 for all groups. 
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4.3.2 Comparison of Antibody responses to CMV and EBV between CFS patients and 
healthy controls 
Next, we compared the IgG, IgM and IgA responses to CMV and EBV in CFS patients and 
healthy controls.  Persistent pathogens such as CMV and EBV are the main focus of study and 
so we tested CMV and EBV specific antibody responses.                         
                            
   
Figure 4.3.2 Comparison of CMV and EBV specific antibody responses in CFS patients and 
healthy controls. A. CMV-specific IgG response in CFS patients and healthy controls (p=0.097); B. 
EBV-specific IgG response in CFS patients and healthy controls (p=0.4708); C. CMV-specific IgM 
response (p=0.0844); D. EBV-specific IgA response (p=0.3018). p<0.05 was considered significant. 
The comparison of two unrelated groups was performed using the non-parametric Mann-Whitney test 
or the parametric unpaired t test. n= 34 for healthy controls and n=50 for CFS patients. 
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We found no difference between CMV and EBV specific immunoglobulin responses in CFS 
patients and healthy control. Only CMV-specific IgG and IgM response were approaching 
significance. 
4.4 NK cell assay 
 
Furthermore, keeping in mind the frequent research reports on the connection between NK 
cells and CFS, it was decided to perform the Natural Killer cell assay to establish optimal 
PBMC response to K562 stimulation. This was achieved by stimulating different volumes (and 
therefore cell numbers) of PBMCs with different volumes of K562 cells. For example, 5µl of 
PBMC was stimulated with 5µl, 10µl, 25µl and 50µl of K562 cells. The volume in a single 
ELIspot well was made up to 100µl using RPMI-1640 medium with 10% FCS (R10). A similar 
process was carried to stimulate a fixed volume of K562 cells with varying volumes of PBMCs.  
The results of the assay are shown in Table 4.4.1. 
PBMC/K562 (µl) 5 10 25 50 
50 22970 33630 38300 34630 
25 3936 7608 6172 3724 
12.5 1466 2626 2732 2482 
5 495 558 789 772 
Table 4.4.1 NK cell assay. ELIspot analysis involving PBMCs and K562 cell line at different volumes 
revealed different IFN-γ spot forming cells/M and thus an optimal combination of the two would help in 
establishing ideal NK cell responses in future experiments.  
For our experiments, we chose 50µl of PBMC and 50µl of K562 cells as we felt this 
combination gave the optimum response without causing a blackout in the ELIspot experiment. 
 
 
 
 
147 
 
4.5 Anti-microbial T cell Responses in CFS patients 
 
 
4.5.1 Composition of stimuli used for T cell assays including pathogen peptides and 
lysates 
 
To perform ELIspot to test for anti-microbial recall responses and to obtain measurable spot 
forming cells/M PBMCs, generating suitable concentrations of pathogenic peptides is essential. 
Table 4.3 shows the list of antigens used for ELIspot analysis. 
Identification code 
used in experiment 
Stimuli tested Composition of antigenic stimulus 
F1 R10 Medium RPMI-1640 medium + 10% fetal calf 
serum+ 2.5ml each of penicillin and 
streptomycin + 2.5 ml of L-glutamine 
F4 P. aeruginosa 
(NCTC) 
Lysate + Peptides 
 
F6 Mycobacterium tuberculosis (TB) Purified protein derivative (PPD) + 6 
peptides 
CMV ALL Cytomegalovirus (CMV)  CD4+ and CD8+ peptides + Lysate. 
EBV ALL Epstein-Barr Virus (EBV)  CD4+ and CD8+ peptides + Lysate 
Mycoplasma  Mycoplasma pneumoniae Lysate (obtained from Native Antigen, 
Oxford, UK) 
RSV(Rh) Respiratory syncytial virus + 
Rhinovirus 
Lysates + 4 peptides for RSV and 
Lysates for Rhinovirus 
Adeno Adenovirus Peptides 
F9 Influenza  55 peptides 
Salmonella Salmonella typhimurium 1 in 500 of the original stock solution. 
(R10 is the medium used). 
BCHP Bkt Rotavirus, Coxsackie Virus,  
Human Herpes virus 6,7 and 
Parvovirus 
Peptides and lysates 
PWM Pokeweed mitogen (B cell 
mitogen) 
5µg/ml 
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PMAi Phorbol 12-myristate 13-acetate 
with ionomycin    
50 μl of Phorbol myristate acetate, 1 μl 
of Ionomycin in 2 ml of R10 = 
20 ng/ml and 1μg/ml, respectively 
F2 α-CD3 Anti-CD3 monoclonal antibody (mAb) 
1 in 200 (Mabtech) 
PHA Phytohaemagglutinin  5 ml of R10, 50 μl of PHA = 5 μl/ml 
Table 4.3 Composition of stimuli used in T cells assays including peptides and lysates. This table 
shows all the solutions used to stimulate PBMCs of CFS patients and healthy controls. Some antigenic 
solutions were diluted from a pre-existing stock solution. Antigenic solutions of pathogens thought to be 
implicated in CFS were used in this study.  
Next, we decided to focus on T cell responses of CFS patients in response to antigenic stimulus. 
This was achieved by performing ELIspot. The analysis of T cell responses along with FIS 
scores would give an initial insight into the functioning of the immune system under diseased 
conditions.  Among all the antigens and positive controls tested, only PHA (p=0.0316) and 
PMAi (p=0.008), positively correlated with FIS scores of patients’ PBMCs. However, patient 
PBMC responses to cytomegalovirus (p=0.123), a mixture of Rota virus, Coxsackie virus, 
human herpes virus and parvo virus (p=0.333), Influenza (p=0.181), Salmonella typhimurium 
(0.293), purified protein derivative of tuberculosis (p=0.225), Pseudomonas aeruginosa 
(p=0.185), Epstein-Barr virus (p=0.463), Mycoplasma (p=0.337) and K562 cell line (p=0.160) 
did not show any correlation with patients’ FIS scores. Production of IL-5 and IL-17 by patient 
PBMCs in response to positive control α-CD3 also did not show any significant correlations. 
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Figure 4.5.1 T cell responses to antigenic stimulus measured by ELIspot. CFS patient samples 
were stimulated with a wide variety of stimuli to measure T cell responses. A. Correlation between FIS 
score and spot forming cell/M for PHA; B. Correlation between FIS and PMAi; n=51, Spearman analysis 
or Pearson analysis was performed to test for associations between two groups.   
We, then proceeded to compare the ELIspot responses between severely affected CFS patients, 
mild/moderately affected CFS patients and healthy controls. We compared the immune 
responses to cytomegalovirus (CMV), Epstein-Barr virus (EBV), Salmonella typhii, 
Adenovirus, Influenza, Respiratory syncytial virus +Rhino virus (RSVRh), Pseudomonas 
aeruginosa, purified protein derivative (PPD) and K562 cell line. We also tested the production 
of IL-5 and IL-17 in response to the positive control α-CD3. 
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Figure 4.5.2 Comparison of ELIspot responses in severely affected, moderately affected CFS 
patients and heathy controls. A, B, C, D, E). Immune responses to purified protein derivative of 
Mycobacterium tuberculosis, Epstein-Barr Virus (EBV), K562 cell line, A mixture of respiratory syncytial 
virus and Rhino virus (RSVRh) respectively and Polyclonal secretion of IL-17 by PBMCs in response 
to stimulation with α-CD3 respectively. p<0.05 was considered as significant. Kruskal-Wallis test with 
Dunn’s multiple comparison test was used to analyse the patient groups and healthy controls. n=29 for 
severely affected CFS patients, n=21 for mild/moderately affected CFS patients, n=7 for healthy 
controls.  
4.6 Multiplex Cytokine analysis 
 
Multiplex cytokine analysis was carried out to test the different cytokines secreted by 
mild/moderate and severely affected CFS patients. PBMCs of CFS patients were stimulated 
with R10 medium and Epstein-Barr virus. The cell culture supernatants were cultured, and the 
release of cytokines was measured. 19 EBV seropositive patients (including mild and severely 
affected patients) were investigated. The production of IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12, 
IL-13 and IL-17 was analysed by Meso Scale Discovery. We found no significant correlations 
between mild/moderately affected CFS and severely affected CFS patients. 
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Apart from the above analysis, we also found some significant differences between EBV 
stimulated production of cytokines and cytokines released with no stimulation (negative 
control), the results of IL-5 and IL-17 is not shown here since the concentration (ng/ml) of both 
these cytokines in both groups were zero. 
 
Figure 4.6.1 Comparing the release to cytokines in steady state and EBV stimulated CFS patient 
PBMCs by Meso Scale Discovery platform. A. Release of IFN-γ in steady state condition and EBV 
stimulated CFS patients (p=0.0002); B. Release of IL-4 in steady state condition and EBV stimulated 
CFS patients (p=0.0144); C. Release of IL-10 in steady state condition and EBV stimulated CFS 
patients (p<0.0001). Either the non-parametric Wilcoxon singed rank test or the paired t test was 
performed to compare the two paired groups. p <0.05 was considered significant. n=19 (including both 
severely and moderately affected CFS patients. M-negative control, EBV- positive control. 
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4.7 Flow cytometric analyses of patient samples 
 
4.7.1 Flow cytometric gating strategy for CFS 
 
Identification of lymphocytes and their different subsets, according to expression of various 
cell surface receptors using multiple fluorescently-labelled antibodies, is the essence of flow 
cytometry, and we used it to analyse T cells, NK cells and B cells along with unconventional 
lymphocytes such as mucosal invariant T cells (MAIT) and γδ T cells (Gamma Delta T cells). 
A typical gating strategy to identify, measure and depict the levels of expression of cell surface 
receptors of CD4+ T cells, CD8+ T cells and B cells is shown below and depicted in Figure 
4.7.1. 
4.7.1.1 Gating strategy 
 
Each sample was analysed on a BD FACS Canto II cytometer with BD FACSDiva acquisition 
software. The samples were run until 10000 T cell events had been acquired, or until just before 
the sample ran dry in cases with low T cell numbers. 
1. Lymphocytes were gated according to their typical forward and side scatter 
characteristics. 
2. Lymphocytes were plotted by CD4 APC-Cy7 against side scatter as well as CD8 
BV510 against side scatter. CD4+ T cells were plotted by CCR7 PE against CD45RA 
PerCP-Cy5.5 to obtain the naïve, effector, effector memory as well as terminally 
differentiated effector memory CD4 sub populations (Figure 4.7.1). Similar process 
was carried out for CD8+ T cells (Figure 4.7.1). 
3. To measure levels of CD95, CD69 as well as PD-1 levels in CD4+ T cells, CD4+ T cells 
(APC-Cy7) were plotted against CD95 (PE-Cy7), CD69 (BV-421) and PD-1 (APC). 
Only double positive cells were taken into consideration (Figure 4.7.1). Similarly, 
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CD8+ T cells (BV-510) were plotted against CD95 (PE-Cy7), CD69 (BV-421) and PD-
1 (APC) (Figure 4.7.1). To correct issues such as non-specific interactions and 
incorrect compensation between the BV521 and BV421, brilliant stain buffer was 
added to optimize the interactions.  
4. Lymphocytes were also plotted by CD3 BV510 fluorescence against side scatter and 
classified into T cells (CD3+) and CD3- lymphocytes. 
5. CD3+ lymphocytes were also plotted by CD161 PE against TCR Vα72 APC. Cells 
positive for both markers were classified as mucosal invariant T cells (MAIT). 
Furthermore, CD3+ lymphocytes were plotted by side scatter against TCR Vα24-Jα18 
PE-Cy7 to identify natural killer T cells (NKT) (Figure 4.7.2). 
6. CD3+ lymphocytes were plotted by CD25 PE against CD127 APC. Cells positive for 
CD25 and CD127 were classified as regulatory T cells. In addition, TCR γδ was plotted 
against side scatter to obtain the γδ T cell population (Figure 4.7.2). 
7. CD3- lymphocytes were then plotted by CD16 APC-Cy7 against CD56 BV421. Cells 
positive for both markers were classified as NK cells (Figure 4.7.3) 
8. CD19 PerCP-Cy5.5 was plotted against side scatter and CD19+ B lymphocytes were 
plotted by CD27 PE-Cy7 against CD38 BV421. Cells were then classified as 
CD27+CD38+, CD27-CD38+, CD27-CD38- and CD27+CD38- B cells (Figure 4.7.3) 
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Figure 4.7.1 Flow cytometry gating strategy and expression of cell surface markers on CD4 and 
CD8 T cells. A, B. The expression levels of naïve (CD45RA+ CCR7+) central memory (CD45RA- 
CCR7+), effector memory (CD45RA- CCR7-) and TEMRA (CD45RA+ CCR7-) populations in CD4+ and 
CD8+ T cells respectively. C, D. The expression levels of CD95, PD-1 and CD69 was investigated on 
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CD4+ and CD8+ T cells respectively. These flow images are representative for one patient and the same 
process was carried out for all CFS patients and healthy controls. BD FACS Diva software was used to 
analyse data after data acquisition.  
 
 
 
Figure 4.7.2 Flow cytometry gating strategy and expression of cell surface markers on NKT cells, 
MAIT cells, Regulatory T cells and  T cells. γδ T cells and regulatory T cell populations were also 
identified and in addition, mucosal invariant T cells (MAIT) and natural killer T cells (NKT) were gated 
on CD3 Cells. These flow images are representative for one patient and the same process was carried 
out for all CFS patients and healthy controls. BD FACS Diva software was used to analyse data after 
data acquisition.  
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Figure 4.7.3 Flow cytometry gating strategy and expression of cell surface markers on B cells 
and NK cells. A. The expression levels of CD38 and CD27 on CD19+ B cells was investigated to identify 
naïve B cells (CD27-CD38-), plasma cells (CD27+ CD38+), immature B cells (CD27- CD38+) and memory 
B cells (CD27+ CD38-). B. To obtain NK cells, all CD3- were chosen and gated on cell surface markers 
CD16 and CD56. In addition, mucosal invariant T cells (MAIT) and natural killer T cells (NKT) were 
gated on CD3 Cells. These flow images are representative for one patient and the same process was 
carried out for all CFS patients and healthy controls. BD FACS Diva software was used to analyse data 
after data acquisition.  
Flow cytometric analyses of patient samples revealed the percentage of total NK cells 
negatively correlated with patient FIS scores (p=0.0036), however, the percentages of NK 
CD57+ cells and CD69+ NK cells showed no correlation. NKT cells also showed no correlation 
with FIS. Percentage of CD3+ mucosal invariant T cells also showed a negative correlation 
158 
 
with FIS scores (p=0.0375). Apart from NK cells and CD3 MAIT cells, there were no other 
associations between the FIS score and other flow cytometric measurements.  
 
Figure 4.7.4 Association between FIS scores and Flow cytometric analyses in CFS patients. A.  
Association between the percentage of NK cells and FIS score, B. Association between CD3 MAIT cells 
and FIS score. Spearman or Pearson analysis was performed to test for correlations. p denotes value 
of significance. P<0.05 were considered significant. n=51.      
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4.8 Analyses of Severe and Mild/Moderate Chronic fatigue patients 
 
Having established the correlation between FIS scores and immune measurements of CFS 
patients, we wanted to find out the differences in immune responses in High and Low chronic 
fatigue syndrome patients. Patients with a FIS score of less than 100 were considered to have 
mild/moderate fatigue whereas patients with a FIS score of above 100 were classified as 
severely affected chronic fatigue patients. IFN-γ spot forming cells/M specific to PMAi 
(p<0.0001) was significantly higher in severely affected patients. In contrast, the percentage of 
NK cells (p=0.0129) in severely affected patients were significantly lower than the NK cell 
levels in mild or moderate patients. Apart from NK cells and PMAi, we found no other 
significant differences between severe and moderately affected CFS patients.  
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Figure 4.8.1 Analyses of High and Low chronic fatigue groups. A. Severely affected chronic fatigue 
patients have higher responses to PMAi (positive control), p<0.0001); B. The percentages of NK cells 
in severely affected patients were significantly lower than in mild/moderately affected patients, 
p=0.0129). Patients with a FIS score of below 100 were classified as mild/moderate and patients above 
the score of 100 were classified as severely affected patients. n= 29 for severely affected CFS patients 
and n=21 for mild/moderately affected CFS patients. Mann-Whitney U test or the unpaired t test with 
welch correction was performed to test the relationship between the two group. P<0.05 was considered 
significant. 
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4.9 Comparison of CFS patients and Healthy control data obtained by Flow cytometry 
 
It is vital to compare the immune parameters of CFS patients to the immune measurements of 
the healthy controls. This will help in the identification of disturbances in the immune system 
of diseased individuals. Keeping that in mind, we decided to compare the percentages of NK 
cells, T cells and B cells in CFS patients to healthy controls, as measured by Flow cytometry. 
The NK cell compartment, being widely researched in patients with CFS, was analysed first.  
The percentage of total NK cells and CD57+ NK cells were significantly lower in CFS patients 
than in healthy controls. However, there were no changes in NKT cells or CD69+ NK cells. In 
addition, percentage of CD3+ MAIT cells were significantly higher in CFS patients than in 
healthy controls. 
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Figure 4.9 A Comparison of NK Cells in CFS patients and Healthy controls. A. Percentage of Toal 
NK cells in CFS patients was significantly lower than in healthy controls (p=0.0047); B. Percentage of 
CD57+ NK cells were significantly lower in CFS patients than in healthy controls (p=0.0056); C. There 
was no significant difference between the two groups in the NK CD69+ cell department (p=0.3577); D. 
Percentage of CD3 MAIT cells were significantly higher in CFS patients than in healthy controls 
(p=0.048); E. There was no difference in NKT compartment between both groups (p=0.2634); For CFS 
group, n=51; for healthy control group, n=8.  Non-parametric Mann-Whitney U test or the parametric 
unpaired t test with Welch correction was used to test the relationship between two unpaired groups.   
Next, we decided to study the differences in CD4+ and CD8+ T cell compartment in CFS 
patients and healthy controls. Variations were seen in the CD4+ T cell compartment. Total 
percentage of CD4+ T cells (p=0.023) was higher in CFS patients than in healthy controls. In 
addition, CFS patients also had higher numbers of naïve CD4+ T cells (p=0.028), but lower 
levels of central memory cells (p=0.0247), PD-1+ CD4+ T cells (p= 0.0045) and TEMRA CD4
+ 
T cells (p=0.0281).  However, activated CD4+ T cells, evidenced by the expression of CD69 
(p=0.4467), CD95+ cells (p=0.3233) and effector memory CD4+ T cells (p=0.0517) did not 
differ among both groups. In the CD8+ T cell compartment, only the total percentage of CD8+ 
T cells was significantly lower than in healthy controls (p=0.004). In addition, CD95+CD8+ T 
cells were significantly higher in CFS patients. The other CD8+ T cells subsets did not differ 
between groups. 
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Figure 4.9 B Analysis of the CD4 and CD8 T cell compartment in CFS patients and Healthy 
controls. A. The percentage of total CD4+ T cells was significantly higher in CFS patients than healthy 
controls (p=0.023); B. Central memory CD4+ T cells was significantly lower in CFS patients (p=0.0247); 
C. Naïve CD4+ T cells were significantly higher in CFS patient (p=0.0128); D. Terminally differentiated 
effector memory T cells (TEMRA) was also significantly lower in CFS patients group (p=0.0281); E. CD4+ 
T cells expressing PD-1 were also lower in CFS patients (p=0.0045); F. Percentage of total CD8+ T 
cells was significantly lower in the CFS patient group (p=0.004); G. CD95+CD8+ T cells were higher in 
the CFS patient group compared to healthy controls (p=0.022). For CFS patients group, n=51 and for 
the healthy control group, n=8. Mann-Whitney U test or the unpaired t test with welch corrections was 
performed to analyse both groups.  
We then analysed the B cell compartment to identify more immune differences between the 
CFS patient group and healthy control group. It was found that CD19+ B cells were 
significantly elevated in the patients’ group (p=0.0065), however, CD27-CD38-(p=0.4675), 
CD27-CD38+(p=0.281), CD27+CD38-(p=0.4632) and CD27+CD38+ B cells (p=0.2299) did not 
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differ between patient and control groups. Percentage of γδ T cells (p=0.2122) and regulatory 
T cells (p=0.2891) also did not differ between the two groups. 
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Figure 4.9 C Comparison of B cells/Tregs in patients and healthy controls. CFS patients had a 
significantly higher number of CD19+ B cells than in healthy controls (p=0.0065). For CFS patients 
group, n=51 and for the healthy control group, n=8. Un-paired Mann-Whitney U test was performed to 
analyse both groups.  
DISCUSSION 
 
The use of Fatigue Impact Scale to diagnose chronic fatigue syndrome patients 
 
In our research, our clinical collaborators used the FIS to measure the extent of chronic fatigue 
in patients. FIS score has been translated and validated in over 30 languages which shows its 
universality (Frith & Newton, 2010).  Fisk et al., in 1994 conducted a study to test the efficacy 
of FIS. Rather than just ask patients to rate their fatigue levels, it was decided that measuring 
the fatigue on functional activities of patients would lead to a much better understanding of 
chronic fatigue in patients. Thus, the Fisk group concluded that patients’ perception of 
functional limitations attributed to fatigue must be examined. The FIS consisted of three major 
domains, the cognitive functioning domain, the psychological functioning domain and the 
physical functioning domain. The internal consistency of three sub domains was determined 
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by Cronbach’s α score, which was very high. The Cronbach’s α score measures the extent to 
which items in the test relate to each other and thus ensures validity of the test (Tavakol & 
Dennick, 2011). Fisk et al., (1994) found that the FIS had a high Cronbach’s α value of 0.98 
and the three sub domains showed a value of 0.87 thereby ensuring that FIS scale is a valid test 
to use to diagnose CFS patients. Another important aspect of the FIS was its ability to 
efficiently distinguish between chronic fatigue patients and patients with multiple sclerosis 
(fatigue is an important component of MS). Furthermore, other fatigue scales such as modified 
fatigue impact scale (MFIS), and daily FIS all derive from the FIS (Frith & Newton, 2010). 
Antibody Responses in CFS patients 
 
IgG, IgM and IgA responses to CMV and EBV were identified by Euroimmun ELISA kits and 
did not correlate with FIS scores although IgM responses to CMV was just outside significance. 
Maes et al., (2006) showed that CFS patients had higher antibody titres of IgM against oxidized 
fatty acids such as oleic acid, palmitic acid and myristic acids than healthy controls. It was also 
found that IgM responses positively correlated with muscular pain, fatigue etc. It is well known 
that IgM responses are abundant during primary infection (Ehrenstein & Notley, 2010) and it 
is possible that recent CMV infection triggered CFS in patients and resulted in the production 
of CMV-specific IgM.  There is growing consensus suggesting that CFS might originate from 
the dysfunctions of the gut mucosa (Navaneetharaja et al., 2016). IgA responses are 
predominant at the mucosal surfaces and act as an indicator of primary EBV infection 
(Mcintosh-Bhaduri et al., 2007). Giloteaux et al., in 2016 showed that the gut microbiota of 
CFS patients had a proinflammatory profile and this led to the microbial migration from the 
gut and thus causing an immune response. CFS patients had significantly higher levels of serum 
LPS. Along with LPS, CD14 (receptor for LBP), and LPS binding protein (LBP) were also 
significantly higher in CFS patients compared to healthy controls. These results suggest that 
the high levels of serum LPS in CFS patients could be due to the presence of high levels of 
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endotoxins in the gut, which in turn could be due to the changes in the gut. Thus, changes to 
the gut microenvironment could lead to microbial translocation and eventually lead to the 
dysregulation of the normal immune functioning. Shukla et al., in 2015 used exercise as a factor 
in determining changes in the gut microenvironment in CFS patients.  It was found that at 72 
hours post maximal exercise, CFS patients had significantly higher levels of bacteria than 
healthy control. In addition, the clearance of bacterial from systemic circulation was 
significantly lower in CFS patients compared to healthy controls. Both these results indicate 
increased bacterial translocation from the gut and into systemic circulation.  
Relationship between ELIspot responses and FIS scores 
 
Only the positive controls PHA and PMAi showed a positive correlation between IFN-γ spot 
forming cells and FIS scores in CFS patients. This indicates that as FIS scores increases the 
levels of pro-inflammatory cytokine IFN-γ also increases. Patients with severe fatigue may in 
fact have higher inflammatory T cell response than patients with mild fatigue or healthy people. 
Apart from positive controls, none of the other antigenic stimulus showed any association or 
correlation with the fatigue impact scale scores. We then proceeded to compare the relationship 
between ELIspot responses among severely affected, mild/moderately affected CFS patients 
and healthy controls. We found that ELIspot responses to purified protein derivative (PPD) of 
Mycobacterium tuberculosis were significantly higher in healthy controls than in severely 
affected and moderately CFS patients. This suggests that CFS patients have deficient ‘IFN-γ 
spot forming cells’ specific to PPD, which suggests that CFS patients have a defective immune 
response against Mycobacterium tuberculosis.  Nunes-Alves et al., (2014) in their review 
mentioned that although increased production of IFN-γ has been generally associated with 
protection from pathogens, increased IFN-γ is also associated with disease progression rather 
than protection in Mycobacterium tuberculosis infection. Thus, they concluded by mentioning 
that IFN-γ is not the sole determinant, but one of the many important factors (including TNF-
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α, IL-1, IL-6) in the protection against TB.  Thus, further investigation is required to understand 
the role mycobacterium plays in chronic fatigue syndrome. We also found that moderately 
affected CFS patients had significantly lower levels of EBV-specific IFN-γ spot forming cells 
than healthy controls. Loebel et al., (2014) reported deficient B cell and T cell response to EBV 
in CFS patients. The IFN-γ producing EBV-specific T cells were significantly reduced in the 
CFS patients group than in the healthy controls. The low levels of IFN-γ may impair anti-EBV 
immune responses in CFS patients and may lead to the increased activation of EBV.  
K562 cells lack the expression of MHC molecules on the cell surface and are killed by natural 
killer cells. Thus, testing the response of NK cells against the K562 cells is a good indicator of 
the cytotoxic capacity of NK cells. In our cohort, we found that severely affected and 
moderately affected CFS patients had significantly lower NK cell responses than healthy 
controls. Fletcher et al., (2010) also showed significantly decreased natural killer cell 
cytotoxicity in CFS patients. Brenu et al., (2012) conducted a longitudinal study to investigate 
the extent of natural killer cytotoxicity in CFS patients. They found CFS patients had 
significantly lower ability to kill K562 cells even at 12 months. Thus, deeper studies into the 
functioning of NK cells in CFS patients may be the key in the identification of a biomarker. 
Reduced function of NK cells may make CFS sufferers more susceptible to viral re-activation, 
thus enhancing the infection-inflammation vicious circle.  
Interestingly, we also found that CFS patients, both severe and moderate had significantly 
lower ELIspot response to respiratory syncytial virus (with the addition of Rhinovirus). This 
indicates impaired immune responses and protection against respiratory syncytial virus. 
However, a definite role for RSV in the pathogenesis of CFS remains to be seen. IL-17 
production by anti-CD3 (α-CD3) was significantly lower in the CFS patient groups than in the 
healthy control group. IL-17C confers pro-inflammatory protection against intestinal 
pathogens by binding to its receptor, IL-17RE (Song et al., 2011). Thus, lower amount of IL-
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17 may lead to decreased protection against mucosal pathogens and might be a trigger for the 
onset on CFS. 
Multiplex Cytokine analysis (Meso-Scale Discovery) 
 
Epstein-Barr virus has long been considered the initiating factor in CFS. Jones et al., (1985) 
found EBV-specific antiviral capsid antigen and anti-early antigen titres of patients with 
myalgia, fatigue and depression was significantly higher than in healthy controls. Sairenji et 
al., in 1995 also showed that antibody titres to ZEBRA, a product of the immediate early EBV 
gene BZLF1, was high in CFS patients compared to healthy controls. Loebel group in 2014 
found significantly lower levels of EBV-specific antibody secreting memory cells as well as 
IFN-γ, IL-2 and TNF-α producing T cells in CFS patients.  However, in contrast, Cameron et 
al., 2010 compared the presence of viral DNA of EBV with healthy controls and found no 
significant differences. Furthermore, no changes were found in the antibody titres as well. So, 
to investigate the effects of EBV on CFS patients, we measured secretion of cytokines in cell 
culture supernatant in severely and moderately affected chronic fatigue patients. We found no 
correlations in the secretion of Th1 (IFN-γ, IL-2, IL-12), Th2 (IL-4, IL-5, IL-13), Th17 (IL-17) 
and the anti-inflammatory cytokine IL-10. We next compared the cytokine levels of cell culture 
supernatants stimulated by EBV and negative control (R10 medium). We found cells 
stimulated with EBV released significantly higher levels of IFN-γ and significantly lower 
amounts of IL-10 compared to PMBCs stimulated with medium only (negative control). In 
addition, we also found significantly higher levels (slightly) of IL-4 in cells stimulated with 
EBV. Apart from these cytokines, we found no other differences between the other cytokines. 
Increased levels of IFN-γ and decreased levels of IL-10 might indicate increased pro-
inflammatory mediators in EBV-seropositive CFS patients.  
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Analyses of Severe and Mild/Moderate Chronic fatigue patients 
 
Firstly, using flow cytometric analysis we found that both NK cells and CD3+ MAIT are 
negatively associated with FIS scores. i.e. as the chronic fatigue of patients increase, the levels 
of NK cells and MAIT cells become lower. Apart from NK cells and non-specific antigenic 
stimulus PMAi, there were minimal other differences between severe and moderate immune 
measurements in other groups. NK cells were significantly lower than moderate patients 
whereas severe CFS patients had a higher level of IFN- than moderate CFS patients. These 
data point to an inflammatory component to CFS as well as the NK cell dysfunction. 
Comparison of CFS patients and Healthy control data obtained by Flow cytometry 
 
We compared the NK cell, T cell and B cell compartment of CFS patients and healthy controls 
and obtained some interesting results. In the NK cell compartment, we found the total 
percentage of NK cells and percentage of NKCD57+ to be significantly reduced in CFS patients 
compared to healthy controls. In addition, percentage of CD3+ mucosal invariant T cells was 
significantly higher in CFS patients. Discrepancies in the NK cells in CFS has been widely 
reported. Brenu et al., in 2010 showed that CFS patients had significantly lower CD56bright cells 
than healthy controls. They also reported the decreased ability of NK cells to lyse K562 tumour 
cells.  Brenu et al., in 2013, again, showed that NK cells of CFS patients displayed significantly 
lower cytotoxicity when cultured with K562 tumour cells along with lower levels of Granzyme 
B, an important cytolytic protein.  Surprisingly, the reduction in cytotoxic or lytic capacity of 
NK cells was associated with increased degranulation in NK cells cultured with K562 and 
PMAi. CD56+ NK cells also produced high amounts of IFN-γ. Thus, reduced levels of NK cell 
cytotoxicity combined with increased degranulation and production of IFN-γ suggested the 
presence of highly activated but non-functional NK cells. We mentioned earlier that apart from 
total NK cells, NK CD57+ cells were also significantly reduced. This has important 
ramifications for the functioning of the immune system. Lopez-Verges et al., (2010) surmised 
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that CD57+ NK cells represent a more mature, terminally differentiated phenotype than other 
NK cell subsets. CD57 was highly expressed on CD56dim mature NK cells but much lower in 
CD56bright cells. CD57+ NK cells also proliferated poorly when stimulated with mitogens. 
CD57+ NK cells have increased cytolytic capacity and are upregulated during viral infections. 
A reduction in CD57- NK cells could severely impact anti-microbial immune responses. 
Decreased levels of CD57- NK cells have also been associated with autoimmune diseases such 
as Sjogren’s syndrome and psoriasis (Nielsen et al., 2013). Thus, is it also possible that CFS 
has an autoimmune component to it. CD3+ mucosal associated invariant T (MAIT) cells were 
significantly increased in CFS patients compared to healthy controls. MAIT cells are 
abundantly present in peripheral blood, mucosa of the lung, and intestine and liver. MAIT 
recognise an MHC class I-like protein called MR1 which captures antigenic peptides and 
displays them on antigen presenting cells (Serriari et al., 2014).  MAIT cells specialize in anti-
bacterial and anti-yeast immune response. It is suggested that MAIT cells interact with 
commensal bacterial flora and initiate an immune response against pathogens (Bourhis et al., 
2010). In CFS, therefore, it is possible that activated MAIT cells produce pro-inflammatory 
cytokines to altered microbiota in the gut and add to the exacerbation of chronic inflammation.  
The CD4+ T cell compartment showed variations between CFS patients and healthy controls. 
The total percentage of CD4+ T cells was significantly higher in the CFS patients than healthy 
controls. It is also interesting to note that central memory CD4+ T cells but not effector memory 
CD4+ T cells showed a significant drop. The increase in CD4+ T cells indicates increased 
propensity to release IFN-γ (Zhu & Paul, 2008). The low numbers of central memory CD4+ T 
cells could affect the numbers of effector memory CD4+ T cells and impair anti-microbial 
immune responses. The levels of naïve CD4+ T cells was significantly higher in the CFS patient 
group compared to the healthy control group. This could indicate that these cells still retain the 
ability to interact with novel pathogenic peptides so that a robust immune response could be 
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mounted (Roederer et al., 1995; Hardcastle et al., 2015). The increase in the naïve CD4+ T cells 
compartment was accompanied by the significant decreases in the PD-1 and TEMRA 
compartments. The CD8+ T cell compartment showed a significant drop in CFS patients 
compared to healthy controls. Curriu group in 2013 also showed a drop in CD8+ T cell levels 
in CFS patients. This could indicate a decrease in cytotoxic functioning against persistent 
pathogenic infections such as CMV and EBV. Among all subsets of CD8+ T cells, only CD95+ 
CD8+ T cells showed a significant increase compared to healthy controls. It is well known that 
CD95 is a marker for apoptosis (Paulsen & Janssen, 2011) and thus the elevated levels in CFS 
patients may indicate that they are marked for cell death through excessive antigenic 
stimulation. This could severely impair anti-pathogenic functions of CD8+ T cells. Brenu et al., 
2010 also reported a significant decrease in the cytotoxic capacity of CD8+ T cells in CFS 
patients.  
In the B cell compartment CD19+ B cells were significantly elevated in CFS patient group 
compared to healthy controls whereas the other B cell subsets showed no differences between 
the two groups. Fluge et al., (2011) investigated the effects of B cell depletion using rituximab 
(anti-CD20) on CFS patients. Although rituximab treatment started to show effects at different 
times for different patients, the general consensus was the quality of life was greatly increased 
after B cell depletion. They also suggested that CFS could be an autoimmune disease caused 
by the production of auto-antibodies by B cells and thus the depletion of auto-antibody 
producing B cells from patients could help in improving health conditions in chronic fatigue 
syndrome patients. 
Conclusion 
 
Chronic fatigue syndrome appears to be a chronic inflammatory disease that is characterized 
by dysfunctions in the immune system. The hallmark of CFS seem to be the low cytotoxic 
potential of NK cells as well as increased levels of IFN secretion. However, apart from NK 
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cells, B cells and T cells are also dysfunctional. There is growing evidence to show CFS 
resembles an autoimmune disease, and it that might be influenced by changes to the gut 
integrity and the microbiota. Further extensive research into associations of immune 
phenotypes with disease presence, and degree of disease, will give valuable insights into CFS 
and will hopefully translate into the identification of an elusive biomarker. Komaroff in 2017 
commented on dysfunctions of the nervous system, energy metabolism, oxidative and 
nitrosative stress along with immune imbalances that have all been implicated in the onset and 
pathology of CFS. CFS patients have been reported to have higher levels of protein, white 
blood cells, lactic acid, abnormalities in their white matter, abnormalities in the secretion of 
growth hormone etc. CFS patients have also been reported to have impaired oxidative 
phosphorylation owing to increased lactate levels in the cerebrospinal fluid, reduced levels of 
antioxidants and increased levels of nitric oxide. Imbalances in the immune system includes 
the well documented dysfunction of NK cells as well as cytotoxic CD8 T cells, presence of 
autoantibodies and increased levels of proinflmmatory cytokines. The pathophysiology of CFS 
is extremely complex. The point of origin of disease is still unclear. Infections could very well 
arise from inside as well as outside the brain. It is also highly unlikely for CFS to be a single 
pathogen disease and it is more likely that a combination of various infections acts as a trigger 
and possibly even contribute to the exacerbation of CFS. Thus, as mentioned earlier, extensive 
multi-disciplinary research is of absolute necessity, particularly longitudinal studies beginning 
at early onset and continuing through the evolution of the disease. 
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CHAPTER 5 
 
General Discussion 
 
In the face of physical injury and microbial infection, the maintenance of a balance between 
pro-inflammatory and anti-inflammatory actions of the immune system is vital to maintaining 
the steady-state condition and for the normal functioning of organs of the human body. Any 
imbalance either in favour of pro-inflammatory reaction or anti-inflammatory reaction may 
lead to the formation of a disease state. In this thesis, the focus is on chronic inflammation, i.e. 
continual pro-inflammatory reaction, in response to persistent infectious microbes (particularly 
herpes virus family) and the regulation of these responses in two major disease states: AMI+R, 
characterized by the presence of injury to the heart and CFS, characterized by debilitating 
fatigue mediated in the central nervous system. The constant activation of the immune system, 
skewing towards a pro-inflammatory profile in the above-mentioned conditions, appears to be 
influenced by the presence of persistent pathogens such as CMV and EBV, and other pathogens 
which chronically activate the immune system. T and B cell mediated immunity is implicated 
in many disease states including MI and CFS and thus it made sense to measure T cell and 
antibody responses to a panel of pathogen antigens, in addition to the careful recruitment, 
clinical characterization, and sampling of the contributing patients. The measurement of 
immune responses by ELIspot, Flow cytometry, MSD, and ELISA gave an insight into chronic 
activation of the immune system in AMI and CFS and that may translate into therapeutic 
interventions in the near future. To make this thesis a coherent whole, it is vital to highlight the 
similarities and differences between these two conditions (Table 5.1). 
Both AMI and CFS are associated with dysfunction of the immune system. T cells, B cells and 
NK cells have all been implicated in both AMI and CFS, and this thesis has confirmed much 
of these findings. In addition, active CMV replication is a major contributor for AMI whereas 
CFS has been more associated with EBV. Thus, herpes viruses seem to be a common link 
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between the two conditions. A main difference between these two conditions is the site of 
inflammation. AMI occurs in the heart muscle, whereas CFS occurs in the brain/central nervous 
system. AMI is associated with CMV reactivation in the elderly whereas CFS is mainly pan-
age with focus on the younger population.    
Table 5.1 Similarities and Difference between AMI+R & CFS 
 AMI+R CFS 
Immune dysregulation   
Lymphocyte involvement     
Involvement of Herpes 
viruses 
 (CMV) (EBV) 
Location Heart Muscle  Brain & CNS 
Treated by B cell depletion  Not treated yet  
Treated by T cell inhibition  Not treated yet 
 
Role of CMV-specific T cells in Acute Myocardial Infarction and reperfusion injury 
(AMI+R) 
 
In patients with ST segment elevated myocardial infarction (STEMI), before PPCI was 
performed to restore blood supply, the CMV-specific Th1 response was significantly stronger 
compared to Th2 or Th17 responses. This was reflected in an increased production of IFN-γ by 
T cells shown in patient groups, which continued even 30 minutes after reperfusion was 
performed to restore blood flow. In addition, CD8+ T cells were present in high numbers before 
reperfusion which lead to focussing on the role of CD8+ T cells. After reperfusion, the CD8+ T 
cells showed a drop in circulation and the terminally differentiated effector memory T cells 
(TEMRA) subset of CD8
+ T cells showed the highest drop in cell number. It was likely that the 
drop in CD8+ TEMRA was facilitated by the high expression levels of programmed cell death 
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ligand-1(PD-1). PD-1 is an indicator of hyper-activation of T cells and marks the cell for 
apoptosis. Thus, there was a permanent loss of PD-1+ CD8+ TEMRA from circulation. In addition, 
TEMRA population in CMV-seropositive patients was significantly higher than the TEMRA 
population in CMV-seronegative patients which suggests that active CMV causes increased 
activation of T cells which are a reservoir of pathogenic T cells ready to home to areas of 
inflammation (Hoffman & Frantz, 2015). 
In our patient sub-group B cohort, we found significantly lower production of IFN-γ at 90 
minutes post reperfusion in CD4+ T cells which could be attributed to the migration or 
trafficking of T cells away from circulation and into the myocardium. In contrast, the levels of 
CD8+ T cells did not change at any time point. The cultured ELIspot response which measures 
memory T cell response and functionality was however different for CD4+ T cells. There was 
no association between IFN-γ spot forming cells before and after reperfusion. In contrast, IFN-
γ production by cultured CD8+ T cells also showed a significant increase at 24 hours compared 
to pre-PPCI levels suggesting stimulation by the myocardial inflammatory process. 
 
Similar to our results, Forteza et al., (2018) also showed in their translational study involving 
a porcine model, significantly reduced lymphocyte count attributed to apoptosis as well as to 
the homing of T cells to the myocardium. Both of CD8+ T cells and Tregs showed reduced 
counts 2 hours after reperfusion. Regulatory T cell count, however, recovered 1 month after 
reperfusion therapy. To ascertain the presence of T cells in the myocardium, the authors used 
immunohistochemical analysis. mRNA levels of transcription factor T-bet significantly 
increased in the heart samples strongly indicating the presence of Th1 subset which further 
indicates the presence of IFN-. The authors suggested that apoptosis of T cells coupled with 
the increase in regulatory T cells was an inhibitory response to curb excess inflammation. Such 
a response may however promote viral-reactivation and an inflammatory vicious circle. 
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Furthermore, they also suggested that the presence of IFN- could severely impact TGF- 
mediated would healing process. The migration of T cells into the myocardium at 90 minutes 
post reperfusion in the present human study may cause an increase in inflammation which 
exacerbates the prevailing condition and might lead to the formation of microvascular 
obstruction (MVO) and hence a poorer outcome for patients. 
 
Although T cells are heavily implicated for causing increased inflammation, they also quench 
inflammation and promote cardiac wound healing.  Borg et al., in (2017) showed that CD73 
on T cells was involved in promoting wound healing. CD4+ T cells lacking CD73 showed 
impaired myocardial would healing and trigger the release the proinflammatory cytokines. Xia 
et al., (2015) reported regulatory T cells attenuate wound healing of the heart through a CD39-
dependent mechanism. Reperfusion injury in mice was aggravated by regulatory T cells lacking 
CD39. Moreover, it was also shown that PBMCs of patients who have undergone PPCI 
treatment also show an increased level of CD39+ regulatory T cells. Thus, targeting CD39 and 
CD73 with neutralizing monoclonal antibodies could have beneficial therapeutic potential in 
treating reperfusion injury.  
Immune responses in CFS 
 
Differences in immune parameters of CFS patients as compared to healthy controls were 
observed in this study. Also, immune parameters showed significant relationships with the FIS 
score. Most research groups studying CFS have uniformly reported the dysfunctional or 
abnormal levels of NK cells in CFS patients. In this work, the NK cell compartment of CFS 
patients was measured. The percentage of total NK cells and CD57+ NK cells (mature 
phenotype) were lower in CFS patients which could severely impact anti-viral immune 
responses allowing viral reactivation and increased systemic inflammation. The levels of CD3+ 
MAIT cells was significantly increased in CFS patients as were the levels of CD4+ T cells. This 
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indicates increased inflammation in CFS patients possibly via increased microbial translocation 
through the damaged gut. The lower numbers of CD8+ T cells suggest a deficit in the capacity 
of these cells to exert their anti-viral cytotoxic function. Furthermore, increased levels of 
CD19+ B cells suggest that CFS has an autoimmune component where excessive self-reactive 
antibodies are produced. The successful treatment of CFS patients with rituximab (anti-CD20) 
therapy, which depletes mature B cells suggests this might be the case (Fluge et al., 2015). 
Secretion of cytokines in cell culture supernatants also did not reveal any associations between 
severely affected and mild/moderately affected CFS patients. However, EBV-specific 
production of IFN-γ was significantly higher than the baseline levels (stimulation using 
negative control). This was accompanied by a significant drop in IL-10 levels in CFS patients. 
This indicates a skew towards a pro-inflammatory profile in chronic fatigue syndrome in 
response to EBV. Montoya et al., (2017), using the Luminex platform, studied the cytokine 
profiles in CFS patients. They found a cytokine profile that was overwhelmingly 
proinflammatory. Cytokines such as IFN-, GM-CSF, IL-12, IL-5, IL-4 were all significantly 
higher in CFS patients.   
Only positive control PMAi correlated with FIS scores in this thesis, showing that as the FIS 
scores increase the production of IFN-γ increases. This suggests that IFN-γ secreted from 
multiple cell sources and specificities mediates disease rather than a single or a few antigens. 
Since no other antigenic stimulus correlated with FIS scores, we compared the ELIspot 
responses of severely affected, mild/moderately affected and healthy controls since their 
grouping could reveal different significances. We found significantly decreased IFN-γ 
production in CFS patient PBMCs stimulated with Mycobacterium tuberculosis, Respiratory 
syncytial virus (RSV) and EBV. Previous work suggests that EBV might be directly involved 
in the pathogenesis of CFS (Loebel et al., 2014; Fremont et al., 2009). The roles of RSV and 
Mycobacterium tuberculosis in the pathogenesis of CFS has not yet been described. 
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CFS patients also showed decreased capacity to respond to K562 cells. The severely and 
moderately affected patients had significantly lower responses to K562 cells than healthy 
controls. Dysfunctional NK cells in CFS patients have been widely reported, and this makes 
NK cells a promising target to identify as biomarkers for fatigue which could help in the 
identification of ideal therapeutic interventions. Bielekova et al., (2006) showed that the 
admisnitration of daclizumab, a monoclobal antibody against the IL-2Rα chain in multiple 
sclerosis patients reduced brain inflammation in a phase II clinical trial. They found that the 
administration of this monoclonal antibody led to the gradual reduction in the level of CD4+ 
and CD8+ T cells while the numbers of CD56bright NK cells increased significantly. The 
percentage of these NK cells positively correlated with inhibition of contrast enhacing brain 
lesions (brain MRI). Perhaps such stimulation of NK cells could be used as a therapeutic 
approach for CFS. 
In addition to the cells of the immune system involved in CFS, a genetic predisposition has 
also been implicated. A genome wide association analysis was conducted by the Schlauch 
group in 2016. They performed a large SNP survey to identify genetic factors that could explain 
CFS pathogenesis. This group identified 442 SNPs that could be involved in the pathogenesis 
of CFS. Some of the genes were RECK (a negative regulator of matrix metalloproteinases) and 
GRIK3(a transmembrane subunit of neuroexcitatory receptors) and two SNPs in the T cell 
receptor alpha locus and the alpha/delta locus. Schlauch also developed a bioinformatic tool, 
Genotype Plotter which allowed to identify genotypic differences near SNPs of interest. This 
tool allowed the athors to identify genotypic signatures that are prominent in CFS patients but 
not in the healthy control cohort. Further research into the role of these genes, in conjunction 
with extended research on immunity such as our own could highlight them as important 
therapeutic targets.  
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Another research study using random peptide microarrays to screen serum antibodies of CFS 
patients and healthy controls was performed. A BLAST search identified the peptides specific 
to CFS patients belonging to human self-antigens and endogenous retroviruses and to a minor 
extent bacterial and viral sequences. Some of the human self-antigens that were identified are 
CD274, cutaneous T cell lymphoma-associated antigen 1, Legumain and electron transfer 
flavoprotein dehydrogenase. Some of the endogenous retroviruses components involved are 
endogenous retrovirus group K members 21 and 25, group 3 member 1 etc. Thus, the use of 
random peptide microarray could be useful in differentiating antibody profiles in CFS patients 
and healthy controls. Such antibodies may be simply markers of CFS rather than being involved 
in immunopathology (Singh et al., 2018). 
Overall Conclusion 
 
In chronic inflammatory diseases it is potentially of great value to measure and use immune 
responses to diagnose and monitor disease (for identification of biomarkers). Both AMI+R and 
CFS showed increase of Th1 type cytokine IFN- associated with disease. Thus, both diseases 
are candidates for therapies with neutralizing IFN- monoclonal Ab. Indeed, Cui et al., (2013) 
used anti-interferon gamma therapy to treat Crohn’s disease, a chronic Th1 inflammatory 
disease. Having similar features to AMI+R, dilated cardiomyopathy is the inflammation of the 
heart muscle caused by either bacterial or viral infection. In addition to being an inflammatory 
disease, dilated cardiomyopathy also has an autoimmune component. Boldizsar et al., (2016) 
used FTY720, a SIP antagonist, to arrest the migration of lymphocytes within the lymphoid 
tissue, instead of homing to the heart, and inhibited the activation of auto-reactive cells. Thus, 
it will be interesting to use therapies like the ones mentioned above on chronic inflammatory 
diseases such as ischemic reperfusion injury and chronic fatigue syndrome. 
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Limitations of Work 
 
With respect to the MI part of the project, investigating patient samples for evolution of 
immune responses and patients, long term clinical outcome beyond the 3-month time frame 
would have been ideal, which unfortunately was not possible due to time and ethical 
constraints. Another drawback of the MI project was the lack of availability of equal numbers 
of patient samples across all points. In addition, immunohistochemical analysis of culprit 
lesions looking for T cell presence would have been extremely beneficial to our research but 
was unfortunately not possible. 
In the CFS part of the project, we had a difficulty trying to recruit sufficient healthy controls 
who were required to be sedentary, female and middle aged. We also received a poor response 
to our advertisements. Thus, a more focussed approach is required to recruit such healthy 
controls. More data on the patients with regard to clinical parameters such as inflammatory 
marker CRP, would have been highly beneficial to investigate associations with T cell 
populations. 
Future Work 
 
A multi-faceted approach could be taken for further work, in order to further solidify and build 
upon the findings of this thesis, and to translate the findings to approaches that could benefit 
patients. Novel developments in ELIspot, such as the multi-parametric Fluorospot, would allow 
the investigation of the T cells that simultaneously secrete pro-and anti-inflammatory 
cytokines. This balance is likely to dictate immunopathology. For the MI patients it would be 
very useful to repeat the findings of the thesis showing the role of homing of herpes viral-
specific T cells, particularly TEM PD-1
+ cells; but on larger cohorts of patients to reveal subtler 
phenotypic differences (e.g. CX3CR1) with sufficient statistical power. Alteast 100 subjects 
would be needed for further tetramer studies of T cells specific for CMV and EBV. Being able 
to sample T cells homing to the heart via the coronary artery would be highly valuable as would 
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the immunohistological examination of heart muscle undergoing reperfusion injury. Such 
approaches are most appropriate to be carried out on animal models of disease and on tissues 
from deceased patients, respectively. Furthermore, several trials are currently being undertaken 
or planned, to modulate T cell migration and activity during MI+R; and so being able to obtain 
PBMC samples from patients in such trials would be important for testing T cell phenotype 
and function (as in this thesis) during this clinical trial process. The hypothesis would be that 
T cells implicated in this study would be regulated by those T cell-targeting therapeutics that 
reduce disease severity (e.g. Atorvastatin). 
In CFS, extended investigation of the immune responses should be carried out. The 
dysregulations in the natural killer cell compartment that were found in our CFS patients, and 
which agreed with the findings from other CFS research groups across the world, need to be 
probed deeper by investigating the activity of key receptors and signalling pathways such as 
KIRs and Transient Receptor Potential Melastatin 3 (TRPM3) ion channel e.g. through targeted 
knockdown with siRNA. Indeed, this molecule could be a target for gene SNP analysis of CFS 
patients. Such a study would require the recruitment of well-characterized CFS patients in the 
100’s, together with matched controls, for sufficient power to observe statistical differences. 
Therapeutic approaches for CFS using molecules such as TLR agonists that specifically 
activate NK cells, thus reversing their dysfunction in CFS, have been suggested 
(Navaneetharaja et al., 2006). Gowen et al., in 2007 showed that in mice deficient in TLR3, 
the introduction of dsRNA analog poly (I:C12U) did not have any protective effect against the 
punta toro virus (PTV) and there was no production of interferon-α, interferon-β and IL-6 
whereas the wild type mice were conferred protective immunity due to the presence of the 
TLR3 receptor. A double blind, placbo controlled, randomized clinical trial to test the efficacy 
of Rintatolimod treatment (poly (I:C12U)) in severe chronic fatigue syndrome patients was 
carried out by Strayer et al., in 2012. They found that treatment with Rintatolimod led to 
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improvement in the cardiopulmonary exercise tolerance as well as decrease in concomitant 
medicine usage. It is possible that the administration of this drug might stimulate NK cells and 
cause increased release of interferons. Trials with such molecules would necessitate the 
measurement of NK numbers and function as carried out in this thesis and suggested in further 
work. 
A recent study of CFS patients showed the use of immunoadsorption to remove IgG against 2 
adrenergic receptor. This led to the significant reduction in autoantibodies as well as memory 
B cell numbers and resulted in the reduction of CFS symptoms in patients (Scheibenbogen et 
al., 2018). This suggests that the T cell responses are likely directed against self-antigens, and 
their measurement would provide a useful biomarker of disease.     
In conclusion, since both diseases (AMI+R and CFS) appear to involve dysregulated immune 
responses, ways of altering these (such as by cell depletion or neutralization of cell products 
like IFN) could be attempted, and their further measurement is warranted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
184 
 
References 
 
Abbas, A.K., Lichtman, A.H. and Pillai, S., 2012. Cellular and Molecular Immunology. 7th 
edition, Philadelphia, PA; Elsevier. 
 
Agrawal, S., Smith, S.A.B.C., Tangye, S.G. and Sewell, W.A., 2013. Transitional B cell 
subsets in human bone marrow. Clinical & Experimental Immunology, 174(1), pp.53-59. 
 
Ait-Oufella, H., Herbin, O., Bouaziz, J.D., Binder, C.J., Uyttenhove, C., Laurans, L., Taleb, S., 
Van Vré, E., Esposito, B., Vilar, J. and Sirvent, J., 2010. B cell depletion reduces the 
development of atherosclerosis in mice. Journal of Experimental Medicine, 207(8), pp.1579-
1587. 
 
Ait-Oufella, H., Sage, A.P., Mallat, Z. and Tedgui, A., 2014. Adaptive (T and B cells) 
immunity and control by dendritic cells in atherosclerosis. Circulation research, 114(10), 
pp.1640-1660. 
 
Ait-Oufella, H., Salomon, B.L., Potteaux, S., Robertson, A.K.L., Gourdy, P., Zoll, J., Merval, 
R., Esposito, B., Cohen, J.L., Fisson, S. and Flavell, R.A., 2006. Natural regulatory T cells 
control the development of atherosclerosis in mice. Nature Mmedicine, 12(2), pp.178-180. 
 
Ammirati, E., Cianflone, D., Vecchio, V., Banfi, M., Vermi, A.C., De Metrio, M., Grigore, L., 
Pellegatta, F., Pirillo, A., Garlaschelli, K. and Manfredi, A.A., 2012. Effector memory T cells 
are associated with atherosclerosis in humans and animal models. Journal of the American 
Heart Association, 1(1), pp. 27-41. 
 
Annunziato, F., Romagnani, C. and Romagnani, S., 2015. The 3 major types of innate and 
adaptive cell-mediated effector immunity. Journal of Allergy and Clinical 
Immunology, 135(3), pp.626-635. 
 
Baetta, R. and Corsini, A., 2010. Role of polymorphonuclear neutrophils in atherosclerosis: 
current state and future perspectives. Atherosclerosis, 210(1), pp.1-13. 
 
185 
 
Bahadir, E.B. and Sezgintürk, M.K., 2015. Applications of electrochemical immunosensors for 
early clinical diagnostics. Talanta, 132, pp.162-174. 
 
Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J. 
and Ahmed, R., 2006. Restoring function in exhausted CD8 T cells during chronic viral 
infection. Nature, 439(7077), pp.682-687. 
 
Bassing, C.H., Swat, W. and Alt, F.W., 2002. The mechanism and regulation of chromosomal 
V (D) J recombination. Cell, 109(2), pp.S45-S55. 
 
Beam, E. and Razonable, R.R., 2012. Cytomegalovirus in solid organ transplantation: 
epidemiology, prevention, and treatment. Current Infectious Disease Reports, 14(6), pp.633-
641. 
 
Bellora, F., Castriconi, R., Dondero, A., Carrega, P., Mantovani, A., Ferlazzo, G., Moretta, A. 
and Bottino, C., 2014. Human NK cells and NK receptors. Immunology Letters, 161(2), 
pp.168-173. 
 
Beqaj, S.H., Lerner, A.M. and Fitzgerald, J.T., 2008. Immunoassay with cytomegalovirus early 
antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in 
patients with chronic fatigue syndrome. Journal of Clinical Pathology, 61(5), pp.623-626. 
 
Bergsbaken, T. and Bevan, M.J., 2015. Proinflammatory microenvironments within the 
intestine regulate the differentiation of tissue-resident CD8+ T cells responding to 
infection. Nature Immunology, 16(4), pp.406-414. 
 
Bhaduri-McIntosh, S., Landry, M.L., Nikiforow, S., Rotenberg, M., El-Guindy, A. and Miller, 
G., 2007. Serum IgA antibodies to Epstein-Barr virus (EBV) early lytic antigens are present in 
primary EBV infection. The Journal of Infectious Diseases, 195(4), pp.483-492. 
 
Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T.A., 
McFarland, H., Henkart, P.A. and Martin, R., 2006. Regulatory CD56bright natural killer cells 
mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple 
sclerosis. Proceedings of the National Academy of Sciences, 103(15), pp.5941-5946. 
186 
 
 
Binder, C.J., Hartvigsen, K., Chang, M.K., Miller, M., Broide, D., Palinski, W., Curtiss, L.K., 
Corr, M. and Witztum, J.L., 2004. IL-5 links adaptive and natural immunity specific for 
epitopes of oxidized LDL and protects from atherosclerosis. The Journal of Clinical 
Investigation, 114(3), pp.427-437. 
 
Blasco, M.A., 2005. Telomeres and human disease: ageing, cancer and beyond. Nature 
Reviews Genetics, 6(8), pp.611-622. 
 
Blom, B. and Spits, H., 2006. Development of human lymphoid cells. Annu. Rev. Immunol., 24, 
pp.287-320. 
 
Boag, S.E., Das, R., Shmeleva, E.V., Bagnall, A., Egred, M., Howard, N., Bennaceur, K., 
Zaman, A., Keavney, B. and Spyridopoulos, I., 2015. T lymphocytes and fractalkine contribute 
to myocardial ischemia/reperfusion injury in patients. The Journal of Clinical 
Investigation, 125(8), pp.3063-3076. 
 
Boldizsar, F., Tarjanyi, O., Olasz, K., Hegyi, A., Mikecz, K., Glant, T.T. and Rauch, T.A., 
2016. FTY720 (Gilenya) treatment prevents spontaneous autoimmune myocarditis and dilated 
cardiomyopathy in transgenic HLA-DQ8-BALB/c mice. Cardiovascular Pathology, 25(5), 
pp.353-361. 
 
Bonetti, P.O., Lerman, L.O. and Lerman, A., 2003. Endothelial dysfunction: a marker of 
atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(2), pp.168-175. 
 
Boppana, S.B., Ross, S.A. and Fowler, K.B., 2013. Congenital cytomegalovirus infection: 
clinical outcome. Clinical Infectious Diseases, 57(suppl_4), pp.S178-S181. 
 
Borg, N., Alter, C., Görldt, N., Jacoby, C., Ding, Z., Steckel, B., Quast, C., Bönner, F., Friebe, 
D., Temme, S. and Flögel, U., 2017. CD73 on T cells orchestrates cardiac wound healing after 
myocardial infarction by purinergic metabolic reprogramming. Circulation, 136(3), pp.297-
313. 
 
187 
 
Bosma, A., Abdel-Gadir, A., Isenberg, D.A., Jury, E.C. and Mauri, C., 2012. Lipid-antigen 
presentation by CD1d+ B cells is essential for the maintenance of invariant natural killer T 
cells. Immunity, 36(3), pp.477-490. 
 
Breart, B. and Bousso, P., 2016. S1P1 downregulation tailors CD8+ T‐cell residence time in 
lymph nodes to the strength of the antigenic stimulation. European Journal of 
Immunology, 46(12), pp.2730-2736. 
 
Brenu, E.W., Huth, T.K., Hardcastle, S.L., Fuller, K., Kaur, M., Johnston, S., Ramos, S.B., 
Staines, D.R. and Marshall-Gradisnik, S.M., 2013. Role of adaptive and innate immune cells 
in chronic fatigue syndrome/myalgic encephalomyelitis. International Immunology, 26(4), 
pp.233-242. 
 
Brenu, E.W., Staines, D.R., Baskurt, O.K., Ashton, K.J., Ramos, S.B., Christy, R.M. and 
Marshall-Gradisnik, S.M., 2010. Immune and hemorheological changes in chronic fatigue 
syndrome. Journal of Translational Medicine, 8(1), pp.1-10. 
 
Brenu, E.W., van Driel, M.L., Staines, D.R., Ashton, K.J., Hardcastle, S.L., Keane, J., Tajouri, 
L., Peterson, D., Ramos, S.B. and Marshall-Gradisnik, S.M., 2012. Longitudinal investigation 
of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. 
Journal of Translational Medicine, 10(1), pp.1-11. 
 
Breton, G., Zheng, S., Valieris, R., da Silva, I.T., Satija, R. and Nussenzweig, M.C., 2016. 
Human dendritic cells (DCs) are derived from distinct circulating precursors that are 
precommitted to become CD1c+ or CD141+ DCs. Journal of Experimental Medicine, 213(13), 
pp.2861-2870. 
 
Bryceson, Y.T., Chiang, S.C., Darmanin, S., Fauriat, C., Schlums, H., Theorell, J. and Wood, 
S.M., 2011. Molecular mechanisms of natural killer cell activation. Journal of Innate 
Immunity, 3(3), pp.216-226. 
 
Buchwald, D., Ashley, R.L., Pearlman, T., Kith, P. and Komaroff, A.L., 1996. Viral serologies 
in patients with chronic fatigue and chronic fatigue syndrome. Journal of Medical 
Virology, 50(1), pp.25-30. 
188 
 
Buono, C., Come, C.E., Stavrakis, G., Maguire, G.F., Connelly, P.W. and Lichtman, A.H., 
2003. Influence of interferon-γ on the extent and phenotype of diet-induced atherosclerosis in 
the LDLR-deficient mouse. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(3), 
pp.454-460. 
 
Burbelo, P.D., Bayat, A., Wagner, J., Nutman, T.B., Baraniuk, J.N. and Iadarola, M.J., 2012. 
No serological evidence for a role of HHV-6 infection in chronic fatigue syndrome. American 
Journal of Translational Research, 4(4), pp.443-451. 
 
Caligiuri, MI., Murray, CH., Buchwald, D., Levine, H., Cheney, P., Peterson, D., Komaroff, 
A.L. and Ritz, J., 1987. Phenotypic and functional deficiency of natural killer cells in patients 
with chronic fatigue syndrome. The Journal of Immunology, 139(10), pp.3306-3313. 
 
Cameron, B., Flamand, L., Juwana, H., Middeldorp, J., Naing, Z., Rawlinson, W., Ablashi, D. 
and Lloyd, A., 2010. Serological and virological investigation of the role of the herpesviruses 
EBV, CMV and HHV‐6 in post‐infective fatigue syndrome. Journal of Medical 
Virology, 82(10), pp.1684-1688. 
 
Cerutti, A., Cols, M. and Puga, I., 2013. Marginal zone B cells: virtues of innate-like antibody-
producing lymphocytes. Nature Reviews Immunology, 13(2), pp.118-132. 
 
Chang, S.Y., Song, J.H., Guleng, B., Cotoner, C.A., Arihiro, S., Zhao, Y., Chiang, H.S., 
O’Keeffe, M., Liao, G., Karp, C.L. and Kweon, M.N., 2013. Circulatory antigen processing by 
mucosal dendritic cells controls CD8+ T cell activation. Immunity, 38(1), pp.153-165. 
 
Chapenko, S., Krumina, A., Logina, I., Rasa, S., Chistjakovs, M., Sultanova, A., Viksna, L. 
and Murovska, M., 2012. Association of active human herpesvirus-6,-7 and parvovirus b19 
infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue 
syndrome. Advances in Virology, 2012, pp.1-7. 
 
Chaplin, D.D., 2010. Overview of the immune response. Journal of Allergy and Clinical 
Immunology, 125(2), pp.S3-S23. 
 
189 
 
Cheent, K. and Khakoo, S.I., 2009. Natural killer cells: integrating diversity with function. 
Immunology, 126(4), pp.449-457. 
 
Cheng, X., Liao, Y.H., Ge, H., Li, B., Zhang, J., Yuan, J., Wang, M., Liu, Y., Guo, Z., Chen, 
J. and Zhang, J., 2005. TH1/TH2 functional imbalance after acute myocardial infarction: 
coronary arterial inflammation or myocardial inflammation. Journal of Clinical 
Immunology, 25(3), pp.246-253. 
 
Chia, J.K. and Chia, L.Y., 1999. Chronic Chlamydia pneumoniae infection: a treatable cause 
of chronic fatigue syndrome. Clinical Infectious Diseases, 29(2), pp.452-453. 
 
Cosmi, L., Maggi, L., Santarlasci, V., Liotta, F. and Annunziato, F., 2014. T helper cells 
plasticity in inflammation. Cytometry Part A, 85(1), pp.36-42. 
 
Crotty, S., 2014. T follicular helper cell differentiation, function, and roles in 
disease. Immunity, 41(4), pp.529-542. 
 
Crough, T. and Khanna, R., 2009. Immunobiology of human cytomegalovirus: from bench to 
bedside. Clinical Microbiology Reviews, 22(1), pp.76-98. 
 
Cui, D., Huang, G., Yang, D., Huang, B. and An, B., 2013. Efficacy and safety of interferon-
gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of 
randomized controlled trials. Clinics and Research in Hepatology and 
Gastroenterology, 37(5), pp.507-513. 
 
Curriu, M., Carrillo, J., Massanella, M., Rigau, J., Alegre, J., Puig, J., Garcia-Quintana, A.M., 
Castro-Marrero, J., Negredo, E., Clotet, B. and Cabrera, C., 2013. Screening NK-, B-and T-
cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. Journal of 
Translational Medicine, 11(68), pp.1-13. 
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PCI-Role of cytomegalovirus seropositivity  
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NHS sites 
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opinion" below). 
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Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
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Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” 
gives detailed guidance on reporting requirements for studies with a 
favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated 
in the light of changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from 
the National Research Ethics Service and the application procedure. If you 
wish to make your views known please use the feedback form available on 
the website. 
 
Further information is available at National Research Ethics Service website > After 
Review 
 
 
 
 
With the Committee’s best wishes for the success of this project. 
 
Yours 
sincerely 
pp 
 
Mr Paddy 
Stevenson 
Chair 
 
Email: Helen.Wilson@suntpct.nhs.uk 
 
Enclosures: “After ethical review – guidance for researchers” 
Copy to: Ms Amanda Tortice, Newcastle upon Tyne Hospitals NHS Foundation 
Trust 
 
 
 
 
A Research Ethics Committee established by the Health Research Authority 
 
12/NE/0225 Please quote this number on all correspondence 
12/NE/0225 Please quote this number on all correspondence 
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Yours sincerely 
 
Gillian Mayer 
Committee Co-
ordinator 
 
E-mail: nrescommittee.northeast-newcastleandnorthtyneside2@nhs.net 
 
 
 
 
Copy to: Sean Scott - Joint Research Office, Newcastle upon Tyne Hospitals 
NHS Foundation Trust 
 
 
 
 
A Research Ethics Committee established by the Health Research Authority 
 
 
 
 
 
 
 
 
 
 
12/NE/0322: Please quote this number on all correspondence 
12/NE/0322: Please quote this number on all correspondence 
12/NE/0322: Please quote this number on all correspondence 
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FIS Questionnaire 
 
 
 
Fatigue Impact Scale 
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1.  I feel less alert      
2.  I feel that I am more isolated from social contact       
3.  I have to reduce my workload or responsibilities      
4.  I am more moody      
5.  I have difficulty paying attention for a long period      
6.  I feel I cannot think clearly      
7.  I work less effectively (this applies to work inside or 
outside the home) 
     
8.  I have to rely more on others to help me or do things for 
me 
     
9.  I have difficulty planning activities ahead of time      
10.  I am more clumsy and uncoordinated      
11.  I find that I am more forgetful      
12.  I am more irritable and more easily angered      
13.  I have to be careful about pacing my physical activities      
14.  I am less motivated to do anything that requires physical 
effort 
     
15.  I am less motivated to engage in social activities      
16.  My ability to travel outside my home is limited      
17.  I have trouble maintaining physical effort  for long periods      
18.  I find it difficult to make decisions      
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19.  I have few social contacts outside my own home      
20.  Normal day to day events are stressful for me      
21.  I am less motivated to do anything which requires 
thinking 
     
22.  I avoid situations that are stressful for me       
23.  My muscles feel much weaker than they should do      
24.  My physical discomfort is increased      
25.  I have difficulty dealing with anything new      
26.  I am less able to finish tasks that require thinking      
27.  I feel unable to meet the demands that people place on me      
28.  I am less able to provide financial support for myself and 
my family 
     
29.  I engage in less sexual activity      
30.  I find it difficult to organise my thoughts when I am doing 
things at home or at work 
     
31.  I am less able to complete tasks that require physical effort      
32.  I worry about how I look to other people      
33.  I am less able to deal with emotional issues      
34.  I feel slowed down in my thinking      
35.  I feel it hard to concentrate      
36.  I have difficulty participating  fully in family activities      
37.  I have to limit my physical activities      
38.  I require more frequent or longer periods of rest      
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39.  I am not able to provide as much emotional support to my 
family as I should 
     
40.  Minor difficulties seem like major difficulties      
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APPENDIX-2 
SDS-PAGE for protein analysis  
SDS-PAGE running buffer X10  
Running buffer was made up to 10X concentration and (diluted to 1X before use).  
Tris-HCl 30.3 g  
Glycine 144.0g  
SDS 10.0 g  
12% (W/V) SDS Acrylamide resolving gel components  
40% (w/v) solution (37.5:1 acrylamide:biscrylamide) 3.0 ml  
Solution B* 2.5ml  
Deionised water 4.50 ml  
10% (w/v) ammonium persulphate (ASP) 50 μl  
TEMED 10 μl  
*Solution B  
2M Tri-HCL, PH 8.8 75ml per 100 ml  
10% (w/v) SDS 4ml per 100 ml  
4% (W/V) Acrylamide stacking gel components  
40% Acrylamide 250 ml  
10% ammonium persulphate (APS) 30μl  
Deionised water 1.2 ml  
Solution C* 500 μl  
TEMED 10 μl  
* Solution C  
1M Tris-HCL, PH 6.8 50 ml per 100 ml  
10 %( w/v) SDS 4 ml per 100 ml  
SDS-PAGE sample buffer  
60mM Tris-HCL pH 6.8 0.6ml per 10 ml  
10 %( w/v) SDS 2.0 ml per 10 ml 237  
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50% (v/v) glycerol 5.0ml per 10 ml  
14.4 mM β- Mercaptoethanol 0.5 ml per10 ml  
0.1% (w/v) Bromophenol Blue 1.0 ml per 10 ml  
Deionised water 0.9ml per 10ml  
Coomassie blue gel stain solution  
Coomassie Brilliant Blue R250 1.0g per L  
Glacial acetic acid 100.0 ml per L  
Methanol 450.0 ml per L  
Coomassie gel destaining solution  
Glacial acetic acid 100.0 ml per L  
Methanol 100.0ml per L 
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APPENDIX-3 
 
LAL Chromogenic Endotoxin Quantitation Kit 
 
Endotoxin-free-water 1 vial, 30mL 
 
Limulus Amebocyte Lysate (LAL), lyophilized, 2vial, 1.4mL 
E. coli Endotoxin standard (011: B4), lyophilized, 1 vial, 15-40 endotoxin unit (EU)/mL 
Upon reconstitution 28EU/ml 
 
Chromogenic substrate, lyophilized, 1 vial, 6.5mL/vial upon reconstitution (7mg of 
lyophilized substrate was reconstituted in 9 ml of in endotoxin-free water). 
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APPENDIX-4 
 
Reagents used for ELISA and ELIspot 
Phosphate buffer saline 
 
 Sodium Chloride (NaCl) -8.17g 
Disodium Hydrogen phosphate (Na2HPO4) -1.12g 
 Mono sodium dihydrogen phosphate (NaH2PO4.H2O) -0.22g 
Then add distilled water till the 1 litre mark. 
For 10 X PBS, add 1 litre of water to 10 times the mass of the above ingredients. 
 
PBS TWEEN (washing buffer for in-between steps) 
 
PBS- 1 Litre 
Tween-0.5 ml 
PBS TWEEN + SKIMMED MILK (blocking buffer for ELISA) 
 
2.5g of milk powder in 50ml of PBST (5%). 
For DILUENT solution, add 5ml of blocking buffer in 50 ml of PBST. 
Citrate phosphate buffer (for substrate solution) 
 
Citric acid- 5.1g 
Na2HPO4-7.31g 
Distilled Water-1 litre 
Substrate Solution 
1) 1 tablet (20mg) - add 25ml of citrate buffer and 20µl H2O2. 
2) 200µl of OPD + 5µl of H2O2 + 12.5ml of citrate buffer. 
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Freezing solution for storing PBMCs in -1500C 
 
For 2 vials: 1.8ml of FCS/FBS & 0.2ml of DMSO. 
For 5 vials: 4.5ml of FCS/FBS & 0.5ml of DMSO. 
Substrate solution for ELIspot  
 
The solution for 1 plate  
AP Conjugate substrate kit 50 μl of each (A&B)  
AP development buffer 200 μl  
Deionised water 4700 μl 
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APPENDIX-5 
 
Reagents used for Meso scale discovery (Multiplex Cytokine Analysis) 
 
Cytokines panel1 (human) multi-spot 96 well (10 spot plates)  
Pro-inflammatory panel 1(human) multi-spot 96well (10 spot plates) 
MSD Blocker B- 1g  
MSD Diluent1- 50ml  
Diluent 3- 5ml  
MSD Read Buffer (4X) with surfactant- 50ml  
Detector antibody pro-inflammatory panel 1(human) kit (calibrator blend):  
Anti-human IL-2 antibody  
Anti-human IL-4 antibody  
Anti-human IL-10 antibody  
Anti-human IL-13 antibody  
Anti-human IFN-γ antibody  
Anti-human IL-12P70 antibody  
Cytokines panel 1 human kit (calibrator blend)  
Anti-human IL-5 antibody  
Anti-human IL-17A antibody  
List of Capture antibodies  
 
IFN-γ: Mouse Monoclonal ; IL-1β: Mouse Monoclonal ; IL-2: Mouse Monoclonal ; IL-4: 
Mouse Monoclonal ; IL-5: Mouse Monoclonal ; IL-8: Mouse Monoclonal ; IL-10: Rat 
Monoclonal ; IL-12p70: Mouse Monoclonal ; IL-13: Rat Monoclonal ; TNF-α: Mouse 
Monoclonal. 
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APPENDIX-6 
 
Isotype controls used in Flow cytometric analysis 
 
 
Figure A6: Isotype controls for Flow experiments. For both Myocardial Infarction and 
Chronic Fatigue syndrome, we first carried out a run with negative controls to measure non-
specific background to primary antibodies. FSC-forward scatter, SSC- Side scatter, PE- 
Phycoerythrin, APC-Allophycocyanin, BV-Brilliant violet.   
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APPENDIX-7 
 
List of other Cytokines tested by MSD 
 
Three MSD panels were tested, 1). Proinflammatory panel, 2). Cytokine panel and 3). 
Chemokine panel. Of the panels tested, only IP-10, IL-10 and IL-16 showed an association 
between CMV seropositive and CMV seronegative patients. The complete list of panels tested 
is shown below: 
Proinflammatory panel Cytokine panel Chemokine panel 
IFN-γ GM-CSF Eotaxin 
IL-1β IL-1α MIP-1β 
IL-2 IL-5 Eotaxin-3 
IL-4 IL-7 TARC 
IL-6 IL-12/IL-23p40 IP-10 
IL-8 IL-15 MIP-1α 
IL-10 IL-16 IL-8(HA) 
IL-12p70 IL-17A MCP-1 
IL-13 TNF-β MDC 
TNF-α VEGF MCP-4 
 
 
 
 
 
 
 
235 
 
APPENDIX-8 
 
Peptide sequences of pathogens used for ELIspot 
 
Peptides sequences used for the AMI and CFS study were obtained following detailed 
investigation from the immune epitope database and analysis resource, http://www.iedb.org/ 
and some of the peptide sequences are shown below: 
CMV epitopes 
CD8 T cell epitopes 
Peptide identifier Peptide sequence 
Cpp65.495 NLVPMVATV 
Cpp65.512 EFFWDANDIY 
Cpp65.415 TPRVTGGGAM 
HCMV3 SDEEEAIVAYTL 
Cpp65.508 KYQEFFWDANDIYRI 
Cpp65.363 YSEHPTFTSQY 
Cpp65.341 QYDPVAALF 
Cpp65.265 RPHERNGFTVL 
Cpp65.113 VYALPLKML 
Cpp65.123 IPSINVHHY 
Cie1.184 KLGGALOAK 
CD4 T cell Epitopes 
Cpp65.508 KYQEFFWDANDIYRI 
Cpp65.281 IIKPGKISHIMLDVAFTSHE 
Cpp65.37 HETRLLQTGIHVRVS 
Cpp65.41 LLQTGIHVRVSQPSL 
Cul86.494 RIPHFYRVRREVPRTVN 
Cpp65.415 RKTPRVTGGGAMAGA 
Cpp65.115 LPLKMLNIPSINVH 
Cpp65.363 YSEHPTFTTSQYRIQGKLEYR 
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EBV Epitopes 
CD8 T cell epitopes 
Peptide identifier Peptide sequence 
EBV LMP2.426 CLGGLLTMV 
EBV BMLF1.259 GLCTLVAML 
EBV BRLF1 RVRAYTYSK 
EBNA3A.603 RLRAEAQVK 
EBV EBNA 4NP AVFDRKSDAK 
EBNA4.416 IVTDFSVIK 
EBV ATIGTAMYK 
EBV RTA/ LRF1.28 DYCNVLNKEF 
EBNA3A.247 RPPIFIRRL 
EBV BZLF-1 RAKFKQLL 
EBV EBNA 3A FLRGRAYGL 
CD4 T cell epitopes 
EBV LMP2 ICLTWRIEDPPFNSILFALL 
EBNA 3C PHDITYPYTARNIR 
EBNA2 PRSTVFYNIPPMPLPPSQL 
EBNA1 NPKFENIAEGLRALLARSHV 
LMP2 TYGPVFMSLGGLLTMVA 
EBNA1.515 TSLYNLRRGTALA 
EBV PYYVVDLSVRGM 
 
Influenza  
CD8 T cell Epitopes 
Peptide identifier Peptide Sequences 
INFLUENZA RNA polymerase catalytic 
subunit 
VSDGGPNLY 
INFLUENZA NP CTELKLSDY 
INFLUENZA M/MATRIX 1 GILGFVFTL 
INFLUENZA NP KTGGPIYKR 
INFLUENZA NP ILRGSVAHK 
INFLUENZA NP ELRSRYWAI 
INFLUENZA NP SRYWAIRTR 
INFLUENZA MP1 ASCMGLIY 
INFLUENZA NP LPFDKTTVM 
INFLUENZA MP1 SIIPSGPLK 
INFLUENZA NP RVLSFIKGTK 
CD4 T cell epitopes 
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FLU(NP) RIAYERMCNILKGKF 
FLU(NP) IRPNENPAHKSQLVM 
FLU(NP) RASVGKMIGGIGRFY 
FLU(MATRIX 1) AVKLYRKLKREITFH 
FLU( MATRIX 1) TKGILGFVFTLTVPS 
 
Chlamydia  
T cell epitopes 
Peptide identifier Peptide sequences 
ChlO.258 RLNMFTPYI 
ChlP.179 ALAYGIDKV 
ChlT.367 DADKYAVTV 
ChlT.121 NAACMALNI 
 
BCHP (Bkt Rota virus, Coxsackie virus, Human herpes virus 6,7 and Parvovirus) 
T cell epitopes 
Peptide identifier Peptide sequence 
ParvoB19 GRMTENIVEVAKA 
ParvoB19 LASEESAFYVLEHSSFQLLG 
ParvoB19 FYTPLADQF 
ParvoB19.NS1.613 GLCPHCINVG 
ParvoB19.NS1.276 LLHTDFEQV 
HHV6.IEAT.57 FESLLFPEL 
HHV6.U14.602 TEMMNDARL 
HHV6.IEAT.39 VEESIKEIL 
HHV7.RdIpR.544 ENIYYSSVRT 
HHV7.Gp KEKNGDVVEL 
COXB3.PP.1505 GIIYIIYKL 
COXB3.PP.1587 ILMNDQEVGV 
COXB3.PP.2050 YGDDVIASY 
COXB4.PP.1137 EVKEKHEFL 
bkT.406 VIFDFLHCIVFNVPKRR 
bkVP1.108 LLMWEAVTV 
bkT.604 RLDSEISMY 
rota1 IIVILSPLLNAQN 
rota2 TLLANVTAV 
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Adenovirus 
CD8 T cell epitopes 
Peptide identifier Peptide sequence 
Adp99.492 SADNNNSEY 
Ad5H37 TYFSLNNKF 
Ad5Ha IPYLDGTFY 
AdHb GLRYRSMLL 
AdHc LPGSYTYEW 
Ad5H114 KPYSGTAYNAL 
CD4 T cell epitopes 
Ad5H917 DEPTLLYVLFEVFDV 
Ad5i IIRFDENGVLLNNSF 
Ad5ii SIALMFVCLIIMWLICCLKR 
Ad5iii FQRPTISSNSHAIFR 
Ad5H317 QQSMPNRPNYIAFRDNFIGL 
Ad5H886 TDLGQNLLYANSAHAL 
 
Respiratory Syncytial virus 
T cell epitopes 
Peptide identifier Peptide sequence 
rsvG.163 FHFEVFNFVPC 
rsvM.238 TTNWKHTATRFAIKPMED 
rsvNP.137 KMLKEMGEV 
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Mycobacterium tuberculosis 
T cell epitopes 
Peptide identifier Peptide sequence 
TB85A.200 KLIANNTRV 
TB85A.12 VPSPSMGRDIKVQFQ 
TB85A.27 GKAGCQTYKWETFLTSELPG 
TB85A.37 YHPQQFVYAGAMSGLLDPSQ 
tbMP.59 WDINTPAFEWYYPSGLSIVM 
TB cons VLVATNFFGINTIPIALN 
 
